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ABSTRACT
Steiger, Scott, Ph.D, December 2014,

Major
Medicinal Chemistry

Synthesis and study of heterocyclic, dimeric and chiral ligands for the multidrugresistance transporter

Chairperson: Nicholas R. Natale
The development of multidrug resistance in tumor cells has been recognized as a
major obstacle to successful cancer treatment. Tumor cells in vitro and in vivo can
develop multidrug resistance (MDR) to the lethal effects of the cytotoxic drugs used to
treat them, with about 40% of cancers going on to develop MDR. There are multiple
factors that lead to MDR but the factor that we will be exploring in this dissertation is the
expression of multiple drug resistance gene 1 and the over expression of multi drug
resistance protein 1(MDR1, also known as P-glycoprotein or P-gp). MDR1 has also been
shown to be a major contributor to the development of MDR in cancer, via preventing
entry of therapeutically relevant drugs into the cancerous cell. As such, MDR1 is highly
investigated as a drug target both for controlling absorption, distribution, metabolism and
excretion (ADME) of clinically relevant compounds and for the production of MDR
inhibitors.
Our efforts in producing novel compounds to reverse MDR by inhibiting MDR1
have shown marked improvement from generation to generation of drug development.
Our first generation of compounds had activitys that ranged from 10.9% to our lead
compound showed a 61.2% inhibiton when compared to cyclosporine A. Our second
generation had a slight increase in activity when we explored tethered compound with
our lead compound showing a 63.0% inhibition when compared to cyclosporine A.
Further exploration of tethered and dimer compounds in generation 3 showed a dramatic
increase in inhibitory activity with our lead compound showing over a 200% inhibition
when compared to cyclosporine A. With such a positive trend in activity generation 4 and
5 compounds where then designed to be more selective for MDR1. Currently, both
generation 4 and 5 are in hand and are waiting for biological testing. Generation 4
compounds explore the effect that more steric groups in the 3-isoxazolyl position would
have on MDR1 inhibition. While generation 5 componds explored chiralities effect on
MDR1 inhibition and how it can be utilized in refining selectivity.
Reversal of MDR is of interest for the clinical application; if a compound could
effectly and safely reverse MDR, it would allow for major advancements in cancer
chemotherapy. If successful, halting the function of MDR1 will stop the outward efflux
of chemotherapeutic agents out of the cell. In combination with chemotherapeutic
treatments, inhibitors could allow for greater penetration of drugs into an MDR cell and
potential allow for the repurposing of out of date drugs where MDR has redered the drug
ineffective. The exploration of this concept and the advancements that our group has
added to this field will be explained in due course.
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Chapter 1:
4-Isoxazolyl-1,4-dihydropyridiens: A tale of two Scaffolds
1.1 Introduction
The concepts of bioisoteric replacement,[1,2] privileged structures,[3-9] and scaffold
hopping,[10,11] all have contributed to the process of drug development as medicinal
chemists endeavors to develop approaches that arrive at bioactive candidates, and avoid
excessive exploration of unproductive terrain. The term privileged structure was first
introduced by Evans et al in 1988 and was defined as “a single molecular framework able
to provide ligands for diverse receptors.”[3] The development of novel compounds from
known privileged structures has found general support due to the appearance of the 32
scaffolds in roughly half of known drugs.[4] Furthermore the inclusion of common
moieties accounts for a large majority of side chains found in most drugs.[5] The
exploration of privileged structures is an emerging theme in medicinal chemistry to aid in
focusing synthetic efforts towards more active compounds. A privileged structure
represents a substructure that is a common chemical motif capable of binding to given
target with high affinity.[6-9] Considerable amounts of effort had been placed into
increasing the success rates of novel drug discovery thus, the inclusion of so called
privileged structures has been employed as a viable tactic for drug development.
Conclusions drawn from using privileged structures and scaffolds lead in turn to the
construction of common pharmacophore models, and as information emerge regarding
the biomolecular target, to more detailed homology models to aid in drug development.
The utility of privileged structures has increased our ability to synthesize libraries based
upon core scaffolds and screen against a variety of targets to yield active compounds.
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This review will focus on two of these structures and their application to complex drug
development issues. Since the introduction of the term several groups have been shown to
fit the criteria such as the 1,4-dihydropyridine (DHP) [12, 13] and the isoxazole [14] have
been described as privileged structures. Both the isoxazole and dihydropyridine appear on
Kubinyi and Muller's list of a dozen more common heterocycles in drug discovery, given
their propensity for polypharmacology, these rings may well be referred to as the "dirty"
dozen.[15]
The 1,2-oxazole or isoxazole 1 (Figure 1) was first isolated by Claisen in 1888 [16]
and the name monoazole was suggested for the substructure. It was later named isoxazole
by Hantzsch.[17] The inclusion of isoxazole in potential drug candidates have produced a
range of pharmacological active compounds,[18] making the isoxazole of considerable
interest to medicinal chemists. The isoxazole ring shows some aromatic character with
the oxygen atom acting as an electron donating group and the nitrogen atom acting as an
electron-withdrawing group.[19-23] The 4 position is the preferred position for electrophilic
substitution and its reactivity is affected to the substituents at the 3 and 5 position.
Electron donating groups activate the electrophilic substitution, while electronwithdrawing groups deactivate it. The 5 position is the thermodynamically more acidic
proton in the ring in most instances.[24] The N-O bond is the weakest among the five
bounds and can be reductively cleaved by many methods. The isoxazole has been
considered by Bauman, et al, as one of the standard five-membered heterocycles to be
considered in drug discovery.[18]
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Figure 1.1: The isoxazole scaffold (1), and the dihydropyridine (DHP) (2), exemplified
by the antihypertensive agent nifedipine. The esters at C-3 and C-5 of the DHP can attain
either a synperiplanar or antiperiplanar conformation. . Representative known modes of
isoxazole to DHP attachment isoxazol-3'-yl-4-DHP (3), isoxazol-4'-yl-4-DHP (4), and
isoxazol-5'-yl-4-DHP (5), benzisoxazole (6,) and fused bicyclic system isoxazolo[5,4b]pyridine (7).
The present review will focus on the type (4) IDHPs. The first synthesis of 1,4
DHPs was from acetoacetic acid esters, aldehyde and ammonia was first published in
1882 by Hantzsch.[25] Since then the synthetic procedure has proved to be highly versatile
showing a considerable structural variation in the aldehydic component as well as in the
1,3 dicarbonyl compounds.[26, 27] As 1,4 DHPs have become more medicinally important
variation of the synthesis have been explored to accommodate analog development.
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Subsequently, the 1,4-DHP substructure has served as a scaffold for both second and
third generation compounds that have shown improve activity.[28]
The 1,4 DHP has been important and highly effective drug substructure due to
their wide range of biological activities. DHPs have a broad range of pharmacological
actions such as vasodilation, brochodilation, antiatherosclerosis, antioxidant and
anticonvulsant effects. The 1,4-DHP substructure is best known for their pharmacological
action as calcium channel blockers, with the prototypical case being nifedipine 2 (Figure
1) which has been in general medical practice since 1975.[29,30,31]
It was noted early in the first generation of calcium channel antagonists exhibited
cardiovascular action, this action was ultimately ascribed to the 1,4 –DHP substructure.
Thus, the substructure is often included in compounds used to treat a variety of
cardiovascular disorders such as hypertension. With further research on the substructure
leading to the discovery that 1,4-DHP structure also having antitumor, antidiabetic, and
anti-platelet aggregation properties. Additionally these compounds have also been
utilized to promote drug transport across the blood-brain barrier,[31] which in turn lead to
the use of DHPs to inhibit the Multidrug resistance transporter efflux pump (MDR, also
known as P-gp).[32-34]
Potential connection of groups to the isoxazole can be accomplished through the
3'-,4'- and 5'- positions (Figure 1). This review will focus primarily on the potential
connections to the 1,4-DHP in the 4'- position of the isoxazole ring system. The first
example of the association of the two scaffolds was claimed in the patent literature,
however, it is not clear whether the IDHP was actually prepared until the first fully
characterized preparation of an IDHP was published in 1982 by Natale and Quincy.[35]
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1.2 Isoxazol-3'-yl-4–IDHP
The connection of the isoxazole to the 3 position (3) is produced via the
producing an alcohol in the 3 positions of the isoxazole. From the alcohol the product is
oxidized to the aldehyde and subjected to the Hantzsch pyridine synthesis to produce the
DHP. The 3,4–IDHP was shown by Shafu and co-workers to have anti-tubercular
activity.[36] Due to multi-drug resistant strains of mycobacterium and to a high prevalence
of MDR tuberculosis the potential use of 3,4–IDHP as a MDR reversing agent was
proposed. The use of DHPs to combat MDR is an emerging trend in DHPs research that
is currently being explored by many groups including our own (vide infra). Further
analog development in this area where developed to explore calcium channel antagonist
activity.[37] Darybari et al observed that activity of these analogs was moderate at best
with maximum calcium channel antagonist activity approximately 10-7 M range
compared to the prototypical DHP nifedipine activity (1.10 x 10-8M). This is expected in
light of Triggle's SAR principles [29] since para-phenyl substitution is well known to
lower voltage gated calcium channel (VGCC) affinity. Further exploration of analogs as
VGCC were not explored, it should be noted that these could potentially represent leads
for designing against the VGCC.
1.3 Isoxazol-4'-yl-4-IDHP
In the course of our early studies in this area,[35] the preparation of the isoxazole
connected to the DHP at the 4' position of the isoxazole (Figure 1, type (4)) was
rationalized by the structure activity relationship (SAR) developing at that time for
antihypertensive activity by virtue of blocking the VGCC: (1) that para substitution on
the 4-aryl ring lowered activity (the isoxazole has no para group) and (2) electron
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withdrawing groups at the 4-aryl enhanced activity (the isoxazole is π-deficient). [28, 30, 3846]

We recognized that chemistry being developed in our laboratories at that time, lateral

metalation and electrophilic quenching of isoxazoles,[24, 47-51] could be applied to study
conformational and configurational issues in antihypertensive SAR. The structure activity
relationship (SAR) that emerges is distinct in critical points from known 4aryldihydropyridines (vide infra).[52] More recently we have recognized that IDHPs of
Type 4 bind the multi-drug resistance (MDR) transporter.[53,54]
1.4 Isoxazol- 5'-yl-4-IDHP
The connection of the isoxazole at position 5'- to the DHP was reported by
Mirzaei, and was performed by producing the 5'- alcohol followed by oxidation to the
aldehyde. The Hantzsch pyridine synthesis was then used to produce the 1,4-DHP.[55]
1.5 Fused Ring Systems
The preparation of benzo 2,1-isoxazole analogs of the 5',4-IDHP (5, where R5
and R6 are fused in a benzene ring) have also been achieved by Phillips.[56-57]
Alternatively, the benzoisoxazole was attached to the DHP via the benzene moiety (6),
analgous to isradipine. The exploration of these analogs was needed to systematically
probe differences in calcium channel activity. The fusion of the isoxazole at the 3 and 2
positions of the DHP to the Isoxazolo[5,4-b]pyridine (7), and their subsequent antitumor
activity, was studied by Hamama.[58] The fused isoxazole analogues were used to study
the receptor ligand interactions because these rigid, geometrically defined derivatives that
allow definition of spatial requirements for receptor binding.
Other heterocyclic 1,4-DHP fused analogues analogous to (7) have be reported to retain
potent receptor affinity as either antagonists or agonists.[59] The most common feature of
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these derivatives is the retention of the 1,4-DHP as a part of a relatively planar bicyclic
ring system (7). Isoxazoline analogues of 1,4-dihydropyridines were prepared by Taylor
and have been used to study conformational effects at the calcium channel receptor,[60]
where they revealed that saturating the ring juncture lead to more pronounced puckering
of the DHP ring, and a lessened biological effect.
While the possible combinations of the isoxazole connected to the DHP are far
from exhausted,in this account we will primarily focus on the study of the type (4) IDHPs
(Figure 1, Structure (4)), which have been the emphasis of the work in our own
laboratories.
1.6 Brief overview of the Synthesis and elaboration of IDHPs
For unhindered isoxazole aldehydes the classic Hantzsch synthesis works easily
and effectively (Figure 2),[26, 27, 35] however, in the course of our studies to challenge the
frontiers of conformationally encumbered structures, we found it necessary to conduct the
reaction in a pressure vessel for optimal results.
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Figure 1.2. The Isoxazole version of the Hantzsch pyridine synthesis.
To address issue of conformationally diverse structures, our main entry into highly
substituted isoxazoles involved primarily (1) the nitrile oxide cycloaddition (exemplified
in the work of Mirzaei, Figure 4.C.) and/or (2) lateral metalation and electrophilic
quenching (Figure 3).
One method we have developed for regioselectively elaborating the functionality
of isoxazoles is lateral metalation and electrophilic quenching (LM & EQ), [24, 47-51, 53]
which has provided many of the branched isoxazoles useful for probing SAR (Figure 3).
The metalation of isoxazoyl-oxazolines was acomplished with n-butyl lithium, and clean
mono-incorporation of electrophiles can be obtained in excellent yields (Figure 3). the
deprotection is accomplished by N-methylation of the oxazoline nitrogen, followed by
hydride reduction, which after mild aqueous hydrolysis affords the aldehyde. The
9

Hantzsch synthesis is best performed under pressure when the groups on the isoxazole
are large.

Figure1.3. Lateral Metalation and Electrophilic quenching is a selective route to
substituted isoxazoles, and hence IDHPs. [24, 46-51, 53]
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Figure 1.4. A. Mirzaei route to IDHP C-2 functionalized products, analogous to
amlodipine. B. Lanthanide double activation amidation of Hantzsch esters. Compound 418 in Table 2 is n=8, Fl = Dansyl [54]. C. Mirzaei's example of a NOC click route to
isoxazole carbaldehydes [57].
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Mirzaei's group brominated the DHP moiety selectively as an entry into IDHP
analogs similar to amlodipine (Figure 4.A) [57]. The 3- and 5- esters of the DHP are
cross-conjugated vinylogous urethanes, and hence quite unreactive. We found it was
necessary to apply our lanthanide accelerated Weinreb amidation to obtain amides
(Figure 4.B), which were then further functionalized to allow for the attachment of
fluorophores.[54]
Among the common methods for regioselective isoxazole synthesis is the nitrile
oxide cycloaddition (NOC), which Folkin and Sharpless included among "Click"
reactions,[61, 62] and is the subject of several excellent reviews.[19-22, 63] The use of the
NOC is exemplified in Mirzaei's approach to IDHP (5) (Figure 4.C.), from isoxazole-5carbaldehydes.[57]
1.7 Conformational Analysis of IDHPs
Conformational correlations from small molecule crystallography have proved of
interest in scaffold hopping,[64] and serve as a useful starting point for understanding the
biological efficacious topology. The sweep volume of rotation about the bond between
the heterocyclic rings in isoxazol-4'-yl DHPs (Figure 8) is dramatic, and one of the main
contrasts with the corresponding 4-aryl DHPs. As the groups on the C-3' and C-5'
position of IDHP (4) are substituted with branched or progressively larger aromatic rings,
the trend in the single crystal structure is for the larger group to orient over the DHP ring
in the unit cell (Table 1, entries 4-4 through 4-12), so that the plausibility that this more
compact arrangement arises from crystal packing forces must be considered. Therefore
we have examined solution nuclear Overhauser effects, and variable temperature studies
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to ascertain the presence of rotation at the heterocyclic ring juncture, and estimated the
energy of this process using a variety of computational methods.

Figure 1.5. Conformation dynamics in type 4 IDHP. The numbering for R1, R2 and R3 are
used in Table 1. E represents an ethoxycarbonyl group.
The IDHP 4-1 [35] crystallizes in the O-endo, and syn- ester conformation (Table
1) [42], however, nOe studies demonstrated that both conformations occur in solution at
room temperature, and MM2 calculations suggested a barrier to rotation on the order of
the cyclohexane chair to chair interconversion. Substitution of the C-3' methyl for a
phenyl (4-2), and the C-5' methyl for ethyl (4-3) resulted in similar O-endo solid state
conformers, however, branching at C-5' in the form of an isopropyl resulted in
conformational flip at the juncture of the heterocycles to O-exo (4-4).
With further substitution on the C-3' aryl (entries 4-6 to 4-9, 4-11), or branching at C-5'
containing an aryl moiety (entries 4-5, 4-10, 4-12), crystallography has revealed that
compact packing in the solid state, where the larger group on the isoxazole orients above
the DHP, appears to be the major factor influencing conformation. Together with Palmer
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and Andersen, [45] our group examined the solution dynamics at the heterocyclic ring for
4-8 and related IDHPs, and the barrier for rotation was found to be below the temperature
attainable at physiological conditions.
The fluorophore IDHP conjugate (4-18) was found to exist almost exclusively as a folded
conformation after chromatographic isolation, as evidenced by NOE. Variable
temperature studies indicated that the conformation equilibrated to an extended
conformation on warming, and that this conformation persisted.
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Table 1.1: Crystal structrues of IDHPs
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1.8 Antagonists at the Voltage Gated Calcium Channel
Triggle had enumerated several germane issues in the SAR of the VGCC which
suggested that the IDHPs could be of advantage. [28, 30] Therefore, once we had IDHPs in
hand, we sought to examine their solid state structure to determine whether they had the
required stereoelectronic characteristics. The IDHPs adopt a shallow boat conformation
in the solid state often associated with robust calcium antagonists. The substitution at the
3'- and 5'- position of the isoxazole gives rise to dramatically different topologies arising
from rotation at the bond connecting the heterocyclic rings, and represented an
opportunity to explore conformational and configurational aspects of SAR.
1.9 Aryl DHPs and their SAR at the Calcium Channel
The 1,4-DHPs have been utilized in general medical practice to treat
cardiovascular disease. Nifedipine was the first calcium channel antagonist approved for
clinical use as an antihypertensive. The success of nifedipine led to its use as a lead
compound and in turn gave rise to an increased interest in the DHP class of molecules.
Using nifedipine as the prototypical 4-Aryl-1,4-DHP the development of numerous
derivatives have been produced that showed superior bioavailability, a slower onset and
longer duration of action. [65] The SAR which has developed in this area, as summarized
in several excellent reviews by Triggle and colleagues, is useful due to its power to
predict drug activity.[66-68] Optimal antagonist activity is obtained when C3 and 5
positions of the DHP are substituted by ester groups. The C4 position is optimally
occupied by a phenyl ring with a meta- or ortho- electron withdrawing groups, with 2,3disubstitution tolerated and which can be incorporated as part of heteroaromatic rings. [69]
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The 1,4-DHP ring itself is essential as N-substitution, reduction to the piperidine,
or oxidation to the pyridine ring system will greatly decrease or completely abolish
activity, via removing the potential hydrogen bonding interaction with the calcium
channel. Additional modification to the C3 and 5 substitution also can modulate activity
and tissue selectivity. It has been observed that electronic features of the oxygen of the
carboxyl ester influenced biological activity, due to the likely event that the carbonyl
oxygen participates in hydrogen bonding with the calcium channel receptor.[70] The
preferential orientation that is adopted is in the plane of the DHP ring itself with smaller
variations being observed between 30-60⁰ from planarity. Additionally the syn or anti
periplanar orientation of the carbonyl groups is another key factor for activity it has been
suggested that syn-periplanar carbonyl groups might be a common feature of DHP
calcium channel antagonists,[12, 71-73] and an anti-periplanar conformer associated with
agonist activity.[59,70] When there are non-identical esters at the C3 and 5 position the C4
carbon is then chiral, and chirality of the DHP is one of the key distinguishing factors
between antagonist and agonist activity. The (S) enantiomers are activators and bind the
open state of the channel, where the (R) enantiomers are antagonists and bind the inactive
state of the channel.[74-77]
1.10 IDHPs and their SAR at the Calcium Channel
The attachment of an isoxazole onto the DHP introduced a number of structural
features that diverge from the 4-Aryl-1,4-DHPs,[12, 28-31, 78,79] yet presented the opportunity
to weigh the importance of stereoelectronic effects in the SAR. The combination of the
isoxazole scaffold with the DHP has been shown to give rise to robust activity at the
VGCC, while lacking pronounced negative ionotropic activity of some DHPs. [38, 40, 42]
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Similar to the 4-aryl DHP, the 1,4-IDHP system requires the DHP ring for activity, and
the relative conformation of the 4-aryl substituents in significant. Roynyak, Andersen and
co-workers[80], Goldman and Geiger [81] and Berntsson and Carter [82] performed NMR
investigations which supported a preferred solution equilibrium conformation in which 4aryl substituent is in a pesudoaxial orientation perpendicularly bisecting the plane of the
1,4-DHP. We have referred to the conformation at the juncture between the DHP and 4isoxazolyl substituent as O-endo and O-exo (Figure 8), to readily distinguish this
conformational feature, and groups at the 3'-and 5'- of the isoxazole describe a large
sweep volume as rotation takes place about the 4,4' ring juncture. While in several cases
the 3'- aryl or 5'-arylethyl group on the isoxazole crystallized with the aryl group over the
DHP (Table 1), in each case studied by NMR it was revealed that facile rotation about the
heterocyclic ring juncture was present. With studies on 1,3-benzothiazocines Baldwin et
al [83] convincingly ruled out boat to boat interconversion for DHPs, and favored the exo
geometry of the 4-aryl substituent with respect to the DHP moiety. Examination of over
30 crystal structures of DHPs lead to two molecular features that highly correlated with
biological activity. These are termed ∑│ρ│

∑│τ│, which refer to the extent of 1,4-

DHP ring pucker as measured by the sum of the six intraring torsional angles, and the
forward presentation of the 4-aryl ring, respectively. As observed in single crystal X-ray
diffractometry, the more active IDHPs usually possessed extremely flat boats, and the
subsequent forward presentation of groups in the 3'- or 5'- isoxazole position was greatly
accentuated.
At the time we initiated our studies it was recognized that unsymmetrical ester
groups in DHP calcium antagonists, which gave rise to a chiral center at C(4) of the DHP,
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exhibited pronounced enantioselectivity of action. We set out to determine if chirality at
the isoxazole would have the same effect. The (+)-1-phenylprop-2-yl group, assigned as
(R)-, was indeed the eutomer with a pronounced eudisimic ratio (R/S 56.7), and was a
robust antagonist with single digit nanomolar binding affinity (3.7 nM) [43]. These results
were emerging as additional information became available about the calcium channel's
primary sequence, and our initial modeling of the DHP binding subunit lead to a
prediction of a potential lipophilic pocket, and exploration of a series of analogs to test
that hypothesis [46]. The appearance of Mackinnon's landmark single crystal structure of
the potassium channel allowed for homology modeling (Figure 9A), and a rational
explanation for the unique SAR of IDHPs [52] (Figure 9B). An interesting issue described
in this study is that docking of the IDHPs in the conformation found in the small
molecule x-ray gave no SAR distinction, and VT NMR indicated that ready
conformational adaptation to the receptor must occur.

Figure 1.6. A. Homology model of the VGCC with docked IDHP, based on the
MacKinnon potassium channel single crystal structure, pdb accession 1BL8 [52,84]. B.
20

Schematic summary of the unique SAR of IDHPs [52]. C. The methyl effect in SAR of
IDHPs (4)
1.11 Multidrug resistance
Chemotherapy is often complicated by drug efflux from tumor cells. One major
factor is the multidrug resistance transporter, known to be over expressed in several
tumor cell types. DHPs have been known for some time to be either competitive alternate
substrates or inhibitors of MDR-1, which in either case can give rise to reduced efflux of
cancer chemotherapeutics. Intensive efforts continue to be directed towards DHP
modification, as resistance is a serious problem. The MDR-1 is a large and complicated
protein with multiple documented and postulated binding sites for xenobiotics. We
considered the possibility that the chemistry we had developed for selective
functionalization of isoxazoles could be applied to enhance MDR selectivity at the
expense of the VGCC. There have been a number of compounds that have been identified
as MDR1 inhibitors.[32-34] The majority of these novel compounds that are known to
inhibit MDR1 have not yet advanced to being utilized in the clinic due mainly to severe
side effects and lack of selectivity. Nevertheless, reversal of multidrug resistance is of
widespread clinical interest and multidrug-resistance reversers (MDRR) are currently
under intensive investigation. Given MDR1’s involvement in MDR it is a viable drug
target for the reversal of MDR.
First-generation inhibitors such as cyclosporin A, and verapamil suffered from
unacceptable high toxicity, and were dropped as potential inhibitors after phase II clinical
trials . The second-generation agents: valspodar, and biricodar have better toxicity
profiles, but showed cross reactivity and unpredictable pharmacokinetic interactions with
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other transporter proteins . Third-generation inhibitors such as tariquidar (XR9576),
zosuquidar (LY335979), laniquidar (R101933), and ONT-093 have high potency and
specificity for MDR1. The structures for the known inhibitors of MDR1 are shown in
Supplementary Material Figure SM-1. The pharmacokinetic studies to date have shown
no significant interactions with CYP450 3A4 drug metabolism and no clinically
significant drug interactions with common chemotherapy agents . The prevalence of
MDR1 expression in several tissues is proving to be a major issue when considering side
effects of potential inhibitors. It is for this reason that most MDR1 inhibitors have had
sub-optimal results in clinical trials.
1.12 DHPs and Current treatment in MDR
With Verapamil being used as the first calcium channel blocker to advance to
clinical trials for its ability to reverse MDR [85], with the compounds failing out due to
high cardio toxicity and unsatisfying clinical outcome [86]. Further exploration in this area
resulted in Nifedipine going through clinical trials. Clinical trials failed for similar
reasons to verapamil, with response being poor and high toxic cardiovascular side effects
being the main reason for not proceeding through clinical trials.
With suboptimal result being observed in clinical trials, leads to the development
of new DHP derivatives with the expressed goal to first increase the MDR reversing
activity and second to decrease the significant of the calcium channel blocking activity.
While there are a number of variations that can be introduced to the DHP structure the
most promising modification are the eudismic ratio that is seen in calcium channel SAR.
The distomeric enantiomer of the DHP has been shown to have the same MDR reversing
activity, while the calcium channel blocking effect are much weaker [87]. Further research
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in this area confirms that MDR1 inhibition is independent of the calcium channel activity,
where the enantiomers of niguldipine exhibit varying calcium antagonism but showed
similar MDR activity [88-89]. Thus, structural modifications can be made to produce a
more active MDR revering agent. The independent action of MDR reversing action and
the calcium channel activity allow for more refinement of structure to produce more
active compounds, making the DHP one of the most appropriate ring system to develop
around to produce more active MDR reversing activity with minimum adverse effects.
To this end, the examination of derivatives of DHP has been shown to be
effective MDR reversing agents, with some compounds currently in clinical trials. Most
of the more successful compound that are being reported are compounds that have
common structural features, with the addition of pyridyl groups on the C3 and 5 positions
being a common theme. [90-91] With other studies making modification to the C3 and C5
removing the ester functionality, thus reducing calcium channel activity and maintain
MDR activity [92]. The C4 position is another potential site of modification, heterocyclic
aryl have been shown to both reduce calcium channel activity and increase MDR activity,
but also introduced toxic side effects in animal models[93-94].
Zhou, Coburn and Morris chose to take existing lead compound such as
dexniguldipine and make derivatives based on structure optimization for MDR1 and
breast cancer resistance protein MDR. [95-97] In an effort to improve on the concept our
research group have made novel 1,4-IDHP derivatives and have had promising results
concerning MDR1 inhibition [53, 54]. The research in this area is developing and the
implementation of the known privileged structures has been prevalent, and has become a
useful strategy for drug development. 4- Isoxazolyl-1,4-dihydropyridines (IDHP) have
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been known to bind L-type voltage gated calcium channels, and dihydropyridines
(DHPs) have been in general medical practice for use as anti-hypertensive agents for
decades[97], and as such the DHPs has been recognized as a privileged scaffold found in
medical chemistry [98]. More recently however, the DHP scaffold has been recognized as
a substructure to design around to produce MDRRs.[32, 93, 100-102] Given that the clinically
used DHPs such as nicardipine and niguldipine are known ligands for MDR1. [102-103]

Figure 1.7.A.: An overlay of minimized niguldipine (gold) and novel IDHPs, containing a
branched C-5 (4-16) (blue) and tethered dansyl (4-18) (salmon), indicating analogous
functionality and topology [53, 54]. B. Left is our homology model based on the open
conformer of MDR1, based on Mus musculus pdb accession 3G5U, on the right is our
human homology thread with sav1866 pdb accession 20NJ. The binding sites of interest
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are known as the DHP binding site resides near the NBDs (Labeled with ATPs). This is
thought to be the general area in which the putative IDHP binding site is located. The
horizontal lines represent the approximant position of the lipid bi-layer. C, the DHP
photoaffinity binding site (red) and the Q-site predicted binding site (blue), D. The
overlapping amino acid sequence (purple) from the photoaffinity binding site and the Qsite binding site. The location of Q475 (gold) a Mg2+ binding residue proximal to the
ATP binding and hydrolysis sequences. The sliding helix 2 sequence (F904 - L910)
shown in cyan is critical to MDR conformational dynamics in xenobiotic efflux.

The constructionof a common pharmacophore model (Figure 11) to visualize
common structure features to direct synthetic efforts towards more valid analogs. Figure
11 shows clinically used 1,4- dihydropyridine niguldipine (pink), and two IDHPs. The
spatial conservation of the function groups is apparent, the most apparent difference
being the conformationally unique structure that the isoxazole moiety imparts to the
IDHP. The IDHP allows for novel and structurally divergent compounds to expand the
library of compounds which have previously been studied, which in turn could
potentially allow for corresponding divergent and novel pharmacology.
To further study the effect of IDHPs as MDRRs on MDR1 and to aid in further
analog development a binding box for IDHP was needed as a working hypothesis. Given
that MDR1 has a large number of potential substrates we chose to focus our efforts on
initial characterization of the IDHP binding site. The characterization of the DHP site
was first attempted by using domain mapping experiments [104]. Domain mapping studies
in combination with immunoprecipitation were utilized to identify the DHP binding site
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[104]

. Other studies[106] have been performed with photo labeled DHP derivatives, the

studies showed binding at two major regions, one in each half of the protein[108] . This
suggested that the DHP derivatives bind to both NBDs.
To define the DHP binding site a niguldipine was chemically modified with a
photoaffinity label which replaced the nitro group of niguldipine with an azido group.
Photolysis of the modified DHP was carried out in the presence of MDR1. The protein
was then identified via PAGE-SDS gels and purified via lectin affinity chromatography
[107]

. Western Blot analysis was carried out using monoclonal anti-MDR1 antibody C219.

The pooled samples of niguldipine bound protein were then analyzed via Matrix-assisted
laser desorption/ionization (MALDI). Edman degradation combined with MS revealed
the amino acids that compose the labeled site. The final localization of the niguldipine
binding site in MDR1 was found to be correspond to the sequence 468-527, this is in
agreement with the previous immunoprecipitation experiments that showed the
dexniguldipine binding site in the N-terminal or the cytoplasmic half of MDR1 [109]. In
other proposed structural model of MDR1 the niguldipine binding site is also in the
cytoplasm assigned to the sequence 491-526 [110]. The results suggest that this region is
near the N-terminal NBD this indicates that the chemo sensitizer binding site and ATP
binding domains interacts with each other. It is known that the drug binding site and ATP
hydrolysis are coupled [111]. Observing that both sequences are closely related to one
another is evidence that this is a reasonable consensus binding sequence.
Many studies have attempted to localize the drug-receptor binding site and key
amino acid residues responsible for the interaction of MDR with its ligands. Studies of
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ligand–ligand interactions on MDR1 revealed that some ligands interact as single
molecules, whereas others show cooperativity [112].
As mentioned above MDR1 contains multiple sites, distinct sites for transport of
rhodamine 123 (R-site) in addition to a modulatory site for prazosin and progesterone [113,
114]

. Binding of ligands at one of these transporters site enhances the interaction at the

others. Equilibrium binding studies on MDR1 provided evidence for three sites for
transported ligands (vinblastine, pacitaxel, and rhodamine), which can interact with
ligand in the absence of externally added nucleotides, in addition to a modulatory site for
niguldipine/GF120918 [115]. The observation that there could be similarities in both the Rsite and the DHP binding site, which could allow for this cooperation and communication
to occur that could cause the conformational changes and allow MDR1 to function. Given
the previous research on the binding of DHP a computer model was used to produce a
refined ligand binding box.
1.13 IDHPs and MDR: towards a working hypothesis
To generate a testable hypothesis for binding at the DHP binding site, computer
modeling was employed. At the time that we initiated out studies an MDR1 human
crystallographic structure did not exist, so a homology model was constructed from the
published X-ray crystal structure Mus musculus (pdb accession number: 3G5U) a close
homolog of the human ABC transporter MDR1. A sequence homology was then
performed between the known human MDR1 sequence and the 3G5U followed by
threading of the known human MDR1 sequence into the published X-ray crystal
structure. As explained above the binding site for the DHP has been broadly defined as
the resides 468-527.To avoid any bias in further defining the DHP binding site, the
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MDR1 human homology model was submitted as the entire MDR1 transporter to the Qsite finder online server .

Figure 1.8.General Structure of IDHPs used for Table 2.
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Table 1.2 IDHP activity at MDR-1, data provided by NIMH PDSP.
MDR1 screening and the establishment of MDR1 inhibition activity was
performed by the Psychoactive Drug Screening Program (PDSP) of the NIMH. The assay
was performed using live Caco-2 cells, a cell line derived from human colonic epithelium
cell that express MDR-1[39]. The assay uses Calcein-AM which passively diffuses in to
the cell, after which it is hydrolyzed turning the compound fluorescent and adding a
negative charge thus trapping the compound in the cell. Calcien-AM can be effluxed out
of the cell via MDR-1, thus MDR-1 inhibition is a function of the fluorescence that is
observed. Fluorescence is measured using a FlexStation II fluorimeter in a 96 well plate
after preincubation with the given IDHP (50μM for 30min). After which calcein-AM was
then added to a final concentration of 150 μM. Fluorescence was then monitored over 4
minutes, with each assay performed in quadruplicate, with 25 μM cyclosporine used as a
control. The value of untreated control cells where taken as 0% inhibition and the slope
of the fluorescene is normalized taking the value of cyclosporine at 100%.
With MDR binding data in hand, the IDHP structures were drawn and energy
minimized using the Sybyl modeling program[54]. Ligand-receptor ensemble structures
were virtually docked into an in silico-activated MDR1 human homology model,
followed by energy minimization, molecular dynamics, and a final energy minimization
simulation,, using the program GOLD and scored using GOLD Score with default
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settings. Aggregates for molecular dynamics and minimization simulations were defined
as residues within 6 Å from the ligand. Binding was localized near the GLN 475, one of
the amino acids also at the interface of the overlapping photoaffinity binding (red in
Figure 7.C) and the Q-site finder amino acids (R467, I470, G471, V472, V473, S474,
Q475, E476, P477, V478, L479, F480, Y490, G491, blue in Figure 7.C). From this
analysis three binding site cohorts were defined from the library of IDHPs in Table 2.
The low affinity cohort consisted of compounds 4-6, 4-11 and 4-13 that were
bound on the outside of the overlap region of the photoaffinity site and Q-site finder
calcualtion, in the vicinity of the Nucleotide binding domain (Shown in Figure 7.D), and
never achieved more than 15% MDR-1 inhibition (Table 2). We have termed the
medium affinity cohort the compounds 4-10, 4-15 and 4-17. Compounds 4-10 and 4-15
were bound in the same location adjacent to the edge of the consensus binding box and
never achieved more than 19% MDR-1 inhibition (Table 2). The branched 4-17 on the
other hand, bound bridging the high affinity cohort, this would explain the relatively high
38% MDR-1 inhibition that was observed. We have termed the high affinity cohort
compounds 4-2, 4-7, 4-9, 4-14 and 4-16, which are predicted to bind esentially in the Qsite finder domain. Compounds bound in this location had robust MDR-1 activity with a
range from 27% to 61% MDR1 (Table 2). Most notably, compound 4-16 was the most
active compound in our initial series, giving credence to the computational model as a
predictive tool. To aid in further development of future generation MDRRs, 4-16 was
selected and all interactions were examined in a 6 Ǻ radius around the IDHP structure.
The binding box interactions were then divided into regions to classify the overall
interactions that permit robust binding, the purple amino acids that are shown in Figure
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7.D represent the overlapping amino acids from the photoaffinity study (red) and Q-site
(blue). The low, medium and high affinity cohorts are illustrated in more detail in
supplementary material (Figure SM-2).
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Figure 1.9. Generating a hypothesis: Homology model of human MDR-1 bound to IDHP
ligand 4-16.A, Region 1 binds the C-5 isoxazole functional group of 4-16. B, Region 2 of
Compound 4-16 includes an interaction with the isoxazole, C, 4-16 interactions with the
DHP and esters.
Our homology model for MDR and docking studies with the IDHPs has generated
our current working hypothesis, and is summarized in Figure 9. A shows region 1 of
compound 4-16 the majority of the interactions are lipophilic from Phe 904, Arg 905 and
Val 908. There is also polar interaction that where are observed with the π cloud of the
phenyl ring with residues Glu 476, Ser 474, and Val 472
Figure 9, B show region 2 of compound 4-16 there are lipophilic interactions on
both the methyl groups by residues Phe 480, Val 478 and a polar interaction with Val 472
with the isoxazolyl.
Figure 9, C shows region 3 of compound 4-16 there are multiple interactions with
the DHP nitrogen with the residues Ser 909, Thr 911 and Tyr 490, with additional polar
interactions involving Ser 909, Arg 547 and Arg 543. This region also highlights a key
anchoring point for the compound, the 1, 4-dihydropyridine substructure has been shown
to be key in binding MDR1. Further analog development will be focused on conserving
the 1,4-dihydropyridine substructure while altering other key structural factors in the
series. In addition to the isoxazole anchoring interactions at the receptor, the spatial
arrangement that is conferred via the inclusion of the isoxazolyl is novel and as such will
be conserved in later analog development. The future IDHP analog development will
focus on the modification of the topology of groups organized by the isoxazole.
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1.14 Concluding remarks
Whether one terms the association of the isoxazole and DHP rings bioisosteric
replacement, or scaffold hopping, substitution at the C-5 of the isoxazole gives rise to
dramatically enhanced biological activity. In the case of the VGCC, a strategically placed
methyl group produced a signifcant change with (R)-(+)-1-phenyl-prop-2-yl (3.7 nM) >
Phenethyl (22.9 nM) > (S)-(-)-1-phenyl-prop-2-yl (210 nM), a eudismic ration of 56.7.
This appears to be a classic example of the methyl [116] or methylation [117] effect. In the
MDR-1 arena branching at the C-5 of the isoxazole produced an increase of binding of
25% (shown in Table 2), and replacing the DHP C-3 ester with a functionalized amide
also lead to a dramatic increase in binding affinity. The lesson for the future is that a
number of the isoxazoles in general medical practice bears an unfunctionalized methyl
group, these are drugs with highly diverse molecular targets: sulfisoxazole,
sulfamethoxazole, the oxacillins, glisoxepid, isocaboxazide, and paracoxib among others
[123]

. That an unadorned methyl is optimum for all biomolecular targets appears to be

extremely unlikely, and it seems apparent that addition of even one methyl in the
correct critical position should enhance activity in many cases. Our work represents an
example of following the structure-based design path, even though that route was not
always easy [123], and required improvement of existing methods and development of new
chemistry. We suggest that numerous other opportunities for combined scaffolds, and
strategically placed branching - including examples containing IDHPs - are waiting to be
discovered in the future: because new biology is driven by new chemistry.

33

1.15 Future Perspective
Several distinctive features have emerged in delineating IDHP selectivity for
MDR-1 verses VGCC, and these general trends (Figure 10) are illustrative of how a
combination of scaffolds could be used to optimize selectivity. (1) While a 4-aryl or 4heteroaryl is a requirement for the VGCC, alkyl groups have been tolerated at MDR-1.
(2) The size of the 4-aryl at the VGCC has strict limits, for example para-substitution is
known to lower activity whereas branching for MDR-1 dramatically enhances activity,
and the limits of substitution here have only been touched on in studies to date, it is likely
that additional lipophilic interactions are available at the transporter. (3) Esters of limited
size are tolerated at the "Port" side of the VGCC, where amide substitution with a linked
lipophilic group enhance MDR-1 activity. (4) Stereochemistry is critical at the VGCC,
with R>>S in most cases, where the efflux pump - as expected - is not particularly picky.
This opens the possibility for the use of the VGCC distomer to enhance selectivity at the
MDR-1. (5) Substitution at the DHP nitrogen or oxidation to the pyridine is well
recognized to abolish VGCC activity, whereas either is tolerated at MDR-1. Finally, it
was established by Triggle [118] that dimerization of DHPs did not give rise to an increase
in VGCC activity, while both the groups of Andrus [119] and Hrycyna and Chmielewski
[120-122]

have established that dimerization of MDR-1 substrates often produces more

active inhibitors. A combination of these factors could well give selectivity that presently
is unknown, and open the door for better theranostic candidates for multidrug resistance.
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Figure 1.10. Emerging SAR that allows for improvements in the Future Medicinal
Chemistry of IDHPs
1.16 Executive Summary
Introduction


Privileged Structures or scaffolds include isoxazoles and 1,4-dihydropyridines



The isoxazole structure was discovered by Claisen, and later found in nature and
useful in drug design



The 1,4-dihydropyridine (DHP) structure known since the work of Hantzsch is
well recognized as the scaffold for the antihypertensives of the nifedipine class



Representative connections of the heterocyclic rings in IDHPs



4',4-IDHP s and their intriguing conformational dynamics

IDHPs and their SAR at the Calcium Channel


Triggle has described the SAR of Aryl DHPs



Aryl DHP conformation likely relates to Ca2+ Channel activity
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IDHPs have characteristic conformational dynamics which significanty affect
their topology



We have developed a homology model for Ca2+ Channel activity of IDHPs which
explains their unique SAR

IDHPs and MDR: towards a working hypothesis


Current efforts to develop treatment for MDR are intensive



Aryl DHPs and the attempts at MDR modulation have provided useful SAR
insights



IDHPs bind MDR and we have developed a homology model as our current
working hypothesis

Future Perspective


Reduction of VGCC activity in IDHPs in favor of MDR1 activity can be driven
by known and emerging SAR



Among intriguing factors is stereochemistry, VGCC usually have a pronounced
eutomer, where MDR-1 is not particularly stereoselective, therefore the VGCC
distomer could be used to select for the MDR-1.



Current literature in dimers and MDR1 modulators suggests another promising
avenue for future study
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Chapter 2
The effect of bromine scanning around the phenyl group of 4-phenylhexahydroquinolone derivatives
2.1 Synopsis
In three quinolone compounds, the 1,4-dihydropyridine (1,4-DHP) rings adopt flat
boat conformations which are bisected by the plane of the pseudo-axial brominated aryl
ring. The cyclohexanone rings adopt envelope conformation. The packing of all the three
compounds are linked through intermolecular N—H…O hydrogen bonds.
2.2 Abstract
Three quinolone compounds were synthesized and crystalized in an effort to
study the calcium channel antagonists structure-activity relationship. In all three
quinolones,

ethyl

4-(4-bromophenyl)-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-

hexahydroquinoline-3-carboxylate (I), ethyl 4-(3-bromophenyl)-2,7,7-trimethyl-5-oxo1,4,5,6,7,8-hexahydroquinoline-3-carboxylate (II), and ethyl 4-(2-bromophenyl)-2,7,7trimethyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate (III), common structural
features such as the flat-boat conformation of 1,4-dihydropyridine (1,4-DHP) ring, the
envelop conformation of the fused cyclohexanone, and the bromophenyl ring at pseudoaxial position and orthogonal to the 1,4-DHP ring are retained. However, due to different
packing interactions in each compound, halogen bonds are observed in compounds (I)
and (III). Compound (III) was crystalized with two enantiomers in one asymmetric unit.
All of the prepared derivatives satisfy basic structural requirements to have moderate
activity as calcium channel antagonists.
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2.3 Introduction
The 1,4-dihydropyridine (1,4-DHP) heterocycle comprises a large family of
medicinally important compounds. The substructure has garnered the most attention as
calcium channel antagonists working as slow calcium channel blockers, which have been
used in the treatment of angina pectoris and hypertension. The examination of Hantzsch
1,4-dihydropyridine ester derivatives have produced more active and longer acting agents
than the prototypical nifedipine molecule. Many other derivatives have been synthesized
to yield compounds as calcium agonists or antagonists (Martin-Leon et al., 1995; Rose,
1990, 1992). A fused cyclohexanone ring is one of the modifications on 1,4-DHP
compounds, which have been shown to have moderate calcium antagonistic activity, as
well as modest anti-inflammatory and stem cell differentiation properties, and have been
implicated in slowing neurodegeneration disorders. Thus, further understanding of the
structure activity relationship will allow for the determination of off target activity and
the reduction of side effect. It has been proven that the flattened boat conformation of the
1,4-DHP ring is one factor that lead to higher calcium channel activity. The N1 and C4
atoms of the DHP ring can be marginally displaced from the mean plane of the boat
(Linden et al., 2002). An aryl group in the 4-position of 1,4-DHP is essential for optimal
activity. A study showed that the aryl ring with halogen or other electron-withdrawing
groups exhibited higher receptor-binding activity (Takahashi et al., 2008). On 1,4-DHP
ring, ester groups are usually substituted on 3- and 5- positions. It is suggested that at
least one cis- ester is required for the calcium antagonistic effect and H-bonding to the
receptor (Fossheim, 1986). In an effort to find more active calcium channel antagonists in
the 1,4-DHP genre, we synthesized a series of 1,4-DHP fused-ring derivatives –
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hexahydroquinolones. In this paper, we report three structures which have bromine
substituted on the para- meta- and ortho- positions on the phenyl moiety attached to the
1,4-DHP ring.

R3
R2

R1
O

O
O
N
H

I. R1 = R2 = H, R3 = Br
II. R1 = H, R2 = Br, R3 = H
III. R1 = Br, R2 = R3= H
Figure 2.1: General structure of the examined compounds
2.4 Synthesis and crystallization
An oven-dried 100 mL round bottom was charged with 0.757 g of dimedone,
0.703 g of ethyl acetoacetate, 0.170 g of ytterbium (III) trifluoromethanesulfonate and a
magenetic stir bar. The mixture was then taken up in 13.5 mL of absolute ethanol, capped
and put under an inert atmosphere of argon, after which the solution was allowed to stir at
room temperature for 20 min. Homologues 1.0 g (5.405 mmol) of bromo-benzaldehyde
and 0.419 g of ammonium acetate were added to the stirring solution, the solution was
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allowed to stir at room temperature for 48 hr. Reaction progress was monitored via TLC.
Once the reaction was complete, excess solvent was removed via rotary evaporation. The
solution was then purified via a silica column chromatography. The product was recrystallized into white to light yellow crystalline solids with hexane and ethyl acetate
[Compound (I) = 1.91 g, 4.57 mmol, 84.00%] [Compound (II) = 1.86 g, 4.45 mmol,
82.30%] [Compound (III) = 1.45 g, 3.466 mmol, 63.76%].
2.5 Characterization information
Melting points were determined in open capillary tubes with a Mel-Temp melting
point apparatus (200watts) and are uncorrected. Structures were confirmed with 1H and
13C NMR, and mass spectroscopy. H NMR spectra were obtained in chloroform-d1 using
a Bruker AMX-400 MHz spectrometer. Chemical shifts are reported as p.p.m. relative to
the tetramethylsilane (TMS). LC-MS (liquid chromatography-mass spectrometry) were
obtained using a Waters LCT Premier XE series spectrometer.
Ethyl 4-(4-bromophenyl)-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3carboxylate (I): 1H NMR: (CDCl3) δppm 7.31 (d, J=8.28Hz, 2H), 7.20 (d, J=8.28Hz,
2H), 6.01 (bs, 1H), 5.02 (s, 1H), 4.05 (q, J=7.03Hz, 2H), 2.38 (s, 3H), 2.21 (s, 2H),
2.17(s, 2H), 1.20 (t, J=7.15Hz, 3H), 1.08 (s, 3H), 0.93 (s, 6H). 13C NMR: (CDCl3) δppm
195.42, 167.19, 148.01, 146.07, 143.60, 130.96, 129.89, 119.82, 111.90, 105.72, 59.94,
50.69, 41.14, 36.33, 32.75, 29.44, 27.15, 19.49, 14.23. HRMS: calculated for
C21H24NO3Br, 418.1018; found, 418.1024. MS: m/z = 418 ([M+1] 100), 419 ([M+2] 10),
420 ([M+3] 100). MP: 254-255°. TLC: SiO2; Hexane:EtOAc 3:2 Rf = 0.19.
Ethyl 4-(3-bromophenyl)-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3carboxylate (II): 1H NMR: (CDCl3) δppm 7.41 (s, 1H), 7.26 (d, J=7.53Hz, 1H), 7.22 (d,
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J=8.53Hz, 1H), 7.07 (t, J=7.78Hz, 1H), 6.09 (bs, 1H), 5.03 (s, 1H), 4.07 (m, J=7.15Hz,
2H), 2.38 (s, 3H), 2.31 (s, 2H), 2.22 (s, 2H), 1.21 (t, J=7.15Hz, 3H), 1.09 (s, 3H), 0.96 (s,
6H). 13C NMR: (CDCl3) δppm 195.39, 167.15, 149.30, 148.24, 143.79, 131.09, 129.17,
126.97, 122.10, 111.71, 105.60, 59.96, 50.69, 41.12, 36.64, 32.78, 29.40, 27.22, 19.51,
14.21. HRMS: calculated for C21H24NO3Br, 418.1018; found, 418.0979. MS: m/z = 418
([M+1] 100), 419 ([M+2] 90). MP: 235-236°. TLC: SiO2; Hexane:EtOAc 3:2 Rf = 0.12.
Ethyl 4-(2-bromophenyl)-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3carboxylate (III): 1H NMR: (CDCl3) δppm 7.44 (dd, J=7.91Hz, 1H), 7.37(dd,
J=7.78Hz, 1H), 7.16 (tt, J=7.53Hz, 1H), 6.94 (tt, J=7.91Hz, 1H), 5.92 (bs, 1H), 5.37 (s,
1H), 4.08(m, J=7.15Hz, 2H), 2.32 (s, 3H), 2.30 (s, 2H), 2.19 (s, 2H), 1.18 (t, J=7.03Hz,
3H), 1.08 (s, 3H), 0.96 (s, 6H). 13C NMR: (CDCl3) δppm 195.30, 167.44, 148.04,
145.88, 143.22, 133.08, 132.03, 127.49, 126.97, 123.38, 111.74, 105.86, 59.84, 50.69,
41.29, 37.98, 32.58, 29.28, 27.38, 19.49, 14.36. HRMS: calculated for C21H24NO3Br ,
418.1018; found, 418.1037. MS: m/z = 417 ([M] 100), 418 ([M+1] 100), 419 ([M+2] 30).
MP: 200-204°. TLC: SiO2; Hexane:EtOAc 3:2 Rf = 0.23.
2.6 Refinement
Crystal data, data collection and structure refinement details are summarized in
Table 1. The methyl H atoms were constrained to an ideal geometry, with C – H = 0.98 Å
and Uiso(H) = 1.5Ueq(C), and were allowed to rotate freely about the C – C bonds. The
rest of the H atoms were placed in the calculated positions with C – H = 0.95 – 1.00 Å
and refined as riding on their carrier atoms with Uiso(H) = 1.2Ueq(C). The positions of
amine H atoms were determined from a difference Fourier maps and refined freely along
with their isotropic displacement parameters. Two low-angle reflections of (I) and four of
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(III) were omitted from the refinement because their observed intensities were much
lower than the calculated values as a result of being partially obscured by the beam stop.
2.7 Results and discussion
Both ethyl 4-(4-bromophenyl)-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8hexahydroquinoline-3- carboxylate (I) (Fig. 1) and ethyl 4-(3-bromophenyl)-2,7,7trimethyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3- carboxylate (II) (Fig. 2) crystallize in
the orthorhombic space group Pbcn with one molecule in the asymmetric unit. The
asymmetric unit of ethyl 4-(2-bromophenyl)-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8hexahydroquinoline-3- carboxylate (III) (Fig. 3) is composed of two enantiomers of (III),
which crystallize in the monoclinic space group P21/c. All three compounds have very
similar structural conformations, which accommodate the requirements for calcium
channel antagonists.
In all three structures, the 1,4-DHP ring is characterized by a shallow or flattened
boat conformation, one factor that leads to higher calcium channel activity. The boat
conformation can be quantified by the ring puckering parameters (Cremer & Pople,
1975). An ideal boat would have θ = 90° and φ = n×60°. In (I), the puckering parameters
are Q = 0.196 (2) Å, θ = 106.5 (6)°, and φ = 5.2 (8)° for the atom sequence N(1)-C(2)C(3)-C(4)-C(10)-C(9). The corresponding parameters for (II) are Q = 0.3014 (17) Å, θ =
107.1 (3)°, and φ = 0.9 (3)°. While for (III), two sets were obtained as QA = 0.162 (3) Å,
θA = 67.3 (10)°, and φA = 197.5 (10)° and QB = 0.279 (3) Å, θB = 106.9 (6)°, and φB = 3.9
(6)° for molecules A and B, respectively. The shallowness of the boat conformation is
indicated by the marginal displacements of N(1) and C(4) from the mean plane (the base
of the boat) defined by the two double bonds [C(2)=C(3) and C(10)=C(9)]. The deviation
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of the N(1) atom from the base of the boat is generally smaller , between 0.00 – 0.19 Å,
while the deviation of C(4) is most frequently found around 0.3 Å (Linden et al., 2004,
2005). These are also observed in our compounds: deviations of N(1) are 0.095(3) Å,
0.142(2) Å, 0.047(3) Å, and 0.134(3) Å for (I), (II), (III)A, and (III)B, respectively; and
the deviations of C(4) are 0.235 (4) Å, 0.365 (2) Å, 0.207 (4) Å, and 0.336 (4) Å for (I),
(II), (III)A, and (III)B, respectively. The sum of the absolute values of the ring internal
torsion angles is also considered a quantitative measure of the "flatness" of the 1,4-DHP
ring. With a flattened or unpuckered ring showing a 0° and 240° for an ideal boat
conformation of the ring. Our compounds show 67.74° for (I), 104.39° for (II), 55.72° for
(III)A and 96.52° for (III)B, indicating a flattened boat conformation, compared to the
sum of angles being 72° for nifedipine, the known standard for the 1,4-DHPs.
The relationship between the 1,4-DHP pyridine ring and the aryl group attached
to the C(4) position is another key factor of DHP structure activity relationship. It has
been reported that the pseudo-axial position of the aryl ring is essential for
pharmacological activity (Langs & Triggle, 1987). In our compounds, the bromophenyl
rings are almost orthogonal to the base of the 1,4-DHP ring defined by atoms C(2), C(3),
C(10), and C(9), with angles between mean planes [plane C(2), C(3), C(10), and C(9) to
plane C(17), C(18), C(19), C(20), C(21), and C(22)] to be 86.32 (8)°, 88.46 (5)°, 99.37
(8)°, and 89.36 (9)° for (I), (II), (III)A, and (III)B, respectively. Another quantitative
descriptive factor is the torsion angle between the N(1) – C(4) axis and the bond in the
phenyl group right above the 1,4-DHP ring [C(17) – C(18) in compounds (I) and (II) and
C(17) – C(22) in compound (III)]. The torsion angles defined by the N(1) – C(4) – C(17)
– C(18) are 6.75 (19)° and 7.14 (12)° for (I) and (II), respectively. The corresponding

60

torsion angles in compound (III) showed even more orthogonal configuration as the
values are 1.88 (18)° and 3.3 (2)° for (III)A and (III)B, respectively. The ortho-bromo
group is placed in a synperiplanar orientation with respect to the C(4) – H bond. Such
orientation has been observed in other ortho-substituted phenyl rings in 4-ary-1,4-DHP
compounds (Linden et al., 2004). It is worth noting that although meta-NO2 substitution
has been reported to be syn-periplanar to the H atom on C(4) carbon (Morales et al.,
1996), the meta-bromine in (II) is in anti-periplanar position. In the same manner as other
reported ortho-substituted structures, compound (III) has the bromine pointing away from
the DHP.
Due to the electron delocalization of the conjugate system, each ester group on the
1,4-DHP is coplanar and at cis orientation to the adjacent endocyclic double bond. The
coplanes extend out through the ester chains in (I) and (II). However, in (III), because of
different packing pattern, the end methyl group in (III)A curled up in the direction of aryl
group. As a result, it pushed the aryl group slightly away from the orthogonal position,
thus making the angle between 1,4-DHP and the aryl ring the most deviated from 90° –
99.37 (8)° in (III)A vs. 89.36 (9)° in (III)B.
Again, Cremer & Pople's ring puckering parameters are used to quantify the
conformation of the fused cyclohexanone ring. In all three compounds, the
cyclohexanone rings adopt the envelope conformation, which ideally would have θ =
54.7° (or θ = 125.3° in the case of absolute configuration change) and φ = n×60°. For
compound (I), the puckering parameters are Q = 0.447 (3) Å, θ = 57.4 (4)°, and φ = 178.6
(4)° for atom sequence C(5) – C(6) – C(7) – C(8) – C(9) – C(10). Correspondingly, for
the same atom sequence in compound (II), (III)A, and (III)B, the puckering parameters
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are Q = 0.4595 (18) Å, θ = 59.4 (2)°, and φ = 122.0 (3)°, Q = 0.462 (3) Å, θ = 122.5 (4)°,
and φ = 2.9 (4)°, Q = 0.477 (3) Å, θ = 59.4 (4)°, and φ = 183.4 (4)°, respectively. All
these parameters are very close to those of the ideal envelope conformation. Because of
the almost perfect envelope conformation, C(7) atom stands out from the plane formed by
the rest of the atoms in the ring and points to the same side as the C(4)-aryl ring. It is also
interesting that the axial methyl group on C(7) is almost syn-periplanar to the bond that
connects C(4) and the aryl ring. The relationship can be shown by the torsion angle of
C(11) – C(7) – C(4) – C(17), which is 13.86 (17)° for (I), 4.51 (13)° for (II), 16.2 (2)° for
(III)A and 5.5 (2)° for (III)B.
One feature, which has not been reported in this type of structures, is the
intermolecular halogen bonding between bromine and the ester carbonyl oxygen. A
halogen bond is defined as a short C – X ··· O – Y interaction, where the X ··· O distance
is less than or euqal to the sums of the respecetive van der Waals radii, 3.37 Å for Br ···
O in this case, with the C – X ··· O angle

165° and the X ··· O – Y angle

120°

(Auffinger et al., 2004). Although (II) has a distance of 3.4837 (14) Å, which is only
slightly longer than the sum of van der Waals radii, the angles being 166.17 (13)° for
Br(1) ... O(2) -- C(14) and 77.24 (6)° for C(19) -- Br(1) ... O(2) are out of range for
halogen bonds. However, the Br ··· O distance is 3.1976 (18) Å in (I) with C(20) –
Br(1) ··· O(2) angle to be 152.24 (9)° and Br(1) ··· O(2) – C(14) angle 111.06 (15)°. Also
in (III), the distance is 3.1764 (18) Å between Br(1A) and O(2B) and the angles are
106.79 (16)° and 160.65 (8)° for Br(1A) ··· O(2B) – C(14B) and C(18A) – Br(1A) ···
O(2B), respectively. These numbers fall into the range for halongen bonds. Halogen
bonding has been known for decades and has been found in biological systems, where the
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halogen acts as a Lewis acid and the interacting atom can be any electron-donating
moiety. For example, in addition to the backbone carbonyl oxygen as the most prominent
Lewis base involved in halogen bonds, hydroxyls and carboxyls in the side chain groups
can also form halogen bonds in the protein binding sites (Wilcken et al., 2013). The
possibility of halogen bonding from bromine in these three compounds needs to be
considered during the structure-activity relationship study.
In all three compounds, hydrogen bonds are formed between the N-H group and
carbonyl O atom in cyclohexanone of another molecule (Table 2, 3, and 4). The hydrogen
bonds link the molecules into extended chains running along c axis in both (I) and (II),
but along a axis in (III) (Fig. 4, 5, and 6). In compound (I), the largest difference hole of 1.21 which is 0.68 Å away from Br(1) may indicate a slight disorder of Br atom. In
conclusion, the structures reported here demonstrate that the conformational features
have been conserved in cyclohexanone-fused 1,4-DHP derivatives. As a promising base
structure for calcium channel antagonists, different substitutions and more structural
modifications are being carried on in our group. The progress will be reported in due
course.
For all structures: C21H24BrNO3, Mr = 418.32, Z = 8. Experiments were carried out at 100
K with Mo Kα radiation using a Bruker SMART BREEZE CCD diffractometer.
Refinement was with 0 restraints. H atoms were treated by a mixture of independent and
constrained refinement.
(I)

(II)

Crystal data
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(III)

Crystal system,
Orthorhombic, Pbcn

Orthorhombic, Pbcn

Monoclinic, P21/c

18.0371 (4), 15.4309

17.0813 (5), 15.4877

14.5012 (18), 18.299

(3), 14.2604 (3)

(5), 14.2544 (5)

(2), 15.1952 (19)

space group

a, b, c (Å)

90, 107.5262 (15),
α, β, γ (°)

90, 90, 90

90, 90, 90
90

V (Å3)

3969.08 (14)

3771.0 (2)

3844.9 (8)

µ (mm−1)

2.09

2.20

2.16

Crystal size (mm)

0.26 × 0.18 × 0.13

0.40 × 0.21 × 0.19

0.34 × 0.16 × 0.08

Multi-scan

Multi-scan

Multi-scan

SADABS v2012/1

SADABS V2012/1

SADABS v2012/1

(Bruker AXS Inc.)

(Bruker AXS Inc.)

(Bruker AXS Inc.)

0.909, 1.000

0.839, 1.000

0.866, 1.000

35271, 4558, 3391

55070, 5055, 4278

45465, 8935, 6859

Rint

0.038

0.032

0.065

(sin θ/λ)max (Å−1)

0.650

0.684

0.653

Data collection

Absorption
correction

Tmin, Tmax
No. of measured,
independent and
observed [I > 2σ(I)]
reflections

Refinement
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R[F2 > 2σ(F2)],
0.042, 0.101, 1.04

0.032, 0.084, 1.03

0.036, 0.081, 1.02

No. of reflections

4558

5055

8935

No. of parameters

243

243

485

1.31, −0.38

1.46, −0.47

2

wR(F ), S

Δρmax, Δρmin (e Å−3) 1.49, −1.21

Computer programs: Bruker APEX2, Bruker SAINT, SHELXS (Sheldrick, 2008),
SHELXL (Sheldrick, 2008), Olex2 (Dolomanov et al., 2009).
Table 2.1: Crystal Structure data
D—H···A

D—H (Å)

H···A (Å)

D···A (Å)

D—H···A (°)

N1—H1···O1i

0.89 (3)

1.94 (3)

2.812 (2)

168 (3)

Symmetry code(s): (i) x, −y, z−1/2.
Table 2.2: Selected hydrogen-bond parameters for (I)
D—H···A

D—H (Å)

H···A (Å)

D···A (Å)

D—H···A (°)

N1—H1···O1i

0.86 (2)

2.05 (2)

2.8896 (19)

166 (2)

Symmetry code(s): (i) x, −y, z−1/2.
Table 2.3: Selected hydrogen-bond parameters for (II)
D—H···A

D—H (Å)

H···A (Å)

D···A (Å)

D—H···A (°)

N1B—H1B···O1Ai

0.80 (3)

2.02 (3)

2.818 (3)

174 (3)

N1A—H1A···O1Bii

0.83 (3)

2.07 (3)

2.884 (3)

165 (2)

Symmetry code(s): (i) −x+1, y−1/2, −z+1/2; (ii) −x, y+1/2, −z+1/2.

65

Table 2.4: Selected hydrogen-bond parameters for (III)

Figure 2.2 The asymmetric unit of (I), showing the atom-labelling scheme with
displacement ellipsoids at 50% probability level.
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Figure 2.3 The asymmetric unit of (II), showing the atom-labelling scheme with
displacement ellipsoids at 50% probability level.

67

Figure 2.4 The asymmetric unit of (III), showing the atom-labelling scheme with
displacement ellipsoids at 50% probability level.
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Figure 2.5 Part of the crystal structure of (I), showing the formation of chains of
molecules running along c axis. Hydrogen bonds are indicated by dashed lines. For the
sake of clarity, H atoms not involved in hydrogen bonding have been omitted.
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Figure 2.6 Part of the crystal structure of (II), showing the formation of chains of
molecules running along c axis. Hydrogen bonds are indicated by dashed lines. For the
sake of clarity, H atoms not involved in hydrogen bonding have been omitted.
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Figure 2.7 Part of the crystal structure of (III), showing the formation of chains of
molecules running along a axis. Hydrogen bonds are indicated by dashed lines. For the
sake of clarity, H atoms not involved in hydrogen bonding have been omitted.
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Chapter 3
Diethyl 4-(biphenyl-4-yl)-1,4-dihydropyridine-3,5-dicarboxylate
3.1 Abstract
The titled compound, C24H25NO4, has a flattened dihydropyridine ring and phenyl
groups that are synclinal to one another. The calculated angle between the two planes of
the phenyl groups is 49.82 (8)o; the axis of the biphenyl rings [C(14)-C(23)] has an 81.05
(9)o angle to the plane of the dihydropyridine ring [C(1)-C(2)-C(4)-C(5)]. The plane of
the central phenyl ring [C(14)-C(15)-C(16)-C(17)-C(18)-C(19)] has 47.77 (8)o angle
from the N(1) and C(3) axis in the dihydropyridine ring. The packing of the molecule
shows strong π-stacking interactions between intermolecular phenyl rings. Intermolecular
hydrogen bonds are also observed.

Figure 3.1: Strucure of the titled compound
3.2 Related Literature
For general structure-activity relationship study of 1,4-dihydropyridines (DHPs)
on calcium channel, see: Bossert et al. (1981) and Triggle (2003). For the binding studies
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of DHPs to multiple drug resistant protein 1 (MDR1), see: Abe et al. (1995), Cole et al.
(1989), Tasaki et al. (1995), Vanhoefer et al. (1999), Tolomero et al. (1994), and Cindric
et al. (2010).
3.3 Comment
Hantzsch 1,4-dihydropyridines (DHPs) are an extensively studied class of
compounds that are known predominantly for their L-type voltage gated calcium channel
modulation. (Bossert et al. 1981, Triggle 2003) There have been extensive structureactivity relationship (SAR) studies done on DHPs that have revealed the basic structural
requirements for robust binding affinity to calcium channels. (Triggle 2003) Other studies
in the field have shown that DHPs bind to multiple receptors, most notably the multiple
drug resistant protein 1 (MDR1) (Abe et al. 1995, Cole et al. 1989, Tasaki et al. 1995,
Vanhoefer et al. 1999, Tolomero et al. 1994, Cindric et al. 2010). Using established SAR
more selective compounds can be designed for greater selectivity resulting in more
clinically relevant compounds.
The title compound, C24H25NO4, has very similar structural feature as other
DHPs. Such features include a flattened boat conformation of the 1,4-DHP ring and two
ester groups coplanar to the double bonds in the 1,4-DHP, with one carbonyl being cis
and the other carbonyl being trans to the double bonds (Figure 1). Although the phenyl
group attached at C(3) is still orthogonal to the bottom [C(1)-C(2)-C(4)-C(5)] of 1,4-DHP
ring (81.05 (9)o), it twists away from the N(1)-C(3) axis with the degree of 47.77 (8)o.
The next phenyl ring twists again, with 49.82(8)o from the center phenyl group,and
becomes almost orthogonal to the N(1)-C(3) axis [12.97(9)o]. Upon anexpanded view, the
π-π stacking between the biphenyl groups from two molecules can be easily seen (Figure
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2). The distances from one biphenyl group to another are 6.771 (3) Ǻ and 6.510 (3) Ǻ for
the two phenyl rings. The packing of this molecule also involves intermolecular hydrogen
bonding between N(1)-H(1)-O(3) with a distance between H(1)-O(3) of 2.029 Ǻ.
3.4 Synthesis and crystallization
An oven-dried 100 mL round bottom flask was charged with 1.90g of biphenyl-4carbaldehyde, 2.86 g of ethyl acetoacetate, 2.49 mL of 14.8M ammonium hydroxide, and
a magenetic stir bar. The mixture was taken up in 50mL of absolute ethanol, and the
round bottom flask was fitted with a dean stark trap and heated until reflux while stirring.
Reaction progress was monitored via TLC. Once the reaction was complete, excess
solvent was removed via rotovap. The solution was then purified via a silica column. The
product was re-crystallized into white to yellow crystalline clumps with hexane and
dichloromethane (yield = 1.24g , 3.06 mmol, 29.31%).
3.4 Refinement
Crystal data, data collection and structure refinement details are summarized in
Table 1. The methyl H atoms were constrained to an ideal geometry, with C -- H = 0.98
Ǻ and Uiso (H) = 1.5 Ueq (C), and were allowed to rotate freely about the C -- C bonds.
The rest of the H atoms were placed in the calculated positions with C -- H = 0.95 \~ 1.00
Ǻ and refined as riding on their carrier atoms with Uiso (H) = 1.2 Ueq (C). The positions
of amine H atoms were determined from a difference Fourier maps and refined freely
along with their isotropic displacement parameters. One low-angle reflection was omitted
from the refinement because its observed intensity was much lower than the calculated
value as a result of being partially obscured by the beam stop.
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Crystal data
C25H27NO4

γ = 73.530 (2)°

Mr = 405.47

V = 1031.25 (7) Å3

Triclinic, P

Z=2

a = 7.3431 (3) Å

Mo Kα radiation

b = 10.6075 (4) Å

µ = 0.09 mm−1

c = 13.8449 (6) Å

T = 100 K

α = 85.762 (3)°

0.15 × 0.14 × 0.13 mm

β = 88.124 (3)°
Data collection
Bruker SMART BREEZE CCD
4752 independent reflections
diffractometer
Absorption correction: multi-scan
SADABS V2012/1 (Bruker AXS

2983 reflections with I > 2σ(I)

Inc.)
Tmin = 0.919, Tmax = 1.000

Rint = 0.072

19956 measured reflections

θmax = 27.6°

Refinement
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R[F2 > 2σ(F2)] = 0.062

0 restraints
H atoms treated by a mixture of

wR(F2) = 0.149
independent and constrained refinement
S = 1.01

Δρmax = 0.43 e Å−3

4752 reflections

Δρmin = −0.37 e Å−3

279 parameters
Table 3.1: Crystal Data

D—H···A

D—H

H···A

D···A

D—H···A

C13—H13B···O2

0.98

2.11

2.857 (3)

131.2

N1—H1···O3i

0.91 (3)

2.03 (3)

2.938 (3)

173 (2)

Symmetry code: (i) x+1, y, z.
Tabel 3.2 Hydrogen-bond geometry
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Figure 3.2 : Crystal structure of the title compound with labeling and displacement
ellipsoids at the 50% probability level.
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Figure 3.3: Packing diagram of the title compound, showing the intermolecular hydrogen
bonds which form chain motifs running along the α axis. For the sake of clarity, H atoms
that are not involved in H-bounds are removed.

Figure 3.4: Packing diagrams of the title compound, showing intermolecular C-H ∙∙∙ O
interactions in dashed lines which cross link the molecules into a sheet motif running
81

slightly off the 110 plane. For the sake of clarity, H atoms not involved in the interaction
are removed

Figure 3.5: Packing diagram of the title compound. The intermolecular interaction from
the three dimensional network in the crystal packing. For the sake of clarity, H atoms that
are not involved in the interactions are removed.
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Chapter 4
Dimeric isoxazolyl-1,4-dihydropyridines inhibitors of the multidrug resistance
transporter-1 (MDR-1)
4.1 Dimeric Compounds Used as MDR1 Modulators
The multidrug resistance transporter-1's (MDR1's) role in altering the
uptake, distribution and bioavailability of xenobiotics is well known. MDR1 has
also been shown to be a major contributor to the development of MDR in cancer,
via preventing entry of therapeutically relevant drugs into the cancerous cell. As
such, MDR1 is highly investigated as a drug target both for controlling
absorption, distribution, metabolism and excretion (ADME) of clinically relevant
compounds and for the production of MDR inhibitors. However, the lack of
effective third generation inhibitors in clinical trials has cast doubt on the
usefulness of compounds that inhibit MDR in cancer treatment.[1,2,3] The
observation that dihydropyridines (DHPs) nicardipine[4] and niguldipine[5,6]
exhibit activity as inhibitors of MDR1[7] has stimulated renewed interest in DHPs
as MDR1 inhibitors and is currently being investigated by multiple groups.[8,9,10]
A relatively new approach in drug design and one that is being utilized
here, is the development of bivalent compounds.[11] Pharmacophore modeling for
MDR-1 indicates several common features for inhibitors,[12,13] notably at least two
aryl pockets, and a tether of approximately 3-5 methylenes, leading to another
functional group that possesses H-bond donor and lipophilic groups.[14] This is in
agreement with previous indications that point to the existence of at least two
spatially distant substrate binding sites inside the nucleotide binding domain
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(NBDs).[15,16] Two distinct binding sites provide the opportunity to inhibit MDR1
in two sites at the same time and as an affect exert twice the inhibitory activity.
Designing multivalent inhibitors that interact at both potential binding sites is an
attractive opportunity for the synthetic chemist to design MDR1 inhibitors.
In the vein of building on this research, some groups have prepared
dimeric inhibitors that have shown improved inhibitory activity verses their
monomer counterparts. Chmielewski’s group used quinine and quinidine as a
starting point (known compounds that are transported by MDR1) and observed
that dimeric derivatives have been shown to have inhibitory activity at
MDR1.[17][18] Andrus’s group has designed stipiamide homodimers that have
shown robust MDR1 inhibitory activity.[19] The synthesized dimers were cross
linked with hydropholic polyethylene glycol (PEG) based tethers and found an
optimum inhibitor of MDR1 with a tether length of approximately 35 Ǻ.[19] Early
work with dimers experimented with different tether compounds include emetine,
abacavir, quinine and quetiapine and have shown overall increased activity.[20,21]
Our hypothesis is that developing dimeric isoxazole-DHPs (IDHPs)
should have an increase in activity, based on the existing precedent that dimers
have a general trend in the literature of showing increased activity due to the
possibility that MDR1 can simultaneously bind two ligands.[22,23] Thus, a
polyvalent inhibitor would bind more tightly to MDR1 and thus be an effective
inhibitor. Additionally, dimeric compounds may introduce an element of
selectivity. In his study of dimeric tethered DHPs at the voltage gated calcium
channel (VGCC), Triggle found that analogs possessing a second 1,4-DHP
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nucleus or possessing an inactive pyridine were less active, leading to the
conclusion that such dimers likely do not bridge adjacent VGCC subunits. We
reasoned we could use this observation, together with other known VGCC
structure-activity relationships (SAR), to design greater selectivity for MDR1 into
the IDHPs. With this general goal, we employed computational modeling as a
guide to direct our synthetic efforts.

Figure 4.1: (left)The calculated distance between the Q-Site binding sites residing
proximal to the nucleotide binding domains in the non-ATP bound state(apo) of MDR-1.
(right) The calculated distance between the C4 position of the IDHP and the variation in
the distance as the tether length increases.
Figure 4.1 shows the non-ATP bound state of MDR1 and the calculated distance
between the two NDBs. The calculated distance of 42.5 Ǻ represents the open to the
inside conformation of MDR1 and as such will be the maximum distance that the NBDs
will be separated. The NBDs will move towards each other after ATP hydrolysis and the
42.5Ǻ distance will become substantially shorter as a result, reaching the minimum
distance in the open-to-outside conformation of 12.7Å. Using our model of the apo state,
we used this as a guide to direct and synthesize bivalent IDHPs with a tether of 34.7Ǻ.
This is consistent with work done by Andrus, his study utilizing stimpiamide dimers
showed that MDR1 inhibition dramatically increases with dimers that were around 20Ǻ.
Thus, the proposed bivalent IDHPs should be an ideal substrate for MDR1 and will trap
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MDR1 in an intermediate inactive state. The direct measurement of the binding affinity
of MDR1 for these compounds is useful in evaluating the computer model and predicting
the overall performance of other potential inhibitors. Additionally, the use of these
divalent IDHP adducts can provide some valuable information on the size of the
substrate-binding pocket and it ability to accommodate multiple drugs.
Our research group has previously prepared divalent DHP-fluorophore conjugates
which were linked by hydrocarbon tethers,[24] but we wish to explore the potential
advantages of longer PEG based tethers in this study. Due to the calculated distances
between our putative targets we wanted to utilize a PEG tether due to the longer distances
we wish to span, since our previous study experimented with hydrocarbon tethers,
wherein folding by hydrophobic collapse was a concern. With a PEG tether we propose
that a PEG won’t undergo hydrophobic collapse in the binding cavity, and as such can be
used as a bridge between the two DHP binding sites. This will potentially allow for both
DHP sites to be blocked at the same time, without the issue of the tether folding. The end
result will be halted function of MDR1.
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Figure 4.2: Synthetic route for synthesis dimeric IDHPs
The synthesis of a library of compounds such as this is difficult and requires
multiple synthetic steps to achieve the target compounds. The DHP substructure is
synthesized from commercially available Bromobenzaldehydes as starting materials. The
aldehyde is converted to an oxime, and followed by conversion to a
bromobenzohydroximinoyl chloride via reaction with N-Chloro succinimide (NCS).
Ethyl acetoacetate was used to perform a cycloaddition in the presence of sodium
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ethoxide.[25] After the cycloaddition the carboxyl group is reduced to the hydroxyl via
Lithium Aluminum hydride (LAH) reduction.[26] The resulting hydroxyl is then oxidized
via Pyridinium Chlorochromate (PCC) to produce the isoxazolyl aldehydes (1a-d). While
these steps have been described previously, it should be noted that the isoxazole
aldehydes (1) in Scheme 4-2 were not commercially available. The isoxazole aldehydes
(1 a-d) were then reacted with ethyl acetoacetate in a Knoevenagel condensation reaction
to produce half of the desired IDHP(2a-d).[27] To produce the other half of the
unsymmetrical IDHP, boronic acid catalyzed transesterification of ethyl acetoacetate with
propargyl alcohol is used to produce prop-2-yn-1-yl 3-oxobutanoate (not shown).[28]
Prop-2-yn-1-yl 3-oxobutanoate is then reacted with the Knoevenagel product (2a-d) to
finish the Hantzsch pyridine synthesis and achieve the desired DHP substructures (4ad).[29] To attach the PEG tether to the synthesized DHP(4a-d)we utilized click
chemistry.[30]A commercially available diol was used as a starting material for the PEG
tether substructure. The diol was mesylated via the reaction with methanesulfonyl
chloride and a PEG dimesylate results. The dimesylate was then reacted with sodium
azide, to provide the diazides (3a-c). The diazide was then reacted with the
unsymmetrical DHP (4a-d) via a copper catalyzed click reaction, forming a triazole ring
in the process (5a-d).[31] Compound 6 was synthesized in a similar matter, utilizing the
unsymmetrical DHP(4d) and clicking it with an azide formed from the commercially
available phenethyl alcohol, initially envisioned as a triazole control (vide infra). By
varying tether lengths as well as conducting a bromine scan around the 3-isoxazolylphenyl group allows us to examine SAR factors for this series of compounds.
4.2 Single Crystal X-ray Diffractometry of 7.c

89

The conformation of DHPs is important to their structure activity relationships,
and IDHPs have particularly pronounced divergent topologies dependent on rotation
about the bond joining the heterocyclic rings. In the VGCC arena, several parameters
have been found to correlate with biological activity: the conformation of the esters at C3 and C-5 of the DHP, and the sum of the six intraring torsion angle in the flattened boat
conformation of the DHP. We had earlier postulated that the heterocyclic ring juncture
could well adapt divergent conformations dependent on the biomolecular target. We have
found single crystal x-ray diffractometry useful to help inform our computational studies
on rotational barriers and drug-receptor modeling.
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Crystal data
C23H25BrN2O5
Mr = 489.36

Dx = 1.459 Mg m−3

Monoclinic, C2/c

Melting point: ? K

a = 17.6211 (9) Å

? radiation, λ = 0.71073 Å

b = 15.3041 (8) Å

Cell parameters from 323
reflections

c = 17.9370 (9) Å

θ = 3.4–28.4°

β = 112.8770 (6)°

µ = 1.88 mm−1

V = 4456.7 (4) Å3

T = 100 K

Z=8

Prism, clear pale yellow

F(000) = 2016

0.52 × 0.51 × 0.24 mm

Data collection
?
diffractometer

4567 independent reflections

Radiation source: ?

4179 reflections with I > 2σ(I)

? monochromator

Rint = 0.021

Detector resolution: 8.3333 pixels
mm-1

θmax = 26.4°, θmin = 1.8°

Absorption correction: numerical
SADABS V2012/1 (Bruker AXS
Inc.)

h = −22 21

Tmin = 0.41, Tmax = 0.66

k = −19 19

24782 measured reflections

l = −22 22

Refinement
Refinement on F2

Secondary atom site location: ?

Least-squares matrix: full

Hydrogen site location: inferred from
neighbouring sites

R[F2 > 2σ(F2)] = 0.035

H-atom parameters constrained
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wR(F2) = 0.098

w = 1/[σ2(Fo2) + (0.0521P)2 + 9.9351P]
where P = (Fo2 + 2Fc2)/3

S = 1.07

(Δ/σ)max = 0.002

4567 reflections

Δρmax = 1.46 e Å−3

285 parameters

Δρmin = −0.45 e Å−3

80 restraints

Extinction correction: none

Tables containing the Fractional atomic coordinates and isotropic or equivalent isotropic
displacement parameters (Å2), Atomic displacement parameters (Å2), and Geometric
parameters (Å, °) are given in the Experimental Section.
4.3 Important Intermolecular interactions of 7c.
There is a plausible Halogen bond in the sc-xrd, as defined by the Br1 to O3'
distance of 3.363Å and halogen to nucleophile angle of 143.1o, which are within the
tolerances for a moderate strength halogen bond according to the criteria suggested by
Auffinger [32], and Wilcken.[33] The distance of the amine is another predicted key factor
for the activity of both the VGCC and MDR. The distance of the hydrogen bound in the
structure is 0.880 Å. The crystal structure shows hydrogen bounding interactions with the
oxygen of an adjacent isoxzaole, O1 with the hydrogen bound to N1 of the DHP. This
interaction could be indicative of key hydrogen bounding interactions with a given
receptors.
4.4 Biological Activity: Comparison of binding at MDR1, the VGCC and mGluR.
While testing at the VGCC is used to establish reactivity with a known binding
receptor for DHPs, the mGluR5 binding was used to establish general off target binding.
mGluR5 is a 7HTM and as such it shares general receptor topology and binding at other
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ubiquitous 7HTM receptors. As such, mGluR5 binding can be seen as a general measure
of promiscuous off target binding.
Structure

R

n

VGCC (nM)

mGluR5 (nM)

MDR-1
(%)
H
0
13.9
ND
48.95
7.a
o-Br
0
909
1,524
59.6
7.b
m-Br
0
208
>10,000
82.1
7.c
p-Br
0
36
>10,000
62.3
7.d
H
5
>10,000
>10,000
49.2
5.a
o-Br
5
>10,000
4,858
78.9
5.b
m-Br
5
3,766
8,638
146.6
5.c
p-Br
5
2,706
193
130.1
5.d
p-Br
3
516
546
30.4
5.e
p-Br
2
603
933
102.9
5.f
p-Br
0
127
1,972
202.7
6
H
0
>10,000
>10,000
102.4
8
Table 4.1: Summary of biological evaluation of Dimer IDHPs and relevant controls.
As a general statement, increased activity is observed with the inclusion of a
triazole, as seen by both the activity of the dimers (5a-f) and with the click control (8),
when comparing them to the monomers (7a-d) and the pyridine (8). The monomeric
IDHPs(7a-d) exhibit robust calcium antagonist activity; and given Natale's previous work
in the field this would be expected. The relationship of activity to substitution at the 3aryl-isoxazole position is as followed p-(7d) > m-(7c) > o-(7b) and is consistent with
previous observations. However, the range is more pronounced for the Br series, with the
p-(7d) over 25 times more potent than the o-, which may be attributed to the halogen
bonding evidenced in the sc-xrd. The relationship for substitution at the isoxazole 3-aryl
is maintained in both monomers(7a-d) and dimers(5a-f), with the activity following a
trend of m-Br > p-Br > o-Br > H, however, the m-Br (5c) and p-Br (5d) dimers have
significantly more binding potency at MDR1.
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The purpose of testing against three different receptor types is to examine
selectivity factors that structural variations can have an effect on. The isoxazolylpyridine, (8) shows the greatest level of selectivity with regards to MDR1. Oxidation to
the pyridine removes the potential hydrogen bound interactions from of the 1,4dihydropyridne nitrogen, this would be predicted to abolish VGCC activity. This was
found to be the case, essentially abolishing the activity at both the VGCC and mGluR5,
however its binding at the MDR1 was comparable to the cyclosporine A control. The
effect of dimerization on the other hand is dramatic when considering selectivity. The
effect of differing tether lengths presents a potential factor to engineer selectivity into
compounds, with longer tethers being more selective for MDR1, and shorter tether
showing more polypharmacology. Contrasting monomeric (7a-d) and dimeric (5a-f)
compounds VGCC activity is essentially abolished for the dimer. The most active MDR1
inhibitor in the series,(6) shows a good deal of poly pharmacology which is consistent
with the observation of shorter tethered compounds in the series. A more in-depth
examination of the compound and the factors that contribute to its activity will be
examined with computational modeling.
4.5 Computational Model for the most efficacious IDHP 6 at MDR1.
The mammalian MDR1 homology model that was engineered previously is
utilized again here to explore the SAR function of the best compound.[34] The proposed
binding box that was established in our previous work is the site that was used to localize
binding calculations. The best MDR1 inhibitor, compound 6, was calculated to bind in
the previously defined, medium affinity cohort with the tethered end of the compound
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extending into the high affinity cohort. The position of the compound as a whole is in
agreement with previous generations of tethered compound development.

Figure 4.3: Binding calculations of the best binder in the series, compound 6 Table 4-1.
Amino acid residues highlighted in purple are the overlap between the DHP covalent
affinity site and the calculated binding site predicted by Q-site finder (Chapter 1, op cit).
A 6Ǻ sphere around compound 6 was then examined to establish close contacts
and construct an SAR. The process taken to establish close contacts and develop an SAR
is identical to that taken in the first generation of compound development (Chapter 1). As
such, the process for this generation of SAR development is truncated and simplified, by
comparison. To simplify the close contact interactions to a manageable amount of data
compound 6 was broken done into three defined binding regions.
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Figure 4.4: Predicted close contact interactions of compound 6.
Close contact interactions were then consolidated into a single figure (Figure 4.4),
to produce an SAR. The majority of interactions new to this series are consolidated on the
triazole substructure along with defined anchoring interaction on the phenethyl portion of
the compound. This is in addition to the interactions that anchor the IDHP substructure,
resulting in a logical increase in binding affinity.
The dimeric compounds were also examined by computational modeling. The
compounds where found to have a number of binding interactions with the PEG tether
clustered in the vicinity of the ATP binding site of MDR1. Thus, the enhanced binding of
dimers my simply arise from the sum of both IDHPs which cluster on the edge of the
site, in addition to the PEG interactions with polar amino acid residues in the ATP site.
The improved activity is another positive trend when comparing drug development
generations. The central pharmacophore of the first generation compounds, the 3-phenyl-
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5-methyl-IDHP, exhibited an inhibitory activity of 48.9% versus cyclosporine A. The
currently most active compound 6 exhibited an inhibitory activity of 202.7%, twice as
efficacious as the cyclosporine A control, a substantial and significant improvement.
Given that cyclosporine A inhibition is known to be around 800-900 nMol[35] at MDR1,
and that compound 6 shows roughly twice the inhibition of cyclosporine A. Thus,
compound 6 can then be assigned as a sub mMol inhibitor.
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Figure 4.5: Computational Drug-receptor interaction for the most active compound at
MDR1.
With the general trend for this generation of compound showing that dimerization
increases activity, we want to further explore selectivity factors that we can introduce
with synthetic modifications. The next generation of compound development (vide infra,
Chapter 5) will focus on increasing selectivity factors while retaining our present level of
inhibitory activity. With our lead compound 6 being more inherently “drug like” than the
dimer compound (based primarily on the MW guidelines of Lipinski) our focus will be
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directed at modifications to the compound 6 core structure. With this in mind, we
examined the aspects that the previous generations have established and what aspects of
the SAR we can leverage to increase selectivity. The continued examination and progress
to this goal will be elaborated on in future chapters.

4.6 Experimental
Synthesis of 1-Azido-2-[2-(2-{2-[2-(2-azido-ethoxy)-ethoxy]-ethoxy}-ethoxy)-ethoxy]ethane. (3.a.) An oven dried round bottom flask (10mL) was charged with 1.0g of
hexaethylene glycol (0.282 mmol), 0.717g of Et3N, and 6.0mL of CH2Cl2 with a
magnetic stir bar at room temperature. The round bottom was then capped with a rubber
septa placed under an argon atmosphere. A solution of CaCl2 and water (25g/200mL) was
then made and placed in an insulated container. The round bottom was then placed in the
CaCl2/water solution and dry ice was added, the solution was then allowed to reach 25°C. 0.830mL of MsCl was then added via gas-tight syringe. The reaction was then kept
at -25°C for two hours. The reaction yielded a white-cream solution. Excess solvent was
then removed via rotovap. The same 10mL round bottom was then charged with 8mL of
EtOH and 0.464g of NaN3 at room temperature. The round bottom was fitted with a
condenser and was then heated to reflux (79-80°C) for an hour. The reaction yielded an
orange solution. The solution was then extracted with EtOAc and brine three times, and
dried over NaSO4. The solution was then contracted via rotovap yielding yellow-gold oil.
(1.187g, 3.52 mmol, 98%)
1

H NMR: (CDCl3) δ 3.54 (bs 16H), 3.26 (bs 4H), 1.5 (s 4H)

13

C NMR: (CDCl3) δ 70.51, 69.88, 50.33
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MS: m/z = 332.18 (m+ 1 ,100% rel. intensity) 333.156 (100), 373.24(70)
TLC: SiO2; EtOAc; Rf = 0.49
1-Azido-2-{2-[2-(2-azido-ethoxy)-ethoxy]-ethoxy}-ethane (3.b.)
1

H NMR: (CDCl3) δ 3.54 (bs 8H), 3.25(bs 4H), 1.46 (s 4H)

13

C NMR: (CDCl3) δ 71.23, 68.75, 51.02

TLC: SiO2; EtOAc 4:1 Rf = 0.36
1-Azido-2-[2-(2-azido-ethoxy)-ethoxy]-ethane (3.c.)
1

H NMR: (CDCl3) δ 3.53 (bs 4H), 3.25(bs 4H), 1.27(bs 4H)

13

C NMR: (CDCl3) δ 70.83, 68.36, 50.56

TLC: SiO2; EtOAc 4:1 Rf = .46
General synthesis of 4-Bromo-benzaldehyde oxime. An oven dried round bottom
(250mL) was charged with 4.3g of 4-bromobenzaldhyde, 3.012g of NH2OH*HCl, and
5.27g of NaCH3CO2. A mixture of THF:EtOH:H2O(2:1:1) was made (60mL) and added
at room temperature to the round bottom along with a magnetic stir bar. The round
bottom was then capped and allowed to stir for 72 hours. The reaction yielded a whitecream color solution. The solution was then extracted with CHCl3 and Brine three times,
and dried over NaSO4. The solution was then concentrated via rotovap yielding a white
solid. (4.24g, 21.692 mmol, 99%)
1

H NMR: (CDCl3) δ 8.08 (d 1H J = 2.20Hz), 7.51 (d 2H J = 0.01Hz), 7.46 (d, 2H J =

0.01), 2.18 (s 1H)
13

C NMR: (CDCl3) δ 149.41, 132.04, 130.78, 128.44, 124.33

MS: m/z = 199 (M+, 100% rel. intensity), 240 ([M+]+CH3CN, 100)
TLC: SiO2; Hexane:EtOAc 9:1 Rf = 0.22
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mp: 112°C (dec.)
2-Bromo-benzaldehyde oxime
1

H NMR: (CDCl3) δ 8.54 (s 1H), 7.58 (d 2H J = 0.01Hz), 7.26 (d 2H J = 0.01), 2.15 (s

1H)
13

C NMR: (CDCl3) δ 149.83, 133.18, 131.26, 127.62, 127.45, 123.86

TLC: SiO2; Hexane:EtOAc 9:1 Rf = 0.32
mp: 94°C (dec.)
3-Bromo-benzaldehyde oxime
1

H NMR: (CDCl3) δ 8.10 (s 1H), 7.74 (s 1H), 7.52 (q 1H J = 0.01Hz), 7.50 (q 1H J =

0.01Hz), 2.13 (s 1H)
13

C NMR: (CDCl3) δ 149.06, 133.87, 132.99, 130.30, 129.79, 125.69, 122.93

TLC: SiO2; Hexane:EtOAc 9:1 Rf = 0.52
mp: 58°C (dec.)
General synthesis of Bromobenzohydroximinoyl chloride. An oven dried round
bottom (250mL) was charged with a magnetic stir bar, 2.78g (0.556 mmol) of 4bromobenzaldehyde oxime, 2.07g (0.276 mmol) of NCS, 0.188 g of pyridine, and
13.2mL of CHCl3 at room temperature. A mineral oil bath was then heated to 40°C and
the round bottom was then placed in the bath for five hours. The reaction yielded a light
yellow solution. The solution was then extracted with CH2Cl2 and brine three times with
50mL, and dried over NaSO4. The solution was then contracted via rotovap yielding a
white-cream solid. (3.139 g; 13.477 mmol; 96.95%)
1

H NMR: (CDCl3) δ 7.70 (d 2H J = 9.23Hz), 7.55 (d, 2H J = 9.65Hz), 2.21 (s 1H)

13

C NMR: (CDCl3) δ 164.24, 130.24, 131.26, 132.51, 125.67
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MS: m/z = 232(M+,100% rel. intensity) 231.94 (M+1, 100), 273 ([M+]+CH3CN 60)
mp: 80.5°C (dec.)
TLC: SiO2; Hexane:EtOAc 10:1 Rf = 0.36
General synthesis of 3-(4-Bromo-phenyl)-5-methyl-isoxazole-4-carboxylic acid ethyl
ester. An oven dried round bottom(500mL) was charged with 5.069g (1.188 mmol) of 4Bromobenzohydroximinoyl chloride, and left under the high vacuum over night. Another
oven dried round bottom (500mL) was charged with 274.99mL of EtOH, and a magnetic
stir bar, the round bottom was then capped with a rubber septum and placed under an
argon environment. 1.29g (0.030 mmol) of Na was then weight out and placed in the
EtOH, the solution was then stirred and the Na was allowed to dissolve. The round
bottom with 4-Bromobenzohydroximinoyl chloride was then removed from the high
vacuum and 7.32 g (0.953 mmol) of ethyl acetoacetate was added. The round bottom was
then capped with a rubber septum and placed under an argon environment. The Na/EtOH
mixture was then added to the 4-Bromobenzohydroximinoyl chloride/ ethyl acetoacetate
mixture at room temperature. The round bottom was then capped with a rubber septum
and placed under an argon environment. The solution was then stirred for three hours.
The solution was then extracted with CHCl3 and Brine three times with 50 mL, and dried
over NaSO4. The solution was then concentrated via rotovap yielding a yellow oil. The
solution was then purified via a silica column. The purification compound yielded a white
solid (2.109g, 6.80 mmol, 45.43%)
1

H NMR: (CDCl3) δ 7.55 (d 2H J = 8.56Hz), 7.50 (d 2H J = 8.56Hz) 4.25 (q 2H J =

7.09Hz), 2.71 (s 3H), 1.24 (t 3H J = 7.09Hz)
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13

C NMR: (CDCl3) δ 176.06, 161.72, 161.63, 131.19, 131.04, 127.42, 124.27, 108.29,

60.85, 29.71, 14.06, 13.66
MS: m/z = 309 (M+, 100% rel. intensity) 311.02(M+2, 100), 350.78 ([M+]+CH3CN, 50)
TLC: SiO2; Hexane:EtOAc 10:1 Rf = 0.33
mp: 71-72°C (dec.)
3-(2-Bromo-phenyl)-5-methyl-isoxazole-4-carboxylic acid ethyl ester
1

H NMR: (CDCl3) δ 7.63 (d 1H J = 7.34Hz), 7.36 (s 1H), 7.32 (s 1H), 7.31 (s 1H), 4.12

(q 2H J = 6.36Hz), 2.74 (s 1H), 1.05 (t 3H J = 5.87Hz)
13

C NMR: (CDCl3) δ 170.42, 157.30, 156.77, 127.66, 126.19, 126.06, 122.29, 188.82,

104.95, 55.84, 8.45
TLC: SiO2; Hexane:EtOAc 10:1 Rf = 0.26
3-(3-Bromo-phenyl)-5-methyl-isoxazole-4-carboxylic acid ethyl ester
1

H NMR: (CDCl3) δ 7.79 (s 1H), 7.59 (q 2H J = 7.83Hz), 7.31 (t 1H J = 7.83Hz), 4.26 (q

2H J = 6.85Hz), 2.73 (s 3H), 1.25 (t 3H J = 6.85Hz)
13

C NMR: (CDCl3) δ 171.51, 156.96, 156.46, 127.97, 127.68, 125.70, 124.75, 123.32,

117.10, 103.62, 56.13, 8.84
TLC: SiO2; Hexane:EtOAc 10:1 Rf = 0.38
General synthesis of [3-(Bromo-phenyl)-5-methyl-isoxazol-4-yl]-methanol. An oven
dried 100ml 2-neck round bottom was charged with 0.434g (1.40mmol) and a magnetic
stir bar and the vessel was sealed and placed under a vacuum. A oven dried condenser
was then attached to the 2 neck round bottom and the system was seal and placed under a
vacuum and flushed with argon, this process was performed three times. The 2-neck
round bottom was then placed in an ice bath and was allowed to reach 0ºC. Freshly
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distilled THF (10ml) was then added to the 2-neck round bottom and the solution was
again allowed to reach 0ºC. 0.065g (0.0025 mmol) of LiAlH4 was then added in potions
to the solution, there was slight foaming that was observed. The reaction was then left to
react and was allowed to come to room temperature. Reaction progress was checked by
TLC, after the reaction was completed the mixture was quenched with sodium sulfate
decahydrate (1g), foaming was observed. The solution was then purified via filtering it
threw a silica plug with Et2O, the resulting solution was then concentrated via rotovap
yielding a yellow oil. (0.283g, 1.06mmol, 75.5%)
1

H NMR: (CDCl3) δ 7.70 (d 1H J = 6.85Hz), 7.61 (d 2H J = 8.07), 7.48 (d 2H J =

8.07Hz), 7.38 (d 1H J = 6.85Hz), 4.43 (s 1H), 4.39 (s 2H), 2.34 (s 3H)
13

C NMR: (CDCl3) δ 168.75, 161.62, 132.09, 129.84, 128.01, 124.26, 112.69, 53.73,

11.17
MS: m/z = 266.98 (M+, 80% rel. intensity), 307.24([M+]+CH3CN, 70), 533.84(M2+ 30)
TLC: SiO2; Hexane:EtOAc:CH2Cl2 3:1:1 Rf =.086
[3-(2-Bromo-phenyl)-5-methyl-isoxazol-4-yl]-methanol
1

H NMR: (CDCl3) δ 7.64 (s 1H), 7.43 (s 1H), 7.35 (s 1H), 7.30 (s 1H), 4.35 (s 2H), 2.47

(s 3H)
13

C NMR: (CDCl3) δ163.52, 157.58, 128.20, 126.99, 126.35, 122.76, 118.16, 109.70,

49.22, 6.63
TLC: SiO2; Hexane:EtOAc:CH2Cl2 3:1:1 Rf =.12
[3-(3-Bromo-phenyl)-5-methyl-isoxazol-4-yl]-methanol
1

H NMR: (CDCl3) δ 7.96 (s 1H), 7.73 (s 1H), 7.56 (s 1H), 7.44(s 1H), 7.31 (s 1H), 4.35

(s 2H), 2.44 (s 3H)
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13

C NMR: (CDCl3) δ 164.15, 156.55, 127.98, 126.39, 125.63, 122.15, 118.09, 108.12,

48.56, 6.63
TLC: SiO2; Hexane:EtOAc:CH2Cl2 3:1:1 Rf =.11
(5-Methyl-3-phenyl-isoxazol-4-yl)-methanol
1

H NMR: (CDCl3) δ 7.73 (d 2H J = 9.54Hz), 7.36 (d 2H J = 9.54Hz), 7.22 (s 1H), 4.40 (s

1H), 2.29 (s 3H)
13

C NMR: (CDCl3) δ 168.76, 162.50, 129.76, 128.81, 128.24, 113.10, 53.04, 10.93

TLC: SiO2; Hexane:EtOAc:CH2Cl2 3:1:1 Rf =0.08
General synthesis of 3-(4-Bromo-phenyl)-5-methyl-isoxazole-4-carbaldehyde. (1.d.)
An oven dried 200ml round bottom was charged with 0.283g (1.06mmol) of [3-(4Bromo-phenyl)-5-methyl-isoxazol-4-yl]-methanol, 15ml of dichloromethane, 2.04g of
anhydrous magnesium sulfate and a magnetic stir bar. .415g of pyridinium
chlorochromate was then added and the vessel was sealed and allowed to react for 2
hours. Reaction progress was checked by TLC, once the reaction was complete excess
solvent was removed via rotovap. The solution was then purified via a silica column. The
purification yielded yellow oil. (.277g 1.04 mmol, 98%)
1

H NMR: (CDCl3) δ 9.95 (s 1H), 7.65 (d 2H J = 7.84Hz), 7.61(d 2H J = 7.84Hz), 2.79 (s

3H)
13

C NMR: (CDCl3) δ 183.87, 177.40, 161.16, 132.18, 130.51, 126.07, 125.19, 115.04,

12.94
MS: m/z =264.97 (M+, 70% rel. intensity), 306.81 ([M+]+CH3CN,60), 530.09 (M2+ 30)
TLC: SiO2; Hexane:EtOAc 4:1 Rf =0.18
3-(2-Bromo-phenyl)-5-methyl-isoxazole-4-carbaldehyde. (1.d.)
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1

H NMR: (CDCl3) δ 9.68 (s 1H), 7.72 (d 1H J = 7.83Hz), 7.46 (d 2H J = 5.38Hz), 7.39 (s

1H), 2.79 (s 3H)
13

C NMR: (CDCl3) δ179.55, 170.72, 157.22, 128.54, 127.06,, 124.43, 122.99, 118.26,

8.31
TLC: SiO2; Hexane:EtOAc 4:1 Rf = 0.14
3-(3-Bromo-phenyl)-5-methyl-isoxazole-4-carbaldehyde. (1.c.)
1

H NMR: (CDCl3) δ 9.61 (s 1H), 7.65 (s 1H), 7.43 (s 1H), 7.35 (s 1H), 7.30 (s 1H), 2.76

(s 3H)
13

C NMR: (CDCl3) δ 186.56, 178.36, 168.03, 133.45, 129.78, 124.21, 121.89, 119.45,

13.05
TLC: SiO2; Hexane:EtOAc 4:1 Rf = 0.84
5-Methyl-3-phenyl-isoxazole-4-carbaldehyde. (1.a)
1

H NMR: (CDCl3) δ9.90 (s 1H), 7.65 (d 2H J = 6.36Hz), 7.47 (d 2H J = 6.36Hz), 7.23 (s

1H), 2.72 (s 3H)
13

C NMR: (CDCl3) δ 194.36, 168.96, 166.03, 132.67, 130.05, 128.93, 128.05, 109.77,

12.31
TLC: SiO2; Hexane:EtOAc 4:1 Rf = 0.21General synthesis of 2-Acetyl-3-[3-(4-bromophenyl)-5-methyl-isoxazol-4-yl]-acrylic acid ethyl ester. (2.d.) An oven dried 50mL
round bottom was charged with 0.95g of 5-methyl-3-phenyl-1,2-oxazole-4-carbaldehyde,
0.799g of Ethyl Acetoacetate, 4 mL of Benzene where added at room temperature. The
solution was allowed to stir, and 0.1325g of glacial acidic acid and 0.054g of piperidine
was added. The round bottom was then fitted with a Dean-Stark trap and a condenser.
The solution was then allowed to reflux for three hours; with the reaction progress
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monitored by TLC. The solution was then cooled to room temperature and the excess
solvent was removed via rotovap. The solution was then purified via a silica column. The
purification yielded yellow oil. (0.761g, 2.53 mmol, 52%)
1

H NMR: (CDCl3) δ 7.54 (d 2H J = 9.78Hz), 7.40 (d 2H J = 8.56Hz), 7.33 (s 1H), 4.13

(q 2H J = 7.09Hz), 2.35 (s 3H), 2.19 (s 3H), 1.20 (t 3H J = 7.09Hz)
13

C NMR: (CDCl3) δ 194.12, 169.17, 165.80, 160.44, 137.70, 132.11, 129.50, 131.45,

127.45, 124.46,109.55, 61.63, 13.75, 12.19
MS: m/z =377.03 (M+, 50% rel. intensity) 418.45 ([M+]+CH3CN, 100)
TLC: SiO2; Hexane:EtOAc 1:1 Rf = 0.39
2-Acetyl-3-[3-(2-bromo-phenyl)-5-methyl-isoxazol-4-yl]-acrylic acid ethyl ester.
(2.b.)
1

H NMR: (CDCl3) δ 7.65 (s 1H), 7.54 (s 1H), 7.36 (s 1H) 7.24 (s 1H), 7.10 (s 1H), 4.17

(q 2H J = 6.57Hz), 2.37 (s 3H), 2.15 (s 3H), 1.17 ( t 3h J = 6.98Hz)
13

C NMR: (CDCl3) δ 194.36, 168.96, 166.03, 161.50, 138.26, 132.30, 130.71, 128.93,

128.05, 109.77, 61.60, 27.82, 13.79, 12.13
TLC: SiO2; Hexane:EtOAc 1:1 Rf = 0.41
2-Acetyl-3-[3-(3-bromo-phenyl)-5-methyl-isoxazol-4-yl]-acrylic acid ethyl ester.
(2.c.)
1

H NMR: (CDCl3) δ 7.65 (s 1H), 7.43 (s 1H), 7.35 (s 1H), 7.30 (s 1H), 7.68 (s 1H), 4.15

(q 2H J = 6.84Hz), 2.34 (s 3H), 2.17 (s 3H), 1.16 (t 3H J = 5.42Hz)
13

C NMR: (CDCl3) δ 194.24, 169.12, 165.83, 162.78, 148.65, 137.68, 132.11, 130.41,

131.96, 124.93, 127.45, 110.15, 59.67, 24.65, 14.04, 12.18
TLC: SiO2; Hexane:EtOAc 1:1 Rf = 0.30
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2-Acetyl-3-(5-methyl-3-phenyl-isoxazol-4-yl)-acrylic acid ethyl ester. (2.a.)
1

H NMR: (CDCl3) δ 7.57 (d 2H J = 12.72Hz), 7.44 (d 2H J = 12.72Hz), 7.25 (s 1H), 3.99

(q 2H J = 7.52Hz), 2.40 (s 3H), 2.37 (s 3H), 1.14 (t 3H J = 6.05Hz)
13

C NMR: (CDCl3) δ 194.36, 168.96, 166.03, 161.50, 137.26, 132.67, 128.93, 128.05,

109.77, 61.60, 27.82, 13.79, 12.31
TLC: SiO2; Hexane:EtOAc 1:1 Rf = 0.39
Synthesis of 3-Oxo-butyric acid prop-2-ynyl ester. An oven dried round
bottom(250mL) was charged with a magnetic stir bar, 4.64g of Ethyl Acetoacetate, 2.00g
of propargyl alcohol, .22g of boric acid, and 40mL of Toluene added at room
temperature. The round bottom was then fitted with a dean stark trap, a condenser and a
drying tube. The solution was then heated to reflux and left for 144 hours. The reaction
yielded a light red solution. The solution was then purified via a silica column. The
purification compound yielded yellow oil. (2.868 g, 20.46 mmol, 57%)
1

H NMR: (CDCl3) δ 4.68 (d 2H J = 2.45Hz), 3.46 (s 2H), 2.49 (t 1H J = 2.45Hz), 2.22 (s

3H),
13

C NMR: (CDCl3) δ 200.03, 166.27, 104.98, 89.06, 52.60, 49.56, 30.08

MS: m/z = 140.047 (M+, 100% rel. intensity) 142.07(M+2, 90), 183.78([M+2]+CH3CN,
60)
TLC: SiO2; Hexane:EtOAc 4:1 Rf = 0.18
General Synthesis of 4-[3-(Bromo-phenyl)-5-methyl-isoxazol-4-yl]-2,6-dimethyl-1,4dihydro-pyridine-3,5-dicarboxylic acid diethyl ester. (7.d.) An oven dried 100ml
round bottom was charged with 0.107g (0.40mmol) of 3-(4-Bromo-phenyl)-5-methylisoxazole-4-carbaldehyde, 0.11g (0.014 mmol) of ethyl acetoacatate, 50ml of benzene
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and a magnetic stir bar. The solution was allowed to stir at room temperature. 0.10ml of
30% aqueous ammonia was measured out along with 0.90ml of methanol, the mixture
was then added to the 100ml round bound bottom containing (2Z)-2-[(5-methyl-3-pheyl1,2-oxazol-4-yl)methylidene]-3-oxobutanoate. The round bottom was then fitted with an
oven dried condenser and the solution was brought to reflux (70ºC). The reaction process
was monitored via TLC. Once complete the solution was then cooled to room
temperature and the excess solvent was removed via rotovap. The solution was then
purified via recrystallized from ethyl acetate and hexanes to give yellow crystals (0.084g,
0.0411 mmol, 42.92%).
1

H NMR: (CDCl3) δ 7.55 (d 2H J = 8.4Hz), 7.37 (d 2H J = 8.7Hz), 5.06 (s 1H), 5.02 (bs

1H), 3.52 (s 6H), 2.43 (s 3H)
13

C NMR: (CDCl3) δ167.27, 166.26, 162.71, 145.31, 143.76, 143.52, 131.24, 130.72,

130.01, 122.88, 119.46, 101.14, 59.85, 51.31, 29.29, 29.16, 19.35, 14.46, 11.46
MS: m/z = 489.15 (M+, 100% rel. intensity), 530.36([M+]+CH3CN, 70)
IR: cm-1 2927.62, 2831.02, 1741.66, 1259.19, 1179.41, 1156.61, 727.32
TLC: SiO2; Hexane:EtOAc 4:1 Rf = 0.17
4-[3-(2-Bromo-phenyl)-5-methyl-isoxazol-4-yl]-2,6-dimethyl-1,4-dihydro-pyridine3,5-dicarboxylic acid diethyl ester. (7.b.)
1

H NMR: (CDCl3) δ 7.60 (d 1H J = 7.91Hz), 7.31 (d 1H J = 7.40Hz), 7.24 (d 1H J =

5.90Hz), 7.18 (d 1H J = 7.53Hz), 4.95 (s 1H), 4.15 (q 2H J = 4.64Hz), 4.13 (q 2H J =
4.64Hz), 2.58 (s 3H), 1.96 (s 6H), 1.25 (t 6H J = 7.15Hz)
13

C NMR: (CDCl3) δ 167.33, 165.60, 162.95, 144.54, 132.46, 132.25, 130.00, 126.24,

125.01, 118.27, 100.47, 59.79, 29.24, 19.61, 14.61, 11.54
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HRMS: calculated for C23H26BrN2O5 489.1023 found 489.1025
MS: m/z = 489 (M+, 100)
IR: cm-1 2917.91, 22831.02, 1734.06, 1361.76, 1213.60, 1164.17, 746.23
TLC: SiO2; Hexane:EtOAc 4:1 Rf = 0.07
4-[3-(3-Bromo-phenyl)-5-methyl-isoxazol-4-yl]-2,6-dimethyl-1,4-dihydro-pyridine3,5-dicarboxylic acid diethyl ester. (7.c.)
1

H NMR: (CDCl3) δ 7.59 (s 1H), 7.56 (s 1H), 7.55(s 1H), 7.33 (s 1H), 5.05 (s 1H), 4.16

(q 2H J = 3.76Hz), 4.09 (q 2H J = 3.76Hz), 2.54 (s 3H), 2.06 (s 6H), 1.25 (t 6H J =
7.03Hz)
13

C NMR: (CDCl3) δ 167.27, 166.09, 162.48, 144.08, 133.18, 132.50, 129.21, 128.44,

121.64, 119.41, 101.00, 59.87, 29.41, 19.51, 14.51, 11.50
HRMS: calculated for C23H26BrN2O5 489.1028 found 489.1025
MS: m/z = 489 (M+, 100) 530 ([M+2]+CH3CN, 20)
IR: cm-1 3001.51, 2975.15, 1737.86, 1351.12, 1224.92, 731.45
TLC: SiO2; Hexane:EtOAc 4:1 Rf = 0.26
2,6-Dimethyl-4-(5-methyl-3-phenyl-isoxazol-4-yl)-1,4-dihydro-pyridine-3,5dicarboxylic acid diethyl ester. (7.a.)
1

H NMR: (CDCl3) δ7.57 (d 2H J = 7.62Hz), 7.30 (d 2H J = 7.62Hz), 7.23 (s 1H), 4.98 (s

1H), 4.09 (q 2H J = 6.85Hz), 4. 01 (q 2H J = 4.89Hz), 2.49 (s 3H), 1.91 (s 6H), 1.18 (t
6H J = 7.09Hz)
13

C NMR: (CDCl3) δ 171.23, 167.44, 166.32, 165. 81, 163.92, 147.32, 130.25, 128.63,

125.77, 121.32, 101.12, 59.81, 31.65, 20.87, 14.51, 12.34
TLC: SiO2; Hexane:EtOAc 4:1 Rf = 0.17
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General Synthesis of 4-[3-(Bromo-phenyl)-5-methyl-isoxazol-4-yl]-2,6-dimethyl-1,4dihydro-pyridine-3,5-dicarboxylic acid 3-ethyl ester 5-prop-2-ynyl ester (4.d.). An
oven dried 100ml round bottom was charged with 0.82g (2.17 mmol) of ethyl (2Z)-2-[(5methyl-3-pheyl-1,2-oxazol-4-yl)methylidene]-3-oxobutanoate, 0.305g (2.17 mmol) of
prop-2-yn-1-yl 3-oxobutanoate, 50 ml of absolute ethanol and a magnetic stir bar the
vessel was sealed and the solution was allowed to stirrer at room temperature. In a 10 ml
graduated cylinder 0.47ml of 30% ammonia was measured out along with 0.53ml of
absolute ethanol, the mixture was then added to the 100ml round bound bottom
containing ethyl (2Z)-2-[(5-methyl-3-pheyl-1,2-oxazol-4-yl)methylidene]-3oxobutanoate and prop-2-yn-1-yl 3-oxobutanoate. The 100ml round bottom was then
placed on a heating mantel and fitted with a oven dried condenser. The solution was then
refluxed (78ºC) for 12 hours during which time the solution turned yellow. The solution
was then cooled to room temperature and the excess solvent was removed via rotovap.
The solution was then purified via recrystallized from ethyl acetate and hexanes to give
off yellow crystals. ( 0.355g, 0.713 mmol, 33%)
1

H NMR: (CDCl3) δ 7.52 (d 2H J =7.83Hz), 7.29 (d 2H J = 8.31Hz), 5.01 (s 1H), 4.98 (s

2H) 4.56 (q, 2H J = 9.78Hz), 4.09 (qq, 2H J = 6.36Hz), 4.00 (qq, 2H J = 6.85Hz), 2.50
(s,3H), 2.47 (s, 3H), 2.05 (s 6H), 1.21 (t, 3H J = 7.03Hz)
13

C NMR: (CDCl3) δ 167.28, 166.21, 162.70, 145.35, 143.78, 131.23, 130.72, 122.84,

119.47, 101.62, 101.12, 74.68, 59.85, 51.31, 29.69, 29.16, 19.35, 14.46, 11.46
MS: m/z = 499.35 (M+, 100% rel. intensity), 540.86 ([M+]+CH3CN,60)
TLC: SiO2; Hexane:EtOAc 4:1 Rf = 0.12
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4-[3-(2-Bromo-phenyl)-5-methyl-isoxazol-4-yl]-2,6-dimethyl-1,4-dihydro-pyridine3,5-dicarboxylic acid 3-ethyl ester 5-prop-2-ynyl ester. (4.b.)
1

H NMR: (CDCl3) δ 7.58 (d 1H J = 8.66Hz), 7.31 (d 1H J = 6.53Hz), 7.24 (d 1H J =

7.65Hz), 7.18 (d 1H J = 7.53Hz), 4.95 (s 1H), 4.67 (d 2H J = 3.04Hz), 4.15 (qq 2H J =
7.15Hz), 2.58 (s 3H), 2.05 (s 1H), 1.96 (s 6H), 1.25 ( t 3H J = 7.15Hz)
13

C NMR: (CDCl3) δ 167.33, 165.50, 162.95, 144.54, 132.46, 132.25, 132.11, 130.00,

126.24, 125.01, 118.27, 100.47, 100.47, 59.79, 29.24, 19.61, 14.61, 11.54
TLC: SiO2; Hexane:EtOAc 4:1 Rf = 0.12
4-[3-(3-Bromo-phenyl)-5-methyl-isoxazol-4-yl]-2,6-dimethyl-1,4-dihydro-pyridine3,5-dicarboxylic acid 3-ethyl ester 5-prop-2-ynyl ester. (4.c.)
1

H NMR: (CDCl3) δ 7.59 (s 1H), 7.56 (s 1H), 7.55 (s 1H), 7.33 (s 1H), 5.05 (s 1H), 4.65

(d 2H J = 2.51Hz), 4. 16 (qq 2H J = 7.15Hz), 2.54(s 3H), 2.08 (s 1H), 2.06 (s 6H), 1.25 (t
3H J = 7.03Hz)
13

C NMR: (CDCl3) δ 167.27, 166.09, 162.48, 144.08, 133.18, 132.50,131.51, 129.21,

128.44, 121.64, 119.41, 101.00, 59.87, 29.41, 19.51, 14.51, 11.50
TLC: SiO2; Hexane:EtOAc 4:1 Rf = 0. 15
2,6-Dimethyl-4-(5-methyl-3-phenyl-isoxazol-4-yl)-1,4-dihydro-pyridine-3,5dicarboxylic acid 3-ethyl ester 5-prop-2-ynyl ester. (4.a)
1

H NMR: (CDCl3) δ 7.57 (d 2H J = 8.72Hz), 7.30 (d 2H J = 8.72Hz), 7.22 (s 1H), 5.37 (s

1H), 5.23 (s 1H), 4.98 (s 1H), 4.55 (q 2H J = 6.36Hz), 4.08 (q 2H J = 6.85Hz), 2.54 (s
3H), 2.08 (s 1H), 1.92 (s 6H), 1.18 ( t 3H J = 7.09Hz)
13

C NMR: (CDCl3) δ 171.18, 167.44, 166.41, 165.79, 163.81, 146.01, 144.39, 130.76,

129.52, 127.55, 119.43, 101.43, 74.59, 60.40, 29.20, 19.15, 14.47, 11.52
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TLC: SiO2; Hexane:EtOAc 4:1 Rf = 0. 18
Synthesis of (2-Azido-ethyl)-benzene. An oven dried 100mL round bottom was charged
with 1.010g (8.268mmol) of 2-Phenyl-ethanol, a magnetic stir bar. Chloroform was then
added and the round bottom was capped with a septum and the solution was then allowed
to stir at room temperature. The round bottom was cooled in bath of a of CaCl2 solution
and water (25g/200mL). The round bottom was then placed in the CaCl2/water solution
and dry ice was added (to the cooling solution), the solution was then allowed to reach 35°C. Methanesulfonyl chloride (MsCl )1.031mL was then added via gas-tight syringe.
The reaction was then kept at -35°C for two hours. The solution was then allowed to
reach room temperate and was then left to stir at room temperature overnight. Excess
solvent was removed via rotovap, to give a white solid. The same 100mL round bottom
was then charged with 25mL of EtOH and 0.585g of NaN3 at room temperature. The
reaction was then allows to stir at room temperature over night. The reaction yielded an
amber solution. The solution was then extracted with EtOAc and Brine three times, and
dried over NaSO4. The solution was then contracted via rotovap yielding a yellow-gold
oil. (0.924g, 6.28 mmol, 77%)
1

H NMR: (CDCl3) δ 7.24 (d, 2H J = 9.30Hz), 7.12 (d, 2H J = 8.85Hz), 7.11(s, 1H),

2.84(d, 2H J = 7.24Hz), 1.41(d,2H J = 7.30Hz)
TLC: SiO2; EtOAc Rf =.76
General Synthesis of 4-[3-(4-Bromo-phenyl)-5-methyl-isoxazol-4-yl]-2,6-dimethyl1,4-dihydro-pyridine 3,5-dicarboxylic acid 3-ethyl ester 5-(1-phenethyl-1H[1,2,3]triazol-4-ylmethyl) ester. (6.) An oven dried 100mL round bottom was charged
with 0.038g (0.259mmol) of (2-Azido-ethyl)-benzene and a magnetic stir bar. The sample
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was then taken up in freshly distilled THF and the solution was allowed to stir at room
temperature. Once the (2-Azido-ethyl)-benzene was completely dissolved 0.129g
(0.259mmol) of 4-[3-(Bromo-phenyl)-5-methyl-isoxazol-4-yl]-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid 3-ethyl ester 5-prop-2-ynyl ester was added in potions.
The round bottom was then capped with a rubber septum and the solution was allowed to
stir. The solution was allowed to stir until all reagents where dissolved, 0.011g of
Copper(I)-bromide was then added and the solution was allowed to stir at room
temperature for 48 Hr. Reaction progress was monitored via TLC, once the compete
excess solvent was removed via rotovap. The solution was then purified via silica column
yielding yellow oil (0.0527g, 0.0816mmol, 32%)
1

H NMR: (CDCl3) δ 7.51(d, 2H J = 8.53Hz), 7.30 (d, 2H J = 7.53Hz), 7.26(s, 1H),

7.24(d, 2H J = 9.29Hz), 7.12(d, 2H J = 8.28Hz), 5.15(q, 2H J = 12.30Hz), 5.03(s, 1H),
4.99(s, 1H), 4.56 (t, 2H J = 7.53Hz), 4.14 (q, 2H J = 7.03Hz), 4.07 (t 2H J = 7.03Hz),
3.20(t, 2H J = 7.28Hz), 2.35(s, 3H), 2.02(d, 6H J = 5.27Hz), 1.27( t, 3H J = 7.28Hz)
13

C NMR: (CDCl3) δ 167.14, 167.04, 166.55, 144.59, 143.54, 136.89, 131.20, 130.79,

129.93, 128.85, 128.69, 127.13, 122.89, 101.52, 100.64, 60.43, 59.89, 56.88, 51.68,
45.91, 36.63, 26.39, 21.08, 19.46, 19.26, 14.45, 19.26, 14.45, 14.22, 11.33, 8.67
HRMS: calculated for C23H32BrN5O5 646.1685 found 646.1665
MS: m/z = 645 (M (79Br), 20% rel. intensity), 646 (M+, 80), 647([M+1]+, 35), 648
([M+1]+(81Br),78)
IR: cm-1 2992.36, 1734.06, 1365.56, 1255.39, 1278.18, 1221.20, 761.51, 746.32
TLC: SiO2; EtOAc:MeOH:CH2Cl2 (4:1:2) Rf = 0.55
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Synthesis of 2,6-Dimethyl-4-(5-methyl-3-phenyl-isoxazol-4-yl)-pyridine-3,5dicarboxylic acid diethyl ester. (8.) The 2,6-Dimethyl-4-(5-methyl-3-phenyl-isoxazol-4yl)-1,4-dihydro-pyridine-3,5-dicarboxylic acid diethyl ester was placed in a 50mL oven
dried round bottom along with a magnetic stir bar and 0.085g of DI water. The solution
was then allowed to stir at room temperature while, 0.227g of HNO3 and 0.0246g of
H2SO4 was added. The solution was then heated to 110ºC and white foam was observed,
after 10 min. at 110ºC the solution turned a light yellow. The solution was then allowed
to cool to room temperature. The solution was then taken up in ice water and LiOH was
added slowly until the solution was neutral. The solution was then added to a speratory
funnel and extracted with CHCl3 and Brine with 50mL three times. The solution was
then dried over NaSO4 and filtered; the excess solvent was then removed via rotovap
yielding a pale yellow oil that was then crystallized with CH2Cl2 and Hexanes. (0.100g,
0.245 mmol, 98%)
1

H NMR: (CDCl3) 7.46 (d, 2H, J = 7.28Hz), 7.34 (d, 2H, J = 7.11Hz), 7.29 (s, 1H), 4.03

(q, 2H, J = 9.56Hz), 2.59 (s, 3H), 2.25 (s, 3H), 0.97 (t, 3H, J = 7.01Hz)
13

C NMR: (CDCl3) δ 167.18, 165.91, 159.70, 155.29, 134.52, 128.66, 127.56, 126.56,

109.18, 60.63, 22.09, 12.57, 10.38
HRMS: calculated for C23H24N2O5 408.1685 found 408.1692
MS: m/z = 409 (M+1, 100), 410 (M+2, 40)
IR: cm-1 3007.46, 1737.86, 1441.54, 1365.56, 1259.19, 1217.60, 746.32
TLC: SiO2; Hexanes:EtOAc (4:1) Rf = 0.31
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General Synthesis of 3-[1-(17-{4-[({4-[3-(4-bromophenyl)-5-methyl-1,2-oxazol-4-yl]5-(ethoxycarbonyl)-2,6-dimethyl-1,4-dihydropyridin-3-yl}carbonyloxy)methyl]-1H1,2,3-triazol-1-yl}-3,6,9,12,15-pentaoxaheptadecan-1-yl)-1H-1,2,3-triazol-4-yl]methyl
5-ethyl 4-[3-(4-bromophenyl)-5-methyl-1,2-oxazol-4-yl]-2,6-dimethyl-1,4dihydropyridine-3,5-dicarboxylate. (5.d.) An oven dried 100ml round bottom was
charged with 0.164g (.328mmol) of 4-[3-(4-Bromo-phenyl)-5-methyl-isoxazol-4-yl]-2,6dimethyl-1,4-dihydro-pyridine-3,5-dicarboxylic acid 3-ethyl ester 5-prop-2-ynyl ester,
0.034g of 1-Azido-2-[2-(2-{2-[2-(2-azido-ethoxy)-ethoxy]-ethoxy}-ethoxy)-ethoxy]ethane, 0.010g of Copper(I) bromide, 0.010g of Copper sulfate anhydride and a magnetic
stir bar. 50ml of freshly distilled THF was then added and the solution was allowed to stir
at room temperature. Sodium ascorbate (0.003g) was then added and the solution was
allowed to react. The reaction progress was monitored by TLC, once the reaction was
completed excess solvent was removed via rotovap. The solution was then purified via a
silica column. The purification yielded yellow oil. (0.0067g, 0.005 mmol, 15.34%)
1

H NMR: (CDCl3) δ 7.65 (s 2H), 7.49 (d 4H J = 8.28Hz), 7.22 (d 4H J = 8.28Hz), 4.99 (s

2H), 4.52 (q 4H J = 4.52Hz), 4.13 (q 2H J = 7.28Hz), 4.07 (q 2H J = 6.78Hz), 3.89 (t 3H
J = 5.52Hz), 3.75 (t 4H J = 6.02Hz), 3.65 (m 16H), 2.33 (s 6H), 2.05 (s 9H), 1.19 (t 6H J
=7.03Hz)
13

C NMR: (CDCl3) δ 168.74, 166.68, 159.89, 156.71, 135.10, 131.91, 131.22, 130.77,

129.04, 128.17, 127.45, 124.90, 124.24, 109.43, 71.36, 70.59, 69.35, 69.303, 61.72,
58.48, 42.76, 37.76, 31.94, 29.71, 23.16, 14.13, 13.63, 11.25
HRMS: calculated for C60H71Br2N10O15 1329.3467 found 1329.3462
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MS: m/z = 1327 (M (79Br) 100% rel. intensity), 1328 (M, 62), 1329 (M+1, 97), 1330
([M+1](81Br),60) 1331 ([M+1]+(81Br),60), 1332 ([M+1]+2(81Br),40)
IR: cm-1 3014.92, 2962.68, 1746.26, 1492.10, 1369.40, 1216.41, 753.73
TLC: SiO2; EtOAc:MeOH:CH2Cl2 (4:1:2) Rf = 0.56
Then run a column in 4:1:3:2 (EtOAc:MeOH:Hexanes:CH2Cl2) Rf = 0.23
3-[1-(17-{4-[({4-[3-(2-bromophenyl)-5-methyl-1,2-oxazol-4-yl]-5-(ethoxycarbonyl)2,6-dimethyl-1,4-dihydropyridin-3-yl}carbonyloxy)methyl]-1H-1,2,3-triazol-1-yl}3,6,9,12,15-pentaoxaheptadecan-1-yl)-1H-1,2,3-triazol-4-yl]methyl 5-ethyl 4-[3-(2bromophenyl)-5-methyl-1,2-oxazol-4-yl]-2,6-dimethyl-1,4-dihydropyridine-3,5dicarboxylate. (5.b.)
1

H NMR: (CDCl3) δ 7.59 (d 2H J = 6.78Hz), 7.58 (d 2H J = 6.78Hz), 7.31 (d 2H J =

7.03Hz), 7.23 (s 2H J = 7.53Hz), 7.15 (d 2H J = 7.03Hz), 4.92 (s 2H), 4.54 (q 4H J =
5.52Hz), 4.10 (q 2H J = 8.78Hz), 3.97 (t 3H J = 5.77Hz), 3.81 (t 4H J = 6.27Hz), 3.66 (m
16H), 2.36 (s 6H), 1.96 (s 9H), 1.23 (t 6H J = 7.03Hz)
13

C NMR: (CDCl3) δ 167.24, 132.21, 131.98, 130.28, 126.40, 100.36, 71.28, 70.56,

69.96, 69.47, 68.96, 65.56, 61.91, 59.69, 50.64, 47.62, 42.81, 37.70, 32.16, 30.48, 29.63,
23.41, 19.16, 15.14, 14.56, 11.28
HRMS: calculated for C60H71Br2N10O15 1329.3467 found 1329.3467
MS: m/z = 1327 (M (79Br) 35% rel. intensity), 1328 (M, 30), 1329 (M+1, 97), 1330
([M+1](81Br),50) 1331 ([M+1]+(81Br),100), 1332 ([M+1]+2(81Br),40)
IR: cm-1 2917.91, 2850.74, 1731.34, 1496.26, 1261.19, 1164.17, 733.12
TLC: SiO2; EtOAc:MeOH:CH2Col2 (4:1:2) Rf = 0.48
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3-[1-(17-{4-[({4-[3-(3-bromophenyl)-5-methyl-1,2-oxazol-4-yl]-5-(ethoxycarbonyl)2,6-dimethyl-1,4-dihydropyridin-3-yl}carbonyloxy)methyl]-1H-1,2,3-triazol-1-yl}3,6,9,12,15-pentaoxaheptadecan-1-yl)-1H-1,2,3-triazol-4-yl]methyl 5-ethyl 4-[3-(3bromophenyl)-5-methyl-1,2-oxazol-4-yl]-2,6-dimethyl-1,4-dihydropyridine-3,5dicarboxylate. (5.c.)
1

H NMR: (CDCl3) δ 7.73 (s 2H), 7.64 (d 2H J = 5.52Hz), 7.51 (s 2H ), 7.25 (s 2H), 7.18

(d 2H J = 10.54Hz), 4.98 (s 2H), 4.53 (q 4H J = 4.02Hz), 4.38 (q 2H J = 4.27Hz), 4.09 (q
2H J = 10.79Hz), 3.86 ( t 3H J = 5.02Hz), 3.76 (t 4H J = 5.02Hz), 3.62 (m 16H), 2.35 (s
6H), 2.01 (s 9H), 1.19 (t 6H J = 7.28Hz)
13

C NMR: (CDCl3) δ 167.18, 166.31, 162.49, 145.12, 144.12, 133.04, 132.73, 132.40,

131.54, 130.44, 13.026, 129.28, 128.39, 126.18, 124.96, 121.62, 199.30, 101.11, 100.33,
71.35, 70.62, 69.39, 69.01, 66.64, 59.85, 58.44, 56.92, 50.69, 43.38, 42.79, 41.44, 37.75,
29.41, 23.17, 23.09, 19.46, 19.29, 14.48, 13.62, 11.30
HRMS: calculated for C60H71Br2N10O15 1329.3467 found 1329.3450
MS: m/z = 1327 (M (79Br) 35% rel. intensity), 1328 (M, 20), 1329 (M+1, 100), 1330
([M+1](81Br),60) 1331 ([M+1]+(81Br),100), 1332 ([M+1]+2(81Br),50)
IR: cm-1 3007.46, 2970.14, 1738.80, 1432.83, 1227.61, 1216.41, 761.51
TLC: SiO2; EtOAc:MeOH:CH2Cl2 (4:1:2) Rf = 0.52
3-(1-{17-[4-({[5-(ethoxycarbonyl)-2,6-dimethyl-4-(5-methyl-3-phenyl-1,2-oxazol-4yl)-1,4-dihydropyridin-3-yl]carbonyloxy}methyl)-1H-1,2,3-triazol-1-yl]-3,6,9,12,15pentaoxaheptadecan-1-yl}-1H-1,2,3-triazol-4-yl)methyl 5-ethyl 2,6-dimethyl-4-(5methyl-3-phenyl-1,2-oxazol-4-yl)-1,4-dihydropyridine-3,5-dicarboxylate. (5.a.)
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1

H NMR: (CDCl3) δ 7.64 (s 2H), 7.52 (d 4H J = 8.28Hz), 7.25 (d 4H J = 8.28Hz), 4.98 (s

2H), 4.54 (q 4H J = 4.77Hz), 4.11 (q 2H J = 7.03Hz), 4.04 (q 2H J = 7.03Hz), 3.87 (t 3H
J = 5.27Hz), 3.75 (t 4H J = 5.77Hz), 3.65 (m 16H), 2.36 (s 6H), 2.03 (d 9H J = 5.27Hz),
1.19 (t 6H J = 7.03Hz)
13

C NMR: (CDCl3) δ 171.15, 168.55, 167.21, 169.96, 151.03, 144.05, 130.90, 129.78,

129.44, 129.30, 128.68, 128.40, 127.51, 106.88, 101.17, 88.97, 71.28, 70.60, 70.51,
69.93, 69.37, 68.94, 66.48, 63.51, 61.56, 59.56, 55.57, 51.58, 50.65, 42.73, 37.64, 35.87,
29.57, 29.20, 23.50, 22.58, 21.50, 18.84, 15.10, 14.40, 14.02, 12.41, 11.06
HRMS: calculated for C60H71N10O15 1171.5100 found 1171.5134
MS: m/z = 1169 ([M-2] 100 % rel. intensity), 1170 ([M-1] 70), 1171([M] 40), 1172
([M+] 10)
IR: cm-1 2972.26, 2831.20, 1734.06, 1571.92, 1357.96, 1225.00, 727.32
TLC: SiO2; EtOAc:MeOH:CH2Cl2 (4:1:2) Rf = 0.52
3-[1-(2-{2-[2-(2-{4-[({4-[3-(4-bromophenyl)-5-methyl-1,2-oxazol-4-yl]-5(ethoxycarbonyl)-2,6-dimethyl-1,4-dihydropyridin-3-yl}carbonyloxy)methyl]-1H1,2,3-triazol-1-yl}ethoxy)ethoxy]ethoxy}ethyl)-1H-1,2,3-triazol-4-yl]methyl 5-ethyl
4-[3-(4-bromophenyl)-5-methyl-1,2-oxazol-4-yl]-2,6-dimethyl-1,4-dihydropyridine3,5-dicarboxylate. (5.e)
1

H NMR: (CDCl3) δ 7.60 (d 2H J = 5.52), 7.50 (t 4H J = 8.28Hz), 7.26 (t 4H J =

8.28Hz), 5.17 (m 4H), 4.99 (s 2H), 4.51 (q 4H J = 5.52Hz), 4.07 (q 2H J = 6.78Hz), 3.94
(q 2H J = 6.78Hz), 3.85 (t 4H J = 5.27Hz), 3.62 (m 8H), 2.34 (s 6H), 2.01 (d 9H J =
5.02Hz), 1.15 (t 6H J = 7.28Hz)
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13

C NMR: (CDCl3) δ 167.21, 162.62, 145.12, 143.89, 131.90, 131.12, 130.78, 129.92,

129.02, 122.88, 119.54, 101.29, 100.39, 72.46, 70.67, 70.06, 69.34, 61.72, 59.81, 50.67,
42.84, 29.69, 19.03, 14.45, 11.30
HRMS: calculated for C56H63 N10O13Br2 1241.2943 found 1241.2950
MS: m/z = 1239 ([M(79Br)] 60% rel. intensity), 1240 ([M] 40), 1241 ([M+1] 100), 1242
([M+1](81Br) 60), 1243([M+2] 70), 1244 ([M+3] 50)
IR: cm-1 2917.91, 2850.74, 1731.31, 1496.26, 1261.19, 1164.17, 697.76
TLC: SiO2; EtOAc:MeOH:CH2Cl2 (4:1:2) Rf = 0.52
3-(1-{2-[2-(2-{4-[({4-[3-(4-bromophenyl)-5-methyl-1,2-oxazol-4-yl]-5(ethoxycarbonyl)-2,6-dimethyl-1,4-dihydropyridin-3-yl}carbonyloxy)methyl]-1H1,2,3-triazol-1-yl}ethoxy)ethoxy]ethyl}-1H-1,2,3-triazol-4-yl)methyl 5-ethyl 4-[3-(4bromophenyl)-5-methyl-1,2-oxazol-4-yl]-2,6-dimethyl-1,4-dihydropyridine-3,5dicarboxylate. (5.f.)
1

H NMR: (CDCl3) δ 7.61 (d 2H J = 7.53Hz), 7.49 (d 4H J = 8.28Hz), 7.25 (d 4H J =

8.53Hz), 5.17 (m 4H), 4.98 (s 2H), 4.51 (q 4H J = 5.27Hz), 4.06 (q 2H J = 6.83Hz), 3.88
(q 2H J = 5.02Hz), 3.72 (t 4H J = 6.02Hz), 3.64 (d 4H J = 6.27Hz), 2.33 (s 6H), 2.01 (s
9H), 1.15 (t 6H J = 7.28Hz)
13

C NMR: (CDCl3) δ 167.25, 143.96, 131.97, 131.18, 130.81, 129.89, 129.03, 122.98,

101.28, 71.30, 70.74, 70.47, 70.32, 69.15, 61.75, 59.83, 53.51, 50.67, 42.92, 29.70, 29.36,
19.04, 15.16, 14.46, 13.64, 11.36
HRMS: calculated for C54H59 N10O12Br2 1197.2633 found 1197.2681
MS: m/z = 1195 ([M(79Br)] 80% rel. intensity), 1196 ([M] 60), 1197 ([M+1] 100), 1198
([M+1](81Br) 80), 1199 ([M+2] 100), 1200 ([M+3] 60)
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IR: cm-1 3014.92, 2962.68, 1746.26, 1429.10, 1369.40, 1216.41, 753.73
TLC: SiO2; EtOAc:MeOH:CH2Cl2 (4:1:2) Rf = 0.5
MDR-1 Assay.
Screening of IDHPs was performed by the Psychoactive Drug Screening Program
(PDSP) of NIMH. The PDSP protocol utilizes live Caco-2 cells, which are derived from
human colonic epithelium cells which express MDR-1.9 The assay is based on the passive
diffusion of calcein acetoxymethyl ester (Calcein-AM), which is hydrolyzed inside the
cell to calcein, which is both fluorescent and negatively charged, and therefore trapped
inside the cell. MDR-1 can transport non-fluorescent Calcein-AM from cells, but not
hydrolyzed calcein. The assay measures the increase in calcein fluorescence as a function
of time using a FlexStation II fluorimeter (Molecular Devices) in 96 well plates in which
AM was added to a final concentration of 150 nM. Fluorescence is monitored over 4

control. The value from untreated cells is 0% and the slope of the fluorescence is
normalized taking the value for cyclosporin as 100%.10
The results are shown in Table 4-1.
mGluR5 Assay
Screening of the IDHP was performed by the PDSP of the NIMH. IDHPs are tested using
cell lines stably expressing Gq protein mGluR5 receptors in a functional assay. Cells are
seeded and cultured in 96 well plates until a level of confluency is established around 3 to
4 days after seeding. After which the cells are incubated overnight and in a glutamine
deprived medium along with myo-[3H]-inositol (NEN) to act as a label on the membrane
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phosphoinosites of the cell. After incubation is complete the cells are washed with a
Locke’s buffer and a second round of incubation with the IDHP is carried out for 45 min
at 37ºC in Lock’s buffer containing 20 mM LiCl to hinder the degradation of the inositol
phosphate. The incubation is then terminated via aspiration and [3H]inosital phosphates
are extracted in 60 ul or 10 mM formic acid for 30 min. Samples of the aspirated media
(40ul) is then transferred to opaque welled plates and incubated with polylysine-coated
yttrium scintillation proximity assay (SPA) beads at room temperature for 1 hour with
vigorous shaking. The sample is then allowed to incubate for an additional 8 hours with
the SPA beads after which the inositol phosphates are quantified via a scintillation
counter.
VGCC Assay
Binding to the Ca2+ channel was conducted by PDSP. The binding assay was carried out
in 125 μl per well with 50mM Tris HCL, 50mM NaCl, 1mM CaCl2, pH 7.4, at room
temperature. The radioactive ligand, [3H] Nitrendipine, was tested at a concentration
close to its Kd of 4.77 ±1.75nM. Total binding and nonspecific binding is determined in
the presence and absence of Nifedipine at 10 μM. Plates are incubated at room
temperature in the dark for 90 min. Reactions are halted by vacuum filtration into a 0.3%
polyethyleneimine (PEI) soaked 96-well filter mats utilizing a 96 well filtermate
harvester. This is followed by washing with a cold wash buffer of 50 nM Tris HCl, pH
7.4. The scintillation cocktail was then melted into a microwave dried filter on a hot
place. The radioactivity is then counted in a microbeta counter and the inhibition is
calculated using excel.
Geometric parameters of 7c.
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Fractional atomic coordinates and isotropic or equivalent isotropic displacement
parameters (Å2)
x

y

z

Uiso*/Ueq

Br1

0.13632 (2)

0.25468 (2)

0.37558 (2)

0.02823 (9)

O1

0.43075 (9)

0.29377 (11)

0.11607 (10)

0.0283 (3)

O2

0.33685 (9)

0.38628 (9)

0.03190 (9)

0.0209 (3)

O3

−0.00779 (9)

0.29679 (11)

0.03098 (9)

0.0257 (3)

O4

0.05653 (8)

0.38995 (9)

−0.02185 (8)

0.0187 (3)

O5

0.23363 (9)

0.57903 (9)

0.13294 (9)

0.0217 (3)

N1

0.23174 (10)

0.19821 (10)

0.17407 (10)

0.0174 (3)

H1

0.2398

0.1592

0.2124

0.021*

N2

0.25085 (11)

0.54099 (11)

0.20923 (10)

0.0201 (3)

C1

0.29821 (12)

0.22402 (12)

0.15734 (11)

0.0169 (4)

C2

0.29080 (11)

0.29224 (12)

0.10686 (11)

0.0141 (3)

C3

0.21215 (11)

0.34605 (11)

0.07315 (10)

0.0130 (3)

H3

0.1986

0.3552

0.0142

0.016*

C4

0.14028 (11)

0.29744 (12)

0.08116 (11)

0.0139 (3)

C5

0.15317 (12)

0.23029 (12)

0.13390 (11)

0.0159 (4)

C6

0.08914 (14)

0.18422 (14)

0.15562 (13)

0.0245 (4)

H6A

0.1132

0.1316

0.1871

0.037*

H6B

0.0426

0.1677

0.1060

0.037*

H6C

0.0699

0.2233

0.1879

0.037*

C7

0.37467 (13)

0.17054 (14)

0.19898 (13)

0.0257 (4)

H7A

0.4155

0.2056

0.2415

0.039*

H7B

0.3974

0.1525

0.1595

0.039*

H7C

0.3609

0.1186

0.2232

0.039*

C8

0.36060 (12)

0.32102 (13)

0.08757 (12)

0.0186 (4)

C9

0.40158 (15)

0.42942 (16)

0.01577 (16)

0.0320 (5)
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H9A

0.3787

0.4559

−0.0389

0.038*

H9B

0.4439

0.3862

0.0172

0.038*

C10

0.44005 (19)

0.4990 (2)

0.0777 (2)

0.0518 (8)

H10A

0.4833

0.5286

0.0658

0.078*

H10B

0.4641

0.4723

0.1316

0.078*

H10C

0.3979

0.5415

0.0764

0.078*

C11

0.05621 (11)

0.32540 (12)

0.03009 (11)

0.0169 (4)

C12

−0.02498 (12)

0.41577 (15)

−0.07884 (12)

0.0251 (4)

H12A

−0.0581

0.4380

−0.0492

0.030*

H12B

−0.0539

0.3649

−0.1117

0.030*

C13

−0.01450 (14)

0.48594 (15)

−0.13250 (13)

0.0265 (4)

H13A

−0.0687

0.5042

−0.1715

0.040*

H13B

0.0183

0.4633

−0.1615

0.040*

H13C

0.0137

0.5362

−0.0995

0.040*

C14

0.20205 (14)

0.54318 (14)

−0.00658 (13)

0.0255 (4)

H14A

0.1532

0.5807

−0.0259

0.038*

H14B

0.1924

0.4920

−0.0419

0.038*

H14C

0.2495

0.5759

−0.0074

0.038*

C15

0.21875 (12)

0.51432 (12)

0.07741 (12)

0.0178 (4)

C16

0.22413 (11)

0.43523 (12)

0.11286 (11)

0.0137 (3)

C17

0.24542 (11)

0.45621 (12)

0.19624 (11)

0.0146 (3)

C18

0.26466 (12)

0.39629 (12)

0.26628 (10)

0.0155 (4)

C19

0.20191 (12)

0.36074 (12)

0.28569 (11)

0.0169 (4)

H19

0.1460

0.3755

0.2551

0.020*

C20

0.22263 (13)

0.30334 (12)

0.35054 (11)

0.0196 (4)

C21

0.30353 (14)

0.28160 (13)

0.39662 (12)

0.0235 (4)

H21

0.3165

0.2426

0.4410

0.028*

C22

0.36550 (14)

0.31774 (14)

0.37688 (12)

0.0259 (4)
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H22

0.4214

0.3034

0.4081

0.031*

C23

0.34645 (12)

0.37472 (13)

0.31184 (12)

0.0215 (4)

H23

0.3892

0.3989

0.2985

0.026*

Atomic displacement parameters (Å2)
U11

U22

U33

U12

U13

U23

Br1

0.04300
(16)

0.02509
(13)

0.02490
(14)

−0.00891
(9)

0.02224
(11)

−0.00250
(8)

O1

0.0180 (7)

0.0354 (9)

0.0343 (8)

0.0043 (6)

0.0131 (6)

0.0014 (7)

O2

0.0214 (7)

0.0203 (7)

0.0271 (7)

−0.0033 (5) 0.0163 (6)

0.0006 (6)

O3

0.0157 (7)

0.0395 (9)

0.0204 (7)

−0.0050 (6) 0.0055 (5)

0.0005 (6)

O4

0.0146 (6)

0.0196 (7)

0.0179 (6)

0.0030 (5)

0.0022 (5)

0.0022 (5)

O5

0.0296 (8)

0.0110 (6)

0.0242 (7)

−0.0007 (5) 0.0100 (6)

0.0018 (5)

N1

0.0229 (8)

0.0126 (7)

0.0178 (7)

0.0012 (6)

0.0090 (6)

0.0034 (6)

N2

0.0249 (9)

0.0138 (8)

0.0204 (8)

−0.0003 (6) 0.0075 (7)

0.0005 (6)

C1

0.0198 (9)

0.0146 (8)

0.0167 (8)

0.0022 (7)

0.0074 (7)

−0.0019 (7)

C2

0.0141 (8)

0.0138 (8)

0.0154 (8)

0.0004 (6)

0.0068 (7)

−0.0020 (7)

C3

0.0152 (8)

0.0116 (8)

0.0133 (8)

−0.0002 (6) 0.0065 (6)

−0.0002 (6)

C4

0.0142 (8)

0.0141 (8)

0.0134 (8)

−0.0014 (6) 0.0055 (7)

−0.0024 (6)

C5

0.0195 (9)

0.0134 (8)

0.0162 (8)

−0.0038 (7) 0.0086 (7)

−0.0042 (7)

C6

0.0284 (11) 0.0225 (10) 0.0269 (10) −0.0084 (8) 0.0154 (9)

0.0003 (8)

C7

0.0255 (10) 0.0235 (10) 0.0282 (10) 0.0110 (8)

0.0070 (8)

C8

0.0193 (9)

C9

0.0343 (12) 0.0296 (11) 0.0450 (13) −0.0098 (9) 0.0297 (11)

0.0195 (9)

0.0202 (9)

0.0104 (9)

−0.0014 (7) 0.0110 (7)

C10 0.0417 (16) 0.0412 (15) 0.081 (2)

−0.0187
(12)

C11 0.0166 (9)

0.0200 (9)

−0.0012 (7) 0.0051 (7)

C12 0.0157 (9)

0.0327 (11) 0.0189 (9)

0.0134 (8)
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0.0044 (8)

0.0336 (16)

−0.0047 (7)
−0.0020
(10)
−0.0231
(15)
−0.0044 (7)

−0.0020 (7) −0.0001 (8)

C13 0.0242 (10) 0.0268 (11) 0.0218 (10) 0.0080 (8)

0.0017 (8)

−0.0017 (8)

C14 0.0321 (11) 0.0200 (10) 0.0250 (10) 0.0003 (8)

0.0117 (9)

0.0082 (8)

C15 0.0180 (9)

0.0141 (8)

0.0218 (9)

−0.0007 (7) 0.0083 (7)

0.0004 (7)

C16 0.0132 (8)

0.0129 (8)

0.0153 (8)

0.0001 (6)

0.0010 (6)

C17 0.0133 (8)

0.0128 (8)

0.0178 (8)

−0.0005 (6) 0.0062 (7)

−0.0009 (7)

C18 0.0207 (9)

0.0118 (8)

0.0134 (8)

−0.0005 (7) 0.0058 (7)

−0.0024 (6)

C19 0.0218 (9)

0.0145 (8)

0.0155 (8)

0.0010 (7)

0.0084 (7)

−0.0024 (7)

C20 0.0318 (11) 0.0141 (8)

0.0167 (9)

−0.0038 (7) 0.0136 (8)

−0.0041 (7)

C21 0.0379 (12) 0.0154 (9)

0.0133 (9)

0.0008 (8)

−0.0002 (7)

C22 0.0249 (10) 0.0236 (10) 0.0204 (10) 0.0014 (8)
C23 0.0194 (9)

0.0207 (9)

0.0212 (9)

0.0059 (6)

0.0056 (8)

−0.0007 (8) 0.0005 (8)

−0.0012 (7) 0.0043 (8)

−0.0011 (7)

Geometric parameters (Å, °)
Br1—C20

1.898 (2)

C9—H9A

0.9900

O1—C8

1.213 (2)

C9—H9B

0.9900

O2—C8

1.358 (2)

C9—C10

1.497 (4)

O2—C9

1.441 (2)

C10—H10A

0.9800

O3—C11

1.216 (2)

C10—H10B

0.9800

O4—C11

1.359 (2)

C10—H10C

0.9800

O4—C12

1.457 (2)

C12—H12A

0.9900

O5—N2

1.407 (2)

C12—H12B

0.9900

O5—C15

1.356 (2)

C12—C13

1.501 (3)

N1—H1

0.8800

C13—H13A

0.9800

N1—C1

1.375 (3)

C13—H13B

0.9800

N1—C5

1.379 (3)

C13—H13C

0.9800

N2—C17

1.315 (2)

C14—H14A

0.9800

C1—C2

1.355 (3)

C14—H14B

0.9800

C1—C7

1.504 (3)

C14—H14C

0.9800
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C2—C3

1.521 (2)

C14—C15

1.485 (3)

C2—C8

1.469 (3)

C15—C16

1.354 (3)

C3—H3

1.0000

C16—C17

1.430 (2)

C3—C4

1.523 (2)

C17—C18

1.484 (2)

C3—C16

1.516 (2)

C18—C19

1.392 (3)

C4—C5

1.355 (3)

C18—C23

1.392 (3)

C4—C11

1.470 (3)

C19—H19

0.9500

C5—C6

1.505 (3)

C19—C20

1.388 (3)

C6—H6A

0.9800

C20—C21

1.382 (3)

C6—H6B

0.9800

C21—H21

0.9500

C6—H6C

0.9800

C21—C22

1.387 (3)

C7—H7A

0.9800

C22—H22

0.9500

C7—H7B

0.9800

C22—C23

1.389 (3)

C7—H7C

0.9800

C23—H23

0.9500

C8—O2—C9

116.28 (17)

H10A—C10—H10C

109.5

C11—O4—C12

114.35 (15)

H10B—C10—H10C

109.5

C15—O5—N2

108.62 (14)

O3—C11—O4

121.46 (17)

C1—N1—H1

118.3

O3—C11—C4

127.02 (18)

C1—N1—C5

123.44 (16)

O4—C11—C4

111.52 (15)

C5—N1—H1

118.3

O4—C12—H12A

110.1

C17—N2—O5

105.22 (15)

O4—C12—H12B

110.1

N1—C1—C7

114.20 (17)

O4—C12—C13

108.09 (17)

C2—C1—N1

119.89 (17)

H12A—C12—H12B

108.4

C2—C1—C7

125.92 (18)

C13—C12—H12A

110.1

C1—C2—C3

121.28 (16)

C13—C12—H12B

110.1

C1—C2—C8

121.10 (17)

C12—C13—H13A

109.5

C8—C2—C3

117.46 (16)

C12—C13—H13B

109.5

C2—C3—H3

107.6

C12—C13—H13C

109.5
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C2—C3—C4

111.14 (14)

H13A—C13—H13B

109.5

C4—C3—H3

107.6

H13A—C13—H13C

109.5

C16—C3—C2

111.21 (14)

H13B—C13—H13C

109.5

C16—C3—H3

107.6

H14A—C14—H14B

109.5

C16—C3—C4

111.38 (14)

H14A—C14—H14C

109.5

C5—C4—C3

121.10 (16)

H14B—C14—H14C

109.5

C5—C4—C11

120.70 (17)

C15—C14—H14A

109.5

C11—C4—C3

118.19 (16)

C15—C14—H14B

109.5

N1—C5—C6

113.55 (17)

C15—C14—H14C

109.5

C4—C5—N1

119.78 (17)

O5—C15—C14

115.69 (16)

C4—C5—C6

126.67 (18)

C16—C15—O5

110.47 (16)

C5—C6—H6A

109.5

C16—C15—C14

133.83 (18)

C5—C6—H6B

109.5

C15—C16—C3

127.80 (16)

C5—C6—H6C

109.5

C15—C16—C17

103.46 (16)

H6A—C6—H6B

109.5

C17—C16—C3

128.74 (16)

H6A—C6—H6C

109.5

N2—C17—C16

112.22 (16)

H6B—C6—H6C

109.5

N2—C17—C18

118.86 (16)

C1—C7—H7A

109.5

C16—C17—C18

128.85 (16)

C1—C7—H7B

109.5

C19—C18—C17

120.71 (17)

C1—C7—H7C

109.5

C23—C18—C17

119.15 (17)

H7A—C7—H7B

109.5

C23—C18—C19

120.13 (17)

H7A—C7—H7C

109.5

C18—C19—H19

120.6

H7B—C7—H7C

109.5

C20—C19—C18

118.75 (18)

O1—C8—O2

122.32 (18)

C20—C19—H19

120.6

O1—C8—C2

127.38 (19)

C19—C20—Br1

118.22 (15)

O2—C8—C2

110.29 (16)

C21—C20—Br1

119.95 (15)

O2—C9—H9A

109.7

C21—C20—C19

121.84 (19)

O2—C9—H9B

109.7

C20—C21—H21

120.6
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O2—C9—C10

110.00 (19)

C20—C21—C22

118.86 (18)

H9A—C9—H9B

108.2

C22—C21—H21

120.6

C10—C9—H9A

109.7

C21—C22—H22

119.8

C10—C9—H9B

109.7

C21—C22—C23

120.5 (2)

C9—C10—H10A

109.5

C23—C22—H22

119.8

C9—C10—H10B

109.5

C18—C23—H23

120.0

C9—C10—H10C

109.5

C22—C23—C18

119.93 (19)

H10A—C10—H10B

109.5

C22—C23—H23

120.0

C5—C4—C11—O3

3.3 (3)

Br1—C20—C21—C22 179.72 (15)
O5—N2—C17—C16

−0.6 (2)

C5—C4—C11—O4

−176.30 (16)

O5—N2—C17—C18

176.85 (15)

C7—C1—C2—C3

−175.27 (18)

O5—C15—C16—C3

−179.90 (17)

C7—C1—C2—C8

0.1 (3)

O5—C15—C16—C17

−1.1 (2)

C8—O2—C9—C10

−83.5 (3)

N1—C1—C2—C3

5.0 (3)

C8—C2—C3—C4

166.75 (15)

N1—C1—C2—C8

−179.71 (16)

C8—C2—C3—C16

−68.6 (2)

N2—O5—C15—C14

−178.08 (16)

C9—O2—C8—O1

−7.6 (3)

N2—O5—C15—C16

0.8 (2)

C9—O2—C8—C2

171.45 (16)

N2—C17—C18—C19

98.0 (2)

C11—O4—C12—C13

−179.11 (16)

N2—C17—C18—C23

−83.0 (2)

C11—C4—C5—N1

172.20 (16)

C1—N1—C5—C4

−7.5 (3)

C11—C4—C5—C6

−8.2 (3)

C1—N1—C5—C6

172.82 (17)

C12—O4—C11—O3

−4.5 (3)

C1—C2—C3—C4

−17.7 (2)

C12—O4—C11—C4

175.21 (15)

C1—C2—C3—C16

106.95 (19)

C14—C15—C16—C3

−1.3 (4)

C1—C2—C8—O1

−5.0 (3)

C14—C15—C16—C17 177.5 (2)

C1—C2—C8—O2

175.95 (17)

C15—O5—N2—C17

−0.2 (2)

C2—C3—C4—C5

19.2 (2)

C15—C16—C17—N2

1.0 (2)

C2—C3—C4—C11

−160.86 (15)

C15—C16—C17—C18 −176.04 (18)

C2—C3—C16—C15

117.1 (2)

C16—C3—C4—C5
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−105.38 (19)

C2—C3—C16—C17

−61.4 (2)

C16—C3—C4—C11

C3—C2—C8—O1

170.49 (19)

C16—C17—C18—C19 −85.1 (2)

C3—C2—C8—O2

−8.5 (2)

C16—C17—C18—C23 93.9 (2)

C3—C4—C5—N1

−7.9 (3)

C17—C18—C19—C20 178.46 (16)

C3—C4—C5—C6

171.74 (17)

C17—C18—C23—C22 −179.06 (18)

C3—C4—C11—O3

−176.57 (18)

C18—C19—C20—Br1 −179.44 (13)

C3—C4—C11—O4

3.8 (2)

C18—C19—C20—C21 0.8 (3)

C3—C16—C17—N2

179.82 (17)

C19—C18—C23—C22 −0.1 (3)

C3—C16—C17—C18

2.7 (3)

C19—C20—C21—C22 −0.5 (3)

C4—C3—C16—C15

−118.3 (2)

C20—C21—C22—C23 −0.1 (3)

C4—C3—C16—C17

63.2 (2)

C21—C22—C23—C18 0.4 (3)

C5—N1—C1—C2

9.0 (3)

C23—C18—C19—C20 −0.5 (3)

C5—N1—C1—C7

−170.77 (17)

74.53 (19)

Hydrogen-bond geometry (Å, °)
D—H···A

D—H

H···A

D···A

D—H···A

N1—H1···N2i

0.88

2.26

3.125 (2)
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C22—H22···O3ii

0.95

2.58

3.302 (3)
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Symmetry codes: (i) −x+1/2, y−1/2, −z+1/2; (ii) x+1/2, −y+1/2, z+1/2.
All esds (except the esd in the dihedral angle between two l.s. planes) are estimated using
the full covariance matrix. The cell esds are taken into account individually in the
estimation of esds in distances, angles and torsion angles; correlations between esds in
cell parameters are only used when they are defined by crystal symmetry. An
approximate (isotropic) treatment of cell esds is used for estimating esds involving l.s.
planes.
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Chapter 5
Synthesis of sterically hindered Isoxazolyl Dihydropyridines (IDHPs), and asymmetric
organocatalytic synthesis of IDHP and Isoxazolyl-Quinolones
5.1 Background
The impact of chirality on drug development has been well established, so much
so, that it is a factor that the Food and Drug Administration (FDA) [1] regulates with new
chemical entities. The reason for the FDAs involvement is based in the established
observation that there are observed differences in the pharmaceutical properties of
enantiomers. [2-4] The FDA has also compiled a list of recommendations regarding
switching enantiomers in treatment settings, which include among other things, switching
to a single enantiomer for an approved racemate where appropriate and that both
enantiomers of a new chemical entities should be tested independently. [5,6] As a general
statement, the toxicology, pharmacokinetics and pharmacodynamics of both enantiomers
of a drug can have widely different effects, and as such both enantiomers of a new
chemical entity should be studied and evaluated independently. Since the number of
chiral medicines increases annually, synthetic strategies that exhibit fine stereo control,
and can be efficiently performed on multi-gram scales are needed. [7, 8]
When considering the 1, 4-dyhidropyridine (DHP) ring; if the substituent’s on the
C3 and C5 positions of the ring are non-identical, the molecule is chiral at the substituted
C4 center. The C3 and C5 positions are most commonly occupied by ester groups, there
arrangement with respect to the DHP ring and the interactions that they form, have been
proposed to be an influencing factor on the pharmacological activities of DHPs at the
voltage gated calcium channel (VGCC).[9] This along with the well established eudysmic
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ratio that exists at the VGCC, makes it so the enantiomers of unsymmetrical DHPs
usually differ in their biological activities [10,11] and could have all together opposite
bioactivity profiles.[12]
The most common method for synthesizing DHPs is the Hantzsch pyridine
synthesis. The synthesis has been known since 1882, and in that time there have been
numerous efforts to improve or otherwise modify the reaction.[13-16] The Hantzsch
pyridine synthesis consists of the condensation of an aldehyde with two equivalents of an
active methylene carbonyl compounds (for example, ethyl acetoacetate) and a subsequent
reaction with ammonia to yield a DHP.[17,18] The Hantzsch pyridine synthesis is what is
known as a multi-component reaction, meaning that it is a chemical transformation in
which three or more reagents form a product derived from all of the reactants.[19] As a
comparison, two component reactions generally require a specific order of addition to
generate a desired product. On the other hand, multi-component reactions such as the
Hantzsch pyridine synthesis don’t have the same requirements and the reagents can be
added in any order as long as all the reagents are present the final product will still be
produced. [20] With this flexibility in the order of addition, multi-component reactions do
have a major drawback. Their ability to resist catalysis, this is in large part a result of the
aforementioned multiple methods that the reaction can take place. This is further
exemplified in the Hantzsch pyridine synthesis by the fact that more than a century has
passed between the discovery of the reaction and the discovery of the first catalysts for
the synthesis. [21]
In the synthesis of symmetrical DHPs, the reaction is a multi-component reaction
or to be more specific, it can be termed a four component reaction. The dicarbonyl
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compounds are independent variables and are incorporated twice to produce symmetrical
products. The limitation of only producing symmetrical DHPs can be avoided by making
modifications to the starting materials. The synthesis can be carried out with one
equivalent of either an enamine or a Knoevenagel condensation product with another
equivalent of a dicarbonyl compound. The two fragments will react in what is known as a
Michael addition to form what will be the C4 center of the DHP. Additionally, if the two
fragments are non-identical they will produce a C4 center that is now chiral. This is
followed by a proton transfer, and finally an intermolecular enamine formation followed
by the loss of water to give the desired DHP final product.
The classical Hantzsch reaction is carried out by reacting the given reagents via
refluxing them in either acetic acid or alcohol. [22] Without a catalysis the reaction,
involves long reaction times, relatively harsh conditions, and often utilizes large
quantities of volatile solvents. There have been attempts over the years, to improve on the
harsh reaction conditions that are required for the un-catalyzed synthesis to be successful.
[23-27]

With more recent research into catalyzing the synthesis, asymmetric or otherwise,

the possibility of synthesizing previously unattainable compounds becomes possible. This
attention has resulted in a substantial amount of effort being put into discovering a useful
catalysis for the reaction. As such, we focused on this recent work to modify our
synthetic efforts to generate our next generation of compounds. Rare earth metal Lewis
acids, such a Yb (OTf) 3 and Sc (OTf) 3 have gained the highest rate of adoption as a
useful catalysis. Yb (OTf)3, which was discovered in 2005, nearly 120 years after the
discovery of the reaction itself, has been shown to give synthetically useful yields for the
reaction as well as address a number of the issues that arise from the un-catalyzed
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reaction method. [28] Other Lewis acid catalysis such as Proline and PhB(OH)2 have also
been shown to catalyze the reaction, but do to by-product formation or additional
purification being needed, they have not seen the same adoption rate. [29-32]
But, even utilizing a catalysis the reaction still has one major drawback, it
produces racemic mixtures. As mentioned above, we want to explore chiralitys effect on
MDR1 inhibition and as such we need a means to synthesis IDHPs stereoselectively.[33-35]
The formation of enantiomers and their separation by means of crystallization or
preparative chromatography has been historically the predominate means of resolving
racemic DHP. But, our goal in this research is to develop a method to asymmetrically
produce enatio-pure compounds. With this being said, there have been attempts that have
recently discovered effective enantioselective asymmetric synthetic methods for DHPs in
the literature. With this research forming the bases of our effort in asymmetric synthesis,
we now have the mean to modify established synthetic methods to produce our desired
final products.
5.2 Chiral resolution of DHPs
The use of classical resolving methods have been the predominate mean of
separating enantiomers of DHPs in the literature. But, it isn’t the only potential means of
obtaining enantiomers. Resolutions of racemic DHPs have been shown to be possible if a
carboxylic acid is present on the DHP ring. DHPs with C3-carboxylic acids can be
resolved via diastereomeric salts. [36] This method utilizes diastereomeric salts that are
formed in the presents of a chiral amine base that functions as a resolving agent. [36] The
most preferred and most successful resolving agents are cinchonidine, [37-39]
cinchonine[40,41] and quinidine.[42] Common factors in these separations, is that a racemic
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DHP is treated with a chiral base, which forms a crystalline diastereomeric salt. The
diastereomeric purity of the salt is improved by repeat crystallization; but to obtain
enantiomerically pure DHPs, the salt needs to be removed, this is usually done via
acidification. The recovery of the monoacid from the mother liquor can then be treated
with another chiral base that will complex the crystalline optical antipode; and after
repeated crystallization the opposite enantiomers can be obtained. A benefit of this
method is that both enantiomers can be obtained. But the need for repeated crystallization
lowers the yield and with this step being essential to obtain a high ee’s it makes the
purification method impractical on small scales. Additionally, chiral acids such as
camphorsulphonic acid and substituted tartaric acids have also been used to separate
enantiomers of basic DHP compounds. [43] The resolution of racemic amlodipine has been
carried out using (-) camphanic acid chloride, and the diastereomeric amides is then
separated via chromatographic methods to give a pure product.[44] This method of
separation is the most suitable for DHPs with basic substituent’s at the 2 position of the
DHP ring.[44]
Chiral resolution of enantiomers by HPLC is another resolution method that is
historically very predominate for obtaining DHP enantiomers. Both enantiomers can be
obtained using conventional stationary phase chromatography. Alternatively, enantiomers
can be directly analyzed on chiral stationary phases.[45] The direct chromatographic enatio
separation of unsymmetrical DHPs on chiral stationary phases has been widely used for
the determination of enantiomeric purity,[46] and for preparing small quantities of
enantiomers,[47][48] for biological investigation.[49,50]
5.3 Asymmetric synthesis of the Hantzsch pyridine synthesis
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Figure 5.1: Historical evolution of the chiral asymmetric synthesis of DHPs
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The use of asymmetric synthetic methods for DHPs has been explored sense the
discovery of the Hantzsch pyridine synthesis with varying degrees of success.
Historically, the first synthetic strategys involves the synthesis of diastereomeric DHPs
with an easily removable chiral auxiliary. This was then followed by the separation of the
diastereomers by means of chromatography or fractional crystallization; although this can
also be followed by regioselective removal of the group containing the chiral auxiliary.
[51][78]

This method was further explored by leaving the chiral auxiliary on the DHP and

using the auxiliary to assign the C4 chiral center. [52]
Other synthetic methods include the use of amino heterocycles that have been
incorporated into the enamine component before the critical Michael addition. The use of
different enamines permits the isolation of unsymmetrical DHPs, with the reaction
requiring that the enamine be used in combination with an active methylene carbonyl
compound to achieve the desired result. [53-55] The mechanism for the reaction involves an
aldehyde that is condensed with an active methylene compound to give α,β-unsaturated
ketone in a reaction known as a Knoevenagel condensation. The product can then be
reacted with a secondary amine to form an enamine that can be reacted with another
equivalent of an active methylene compound to give an unsymmetrical and definably
chiral DHP.[56] Enantioselective synthetic methods utilizing chiral auxiliaries attached to
the nitrogen atom as described above have proven to be practically useful.[57] However,
low yields of N-substituted DHP and formation of cyclohexenes as by-products have
been observed.[58] As a general statement, this alternative synthetic method of first
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synthesizing a Knoevenagel or enamine product and then reacting it usually gives good
results when the traditional Hantzsch synthesis fails.
5.4 Chiral BIONL phosphoric acids
The development of chiral ester of phosphoric acid as catalysts was initially
slower than that of the corresponding phosphor amides, with far fewer examples of the
phosphoric acid class of ligand being reported. More recently however interest in
phosphoric acids as catalysts has grown; initial work done by two research groups’ first
explored phosphoric acids as catalysts. Terada and Akiyama independently reported on
the catalytic activity of phosphoric acids esters. [59,60] Terada reported the use of a
binaphthyl mono-phosphoric acid being utilized in highly enantioselective 1,2-aza
Freidal-Crafts reactions, generating the product in a good enantiomeric excess.[61]
Akiyama reported the use of a chiral phosphoric acid ester in the enantioselective
Mannich-type reaction of ketene silyl acetals with aldimines. Akiyama studies also
explored the effect that the R groups present in the 3, 3-positions of the BINOL scaffold,
have on the enantiomeric excess of the product. [62]
Many chiral phosphoric acid esters are based on the 1, 1-binaphthol (BINOL)
scaffold. Synthetically obtaining the phosphoric acid ester is done via reacting the
BINOL diol with phosphoryl chloride in the presence of a base. This is followed by an
aqueous work up to give a phosphoric acid ester. The phosphoric acid ester allows the
molecule to act as a bi-functional catalyst that contains both a Bronsted acid and Lewis
base.[60] Additionally, the phosphoric acid ester is conformationally rigid with one proton
being highly acidic, and as such it has been predicted to form hydrogen bonding
interactions in transition states.[79] Moving out from the phosphoric acid ester to other
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areas of the catalysis, the 3,3-substituents on the BINOL can be varied to change the
properties of the catalyst. Studies done where the substituent’s at the 3 positions where
modified showed the general trend that sterically bulky groups enhance
enantioselectivity, whereas less sterically demanding groups gave diminished
enantiomeric excesses. [64]
As a class of catalysts, phosphoric acids have been shown to have a wide array of
potential uses synthetically. Most commonly phosphoric acid catalysis have been used as
hydrogen bonding catalysts for a wide variety of reactions.[65] Additionally, chiral BINOL
phosphoric acids have been reported to be used as a chiral resolving agent, but the
predominate application of the compound has been it uses as a catalysis.[66]
There have been examples of asymmetric catalysis of the Hantzsch reaction,
recently reported by Gong and Gestwicki. [67-69] Phosphoric acid esters exhibit comparable
chemical reactivity to Yb (OTf)3 and have been shown to induced high enantioselectivity.
Building on this work we have decided to utilize Yb (OTf)3 to produce racemic
isoxazole-dihydropyridines (IDHP) s and isoxazol-hydroquinolines (IHQ) s. This will
then be follow up with the use of a chiral phosphoric acid ester to produce enatio
enriched IDHPs and IHQs for the next generations of drug development.
5.5 Next Generation of Compounds
Examining the variations that we have introduced into each generation of IDHP
analog development up to this point allows us to pinpoint areas in the SAR that we still
want to address. The R2 position (Figure 5.11) and the chirality of IDHP are the
remaining aspects that we decided to explore. With these two goals in place, we focused
our efforts on pursuing a series of IHQ analogs. Literature pertaining to the 4-aryl-
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hydroquinolines has been observed to produce compounds that possess reduced calcium
channel activity; this added benefit of being less selective at VGCC is another aspect that
makes this sub-structure an ideal lead scaffold to examine. Additionally, to date the
compounds haven’t been tested at MDR1. The hydroquinolines also contain a chiral
center, and this also allows us to examine the effect that chirality has on MDR1 inhibitory
activity. With this being said, the need to establish an alternative method of synthesis is
key to the next generations of drug development. There have been similar synthetic
methods that will allow us to produce our desired product but, the differences that our
starting materials have verses the known methods will need to be considered and taken
into account; the exploration of these methods will be discussed later in the chapter.

Figure 5.2: The breakdown of the generations of drug development as it relate to this
project.
Generation 4 compounds will function as a bridging generation of compounds,
which will work to both explore a remaining aspect of the SAR and function as stepping
stones to set up the 5th generation of chiral compounds by producing racemic IDHPs and
IHQs. Going back to generation 1 compounds and comparing it with generation 3
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monomers we observe a defined increase in activity as we go from Cl to Br IDHP
analogs. The observation that as groups in this position become more sterically imposing
there is an increase in MDR1 inhibition is an SAR factor that we want to examine further.
Thus, we decided to pursue synthetic targets that would examine the degree of steric bulk
that would allow for optimal MDR1 inhibitory activity. Additionally, we have the
opportunity to examine the potential effect halogen bonding interactions could have with
binding to MDR1. In chapter 2 and 3 we observed halogen bonding interactions in the
crystal structure, and as such we want to see if the increase in activity is potentially due to
steric bulk or halogen bonding interactions. Also previous work that relates to the
selectivity of similar compounds was done by Triggle and Natale. Both groups noted that
more steric aryl-DHPs and IDHPs have reduced calcium channel activity. [70-72] As such,
we are looking to take advantage of this SAR factor to allow for more MDR1 selective
compounds. But, we are encouraged to not utilize the conventional un-catalysized
Hantzsch pyridine synthesis. The un-catalyzed Hantzsch pyridine synthesis isn’t an
optimal synthetic strategy for synthesizing more steric compounds due to that previous
studies attempting to produce more sterically demanding compounds often results in
almost none of the desired product being formed due; to what has been termed the tennis
racket effect. Thus, a new synthetic method is needed to synthesize the desired target
compounds. As mentioned above, the use of Ytterbium (III) trifluoromethanesulfonate
(Yb) was recently reported as a catalysis for synthesizing aryl-hydroquinolines. [73] As
such, we manipulated the method to work as a catalysis to produce our desired generation
4 IDHPs and IHQs compounds. Using Yb III as a catalysis also requires less harsh
reaction conditions and as a general statement provides higher yields.
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Entry R
% yield HRMS calc'd Found
1a
1'-Naphthyl
64.04
501.2026
501.2019
2a
1'-(2'-methoxy-Naphthyl)
50.21
491.2182
491.2205
3a
9'-Anthryl
41.98
511.2233
511.2228
4a
3,4-Bis –benzyloxy-benzene 67.95
469.1975
469.1990
5a
3-Phenoxy-benzene
60.98
501.2026
501.2019
6a
4-Methoxy-benzene
60.96
441.2026
441.2057
7a
2,4-Dimethoxy-benzene
63.98
623.2757
623.2709
8a
3,4-Dimethoxy-benzene
53.19
623.2757
623.2807
9a
4-Biphenyl
46.23
487.2233
487.2256
Table 5.1. Lanthanide catalyzed synthesis of sterically hindered isoxazolyldihydropyrdines
The fifth generation of compounds will focus on establishing a eudysmic ratio for
the IHQs and IDHPs at MDR1. Given Triggles work on aryl-DHPs, a syn-periplanar
conformation for the carbonyl groups at C3 and C5 on the DHP ring is suggested as a
common feature of DHPs that lead to their calcium channel antagonist activity. [74-76] To
capitalize on this factor and increase the selectivity of our compounds while still focusing
on producing chiral center at the C4 center of the DHP ring. We propose that one of the
carbonyl groups can be forced into an anti-periplanar conformation. This can be
accomplished by using dimedone as one equivalent of our dicarbonyl fragment, while
using ethyl acetate as the second equivalent in a standard Hantzsch pyridine synthesis.
Additionally, as a proof of concept that the modification leads to reduced VGCC activity
4-aryl-hydroquinolones have been observed to have weak calcium channel activity [77]
when compared to their DHP counterparts. This could be contributed to the
aforementioned locking of the carbonyl group, thus giving us the bases to pursue IHQs
that should show less activity at the VGCC and be more selective for MDR1.
Additionally, the modification introduces chirality at the C4 center and will allow us to
take advantage of the eudysmic ratio that is known at the VGCC. It consequently, allows
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us to examine if there is also a lack of a eudysmic ratio at MDR1. The synthesis and
exploration of the proposed concepts will be discussed later in the chapter.
5.6 Generation 4 Synthesis
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Figure 5.3: Representative Synthetic Route for sterically hindered IDHP compounds.
The synthetic route proposed to obtain generation 4 compounds is similar to
methods used in previous generations of drug development. The utilization of an alcohol
as a starting material requires that the alcohol needs to be oxidized to an aldehyde via
Pyridinium chlorochromate (PCC) to allow for the formation of an oxime. But, once an
oxime is in hand the synthetic methods for the formation of the isoxazolyl-aldehyde is
identical to that described in earlier chapters. The notable exception to generation 3
synthetic methods is that the Hantzsch pyridine synthesis is carried out with the Yb (III)
catalysis. This method allows for better yields and more sterically hindered systems to be
synthesized effectively. The catalyzed method also requires less solvent and it can be ran
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at room temperature, with the one down side that it requires longer reaction times for
larger reaction scales. We also wanted to examine unsymmetrical IHQ derivatives in the
next generation of compounds so we synthesized, racemic IHQs using the Yb (III)
catalytic method.
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Figure 5.4: Synthetic Route for IHQs utilizing Yb (III) catalytic method
The exact mechanism for the YB (III) catalyzed reaction isn’t known with
certainty, but it is speculated on in the literature. Generally the mechanism involves the
Yb (III) catalysis complexing with an activated methylene compound in its enol form.
The activated enol can then react with an aldehyde to give rise to a Knoevenagel product.
The Knoevenagel product then reacts in a Michael addition with an equivalent of
dimedone or ethyl acetoacetate to from an intermediate where the catalysis is released.
From this point in the mechanism the remaining steps in the standard Hantzsch pyridine
synthesis are allow to occur to produce a IDHP or IHQ.
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Figure 5.5: Generation 4 library of compounds, using Yb (III) catalyst method
5.7 Generation 4 Compound (1a, 2a, 1b) Crystal Structures
A

149

Crystal data
C27H28N2O5

?

Mr = 460.51

Dx = 1.305 Mg m−3

Monoclinic, P21/c

Melting point: ? K

Hall symbol: ?

Mo Kα radiation, λ = 0.71073 Å

a = 8.2709 (7) Å

Cell parameters from 9866 reflections

b = 20.1782 (16) Å

θ = ?°

c = 14.0531 (12) Å

µ = 0.09 mm−1

β = 92.412 (4)°

T = 100 K

V = 2343.3 (3) Å3

Prism, translucent white

Z=4

0.44 × 0.30 × 0.17 mm

F(000) = 976

Data collection
Bruker SMART BREEZE CCD
diffractometer

5938 independent reflections

Radiation source: 2 kW sealed X-ray tube

4468 reflections with I > 2σ(I)

Graphite monochromator

Rint = 0.048
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Detector resolution: ? pixels mm-1

θmax = 28.9°, θmin = 1.8°

φ and ω scans

h = −11 11

Absorption correction: multi-scan
SADABS v2012/1 (Bruker AXS Inc.)

k = −27 25

Tmin = 0.703, Tmax = 1.000

l = −18 13

20554 measured reflections

Refinement
Refinement on F2

Secondary atom site location: ?

Least-squares matrix: full

Hydrogen site location: inferred from
neighbouring sites

R[F2 > 2σ(F2)] = 0.051

H-atom parameters constrained

wR(F2) = 0.142

w = 1/[σ2(Fo2) + (0.0695P)2 + 0.5936P]
where P = (Fo2 + 2Fc2)/3

S = 1.04

(Δ/σ)max = 0.001

5938 reflections

Δρmax = 0.38 e Å−3

312 parameters

Δρmin = −0.33 e Å−3

0 restraints

Extinction correction: none

? constraints

Extinction coefficient: ?

Primary atom site location: structureinvariant direct methods
B
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Crystal data
C28H30N2O6

calculated from global refinement

Mr = 490.54

Dx = 1.331 Mg m−3

Monoclinic, C2/c

Melting point: ? K

Hall symbol: -C 2yc

Cu Kα radiation, λ = 1.54178 Å

a = 19.5698 (9) Å

Cell parameters from 5879 reflections

b = 15.3341 (7) Å

θ = 2.7–68.4°

c = 17.2324 (7) Å

µ = 0.77 mm−1

β = 108.724 (3)°

T = 100 K

V = 4897.5 (4) Å3

Prism, translucent pale yellow

Z=8

0.31 × 0.15 × 0.06 mm

F(000) = 2080

Data collection
Bruker D8 Venture PHOTON 100 CMOS
diffractometer

4278 independent reflections

Radiation source: INCOATEC ImuS
micro-focus source

2418 reflections with I > 2σ(I)

Mirrors monochromator

Rint = 0.076
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Detector resolution: 10.4167 pixels mm-1

θmax = 66.6°, θmin = 3.7°

ω and phi scans

h = −23 22

Absorption correction: numerical
SADABS V2008/1 (Bruker AXS Inc.)

k = −18 15

Tmin = 0.70, Tmax = 0.96

l = −19 20

16347 measured reflections

Refinement
Refinement on F2

Secondary atom site location: difference
Fourier map

Least-squares matrix: full

Hydrogen site location: inferred from
neighbouring sites

R[F2 > 2σ(F2)] = 0.091

H atoms treated by a mixture of
independent and constrained refinement

wR(F2) = 0.265

w = 1/[σ2(Fo2) + (0.1199P)2 + 11.9275P]
where P = (Fo2 + 2Fc2)/3

S = 1.03

(Δ/σ)max = 0.005

4278 reflections

Δρmax = 0.88 e Å−3

335 parameters

Δρmin = −0.26 e Å−3

0 restraints

Extinction correction: none

? constraints

Extinction coefficient: ?

Primary atom site location: structureinvariant direct methods
C
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Crystal data
C25H28N2O4

?

Mr = 420.49

Dx = 1.286 Mg m−3

Monoclinic, P21/c

Melting point: ? K

Hall symbol: ?

Mo Kα radiation, λ = 0.71073 Å

a = 16.0832 (7) Å

Cell parameters from 7766 reflections

b = 9.8265 (4) Å

θ = 2.5–27.5°

c = 13.7577 (6) Å

µ = 0.09 mm−1

β = 93.053 (3)°

T = 100 K

V = 2171.20 (16) Å3

Prism, yellow

Z=4

0.18 × 0.13 × 0.13 mm

F(000) = 896

Data collection
Bruker SMART BREEZE CCD
diffractometer

4980 independent reflections

Radiation source: 2 kW sealed X-ray tube

3220 reflections with I > 2σ(I)

Graphite monochromator

Rint = 0.068

Detector resolution: ? pixels mm-1

θmax = 27.5°, θmin = 1.3°
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φ and ω scans

h = −17 20

Absorption correction: multi-scan
SADABS v2012/1 (Bruker AXS Inc.)

k = −12 12

Tmin = 0.938, Tmax = 1.000

l = −17 17

30941 measured reflections

Refinement
Refinement on F2

Secondary atom site location: ?

Least-squares matrix: full

Hydrogen site location: inferred from
neighbouring sites

R[F2 > 2σ(F2)] = 0.052

H-atom parameters constrained

wR(F2) = 0.120

w = 1/[σ2(Fo2) + (0.0472P)2 + 0.7827P]
where P = (Fo2 + 2Fc2)/3

S = 1.02

(Δ/σ)max < 0.001

4980 reflections

Δρmax = 0.34 e Å−3

285 parameters

Δρmin = −0.34 e Å−3

0 restraints

Extinction correction: none

? constraints

Extinction coefficient: ?

Primary atom site location: structureinvariant direct methods
Figure 5.6 ORTEPs of (A) Naphthyl-2. (B) Methoxy-Naphthyl-2. (C) IQ 3a, 50%
probability ellipsoids. Complete crystallographic information files (cif's) are available
from the authors upon request.
Single crystal x-ray diffractometry (sc-xrd) was used to characterize the
conformation of IDHPs 1a, 2a and IHQ 1b. Interestingly, the both hindered naphthyl
IDHPs 1a and 2a, adopt a solid state conformation where the isoxazole is endo to the
DHP, likely due to crystal packing forces. In contrast, the IHQ 1b orients the C-3
isoxazole phenyl exo to the hydroquinolines ring, probably due to the influence of the
axial of the geminal dimethyls on the hydroquinolines B ring.
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5.8 HPLC Traces
The generation 4 IHQs and IDHP that where synthesized above were made to
examine both SAR elements and to establish racemic compounds to allow for a
comparison to generation 5 chiral compounds. To set the ground work for this
comparison to take place, traces of the racemic IHQs and IDHPs were collected to
compare to the chiral IHQ and IDHP in generation 5. The racemic IHQ and IDHP
compounds were analyzed on a cellulose based chiral pack AD chiral stationary phase
(CSP) column (Fig. 5.7).

HN

O
O

O

O
O
NH

NH

n

Figure 5.7: Structure of Cellulose Based Chiral Stationary Phase (CSP) Column

As one would expect with racemic compounds, both enantiomers can be observed
in the HPLC traces (Figure 5.8). This establishes a control resolution of the IHQ and
IDHP enantiomers and will be utilized in the analysis of putative asymmetric induction
(vide infra). The mobile phase solution that was used in the process was a 90/10 HPLC
grade hexane/isopropanol solution at a flow rate of 0.85 mL/min.
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Figure 5.8: HPLC trace of the Racemic Generation 4 compounds
With racemic traces of our desired compounds in hand we moved on to examine
the potential interaction that generation 4 compounds could have with MDR1 and see if
we could establish a tentative SAR before moving on to synthesizing generation 5
compounds.
5.9 Computational modeling for generation 4 compounds
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Due to a lack of biological data for this generation of compounds, computational
modeling was employed and the compounds were bound into the previously established
homology model. This process is identical to the process used in previous generations of
drug development, with the exception that we utilized CHEM PLP scores to establish a
gradation between the proposed compounds. As a result of this we used CHEM PLP
scores to establishing the lead compound in this generation of drug development and to
allow us to have a reason to examine one compounds SAR factors over another. The
library of compounds was localized and binding calculations were done identically to the
past generations of compounds, as such the process isn’t described in detail here.

Figure 5.9: Generation 4 binding energies predicted using ChemPLP.
The most energetically favorable compound is predicted to be the 4-biphenyl
IDHP. The establishment of an SAR was identical to previous generations, and as such
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the compound was isolated and a 6 Ǻ sphere was examined to establish the close binding
contacts.

Figure 5.10 Computational prediction for binding box interactions and SAR of compound
9a.
The anchoring interactions that are observed in the calculated best binder are far
more spread throughout the structure when compared to the past generations of drug
development. The DHP substructure is a more substantial anchoring point in this
generation. We also observe that the isoxazole has two key anchoring residues: GLN476
and SER 474 which further validates the inclusion of both the DHP and isoxazole
substructures. Additionally, the inclusion of the more steric and liphophilic groups in the
3-isoxazole position of the IDHPs, increase the calculated binding energies. The overall
SAR that can be taken from the 4th generation of compounds is that both of the isoxazole
and DHP substructures should be maintained in future drug development cycles.
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Additionally, the inclusion of more steric and liphophilic groups produces compounds
that are calculated to be more active. This also tentatively excludes the prediction that
halogen bonding is having an effect on increasing MDR1 inhibition. Computational
modeling of compounds in generation 4 that could potentially halogen bond don’t show
this interaction, and the increase in activity seems to be attributed to the increase in steric
bulk.
5.10 Chiral IHQ and IDHP synthesis
With generation 4 racemic compounds in hand, we then shifted our attention to
synthesizing chiral IHQs and IDHPs. As mentioned above, chiral phosphoric acid
BINOL catalyses have been used to synthesize chiral aryl-DHPs. The asymmetric
induction is the result of the BINOL catalysis forcing the Hantzsch pyridine synthesis to
react in a very defined and deliberate way. The reaction for the IHQs requires a specific
order of addition to be successful in producing the desired chiral product. 1.5 equivalents
of dimedone and 1 equivalent of ethyl acetoacetate are added in the presents of the chiral
BINOL catalysis. This is then followed by the addition of the aldehyde and ammonium
acetate. The mixture is then allowed to stir at room temperature and the product can be
isolated.
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Figure 5.11: Asymmetric organocatalytic syntheses of 4-isoxazolyl-Quinolones.
R1
-Ph

Catalyst
Yield
[]D
Yb(OTf)3
30.25
(R)-BINOL
25.92
-11.2
-o-Br-Ph
Yb(OTf)3
71.60
(R)-BINOL
64.35
-13.5
-m-Br-Ph
Yb(OTf)3
62.07
(R)-BINOL
60.40
-2.36
-p-Br-Ph
Yb(OTf)3
67.19
(R)-BINOL
65.34 -0.032
R2
Catalyst
Yield
[]D
-p-Br-Ph
Yb(OTf)3
31.56
(R)-BINOL
21.32
-2.68
Table 5.2 Asymmetric organocatalytic synthesis of 4-isoxazolyl-Quinolones.
The difference in the activity between the dimedone and ethyl acetoacetate is
what we are hypothesizing as the main factor that leads to the asymmetric induction. The
bases of our argument is an observation made by Gestwicki, during his studies with a
similar BIONL catalysis. He ran reactions with equal equivalents of ethyl acetoacetate
and dimedone, the end result of the study was that 20-30% of the recovered yield was
symmetrical ethyl acetoacetate DHP. This would suggest that ethyl acetoacetate is 2030% more reactive with the BIONL catalysis then dimedone. The catalysis allows the

161

ethyl acetoacetate to react faster than dimedone and to form the enolate. This then leads
to the subsequent Knoevenagel reaction to be held in place by the BIONL catalysis. The
mechanism for the catalysis isn’t known with any certainty, but the suggested route is
similar to a reaction mechanism proposed by Gong in his studies with a similar catalysis.
This also suggest that the Michael addition that occurs to form the C4 center, occurs by
the Knoevenagel product being held in place by the BINOL and the slower reacting
dimedone reacts to form the C4 center, again showing similarities to the reaction
mechanism proposed by Gong.(Figure 5.11) This would also explain why there is a need
to add an additional half of an equivalent of dimedone to the reaction to compensate for
the lower reactivity and to aide in the addition to allow for the desired IHQ product being
formed.
Another factor leading to the stereo-selective synthesis is what has been termed
the stereo-controlling groups at the 3’ positions of the BINOL. These groups allow for
the selectivity of both a specific geometric isomer and a stereo face for the reaction to
occur. The most energetically favorable combination of these factors being the E
geometric isomer and the Si face (Figure 5.11). The three other combinations ether place
the fragments to far from one another to react or showed extremely unfavorable steric
interaction with the stereo-controlling groups. The BINOL catalysis has the most
favorable interactions with the E geometric isomer while only allowing the si face to be
accessible for any addition. The end result of this is that a si face attack occurs during the
Michael addition, leading to the synthesis of the S enantiomer. The control that the
BINOL catalysis maintains on both the geometric isomer and facial selectivity allows for
the reaction to produce enatio pure compounds.
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Figure 5.12: Predicted reaction mechanism for the BINOL catalysis. (Left) The predicted
critical Michael addition for the reaction, the reaction show several similarities with a
predicted reaction that Gong et al. made for a similar reaction with a similar catalysis.
(Right) Computational representation of the key Michael addition in the Hantzsch
pyridine synthesis, showing the most favorable E geometric isomer and the si face.
The order of addition for the click control, (1c) diverges from the IHQs chiral
synthesis in that a Knoevenagel condensation is preformed with 3-Oxo-butyric acid prop2-ynyl ester and an isoxazole aldehyde to produce an isoxazole α, β-unsaturated ketone
before being introduced to the BINOL catalysis. The product is then reacted with the
phenylethyl azide in a click reaction to give one fragment in the Hantzsch pyridine
synthesis (Figure 5.12). This was done due to that there is essentially no difference in the
activity between the first equivalent of a transesterified ethyl acetoacetate and the second
equivalent of ethyl acetoacetate to form an enolate. As such the pre-assembly of the
Knoevenagel condensation and reacting the product in a click reaction allows us to
introduce a larger more sterically encumbered fragment that allows for a difference in
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activity verses the second equivalent of ethyl acetoacetate. This allows for a difference in
how the fragments interact with the catalysis. This difference allows for the catalysis to
force the same specific order of addition between the two fragments in the Michael
addition and as a result allows for enatio pure compounds to be produced.
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Figure 5.13: Reaction scheme for 1c.
Once the Michael addition is complete, the remaining steps of the Hantzsch
pyridine synthesis occur to give either an IDHP or an IHQ product. The remaining
reactions that occur to finish off the Hantzsch pyridine synthesis don’t have additional
effects on the C4 center thus the stereo center that is formed in the Michael reaction
remains unchanged, and the center is retained until the final product is formed.
5.11 Chiral HPLC Traces
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The same chiral cellulose based column that was utilized in the racemic IHQs was
utilized again here. As you would expect only one enantiomer is observed with the main
source of error being the baseline. As such, while the reaction seems to produce 100%ee
product we can only prove that the reaction produces compounds that are around 95% ee
due to the aforementioned baseline errors.

Figure 5.14: HPLC trace of chiral generation 5 compounds
Now with both racemic HPLC traces and chiral HPLC traces in hand we can
compare and contrast the two traces.
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Figure 5.15: Combined HPLC trace of the chiral and racemic IHQs
As a final step we combined the traces of the enatio-enriched IHQ and the
racemic IHQ (Figure 5.11). This allows us to make a tentative assignment that the first
peak in the HPLC trace is the (-) enantiomer with the second peak being the (+)
enantiomer. The absolute configuration was assigned via unpublished work done by Dr.
Schade. A personal communication with Dr. Schade informed us that in a similar 4-arylhydroquinolones series, compounds that showed a (-) rotation were assigned as the S
enantiomer. Dr. Schade’s assignment of the absolute conformation was established via xray crystallography. As such, we can conclude that our compounds that gave a (-) rotation
are the S enantiomer by association.
With both racemic and chiral compounds in hand biological testing would allow
for the examination and establishment of a eudysmic ratio at MDR1 for IDHPs and IHQs.
Computational modeling for this generation wasn’t conducted due to that the literature in
the field has established that MDR1 has a minimal eudysmic ratio for aryl-DHPs. This
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coupled with the several papers that detail the eudysmic ratio at the calcium channel; we
can make an informed hypothesis. With experimental results already in place to predict
the outcome of this study, computational modeling wasn’t employed as a predictive tool.
Additionally, from the previous generations of drug development we would predict that
the most active and selective compound in the library would be the (S)-m-Br IHQ.
Our prediction for the results of the biological testing is that there shouldn’t be a
eudysmic ratio at MDR1. The basis for this argument is that a similar experiment has be
conducted by Hollt et al. Hollt observed that 4-aryl-DHPs showed a defined eudysmic
ratio at the calcium channel, but his work also showed that MDR1 didn’t discriminate
between different enantiomers. As such, we would propose that the lack of a eudysmic
ratio at MDR1 can be used to our advantage. If the S enantiomer is utilized the compound
will be less active at the VGCC, while still retaining an unchanged level of activity at
MDR1. This synthetic modification allows us to engineer selectivity into compounds and
reduce off target polypharmacology. This coupled with the lower doses that will be
needed to treat MDR due to the increase penetration rate of drug to MDR cells will give
options in treatment to both treat MDR cells and allow for lower doses to be utilized to
achieve a desired pharmacological effect. Both of these factors will allow for safer and
more effective cancer treatment and should be considered as a vast improvement on
current methods of treatment in MDR cancer chemotherapy.
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5.12 Generation 4 experimental
General synthesis for Biphenyl-4-Carbaldehyde: An oven dried 100mL round bottom
was charged with 2.00g (10.855mmol) of Biphenyl-4-yl-methanol, 30ml of Chloroform,
10.5g of anhydrous magnesium sulfate and a magnetic stir bar. The solution was then
allowed to stir until the solution was homologous, 4.5 g of Pyridinium chlorochromate
was then added and the vessel was sealed and allowed to react for 3 hours. Reaction
progress was checked by TLC; once the reaction was complete excess solvent was
removed via rotovap. The solution was then purified via a silica column. The purification
yielded yellow oil that was then re-crystallized into a white crystalline solid with hexane
and dichloromethane. (1.90g, 10.43mmol, 96%)
1

H NMR: (CDCl3)  ppm 9.82 (s, 1H) 7.36 - 7.41 (m, 2 H) 7.45 - 7.50 (m, 4 H) 7.55 (s, 1

H) 7.59 - 7.64 (m, 4 H)
TLC: SiO2; Hexane:EtOAc 4:1 Rf = 0.54
General synthesis of Biphenyl-4-carbaldehyde oxime. An oven dried round 100mL
bottom was charged with 1.90g (10.43mmol) of Biphenyl-4-carbaldehyde, 1.49g of
NH2OH*HCl, 2.54g of NaCH3CO2, and a magnetic stir bar. A solution of
THF:EtOH:H2O(2:1:1) was made (40mL) and added at room temperature to the round
bottom. The round bottom was then capped and allowed to stir for 72 hours. The reaction
progress was monitored via TLC, once the reaction went to completion the solution as
place on a rotovap to remove EtOH from the solution. The remaining mixture was then
extracted with CHCl3 and Brine three times, and dried over NaSO4. The solution was
then concnentrated via rotovap yielding a white solid. (2.01g, 10.19 mmol, 98%)
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1

H NMR: (CDCl3)  ppm 8.18 (s, 1H) 7.36 - 7.41 (m, 2 H) 7.45 - 7.50 (m, 4 H) 7.55 (s, 1

H) 7.59 - 7.64 (m, 4 H)
TLC: SiO2; Hexane:EtOAc 4:1 Rf = 0.65
General synthesis of 3-Biphenyl-4-yl-5-methyl-isoxazole-4-carboxylic acid ethyl
ester. An oven dried round bottom 100mL was charged with 2.01g of Biphenyl-4carbaldehyde oxime, a magnetic stir bar. The solution was then allowed to stir at room
temperature until the mixture was homologous. 0.117 mL of pyridine was then added
along with 2.12g of N-chlorosuccinimide, the round bottom was then capped and allowed
to stir at room temperature for 3 hours. The reaction mixture was extracted with brine and
CHCl3, the mixture was then dried over NaSO4, then filtered and concentrated via
rotovap. The resulting Biphenyl-4-benzohydroximinoyl chloride was then left under the
high vacuum. Another oven dried round bottom 250mL was charged with 100mL of
EtOH, and a magnetic stir bar, the round bottom was then capped with a rubber septum
and placed under an argon environment. 0.523g of Na was then weight out and placed in
the EtOH, the solution was then stirred and the Na was allowed to dissolve. Once
dissolved 2.97g of ethyl acetoacetate was then added and the solution was allowed to stir
at room temperature. The 100mL round bottom containing Biphenyl-4benzohydroximinoyl chloride was then removed from the high vacuum and capped with a
rubber septum and placed under an argon environment. The Biphenyl-4benzohydroximinoyl chloride was then taken up in a minimal amount of EtOH and added
to the Na/EtOH mixture at room temperature. The round bottom was then capped with a
rubber septum and placed under an argon environment. The solution was then allowed to
stirred over night. The solution was then extracted with CHCl3 and Brine three times, and
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dried over NaSO4. The solution was then concentrated via rotovap yielding a yellow oil.
The solution was then purified via a silica column. (1.96g, 6.38 mmol, 61.9%)
1

H NMR: (CDCl3)  ppm 7.36 - 7.41 (m, 2 H) 7.45 - 7.50 (m, 4 H) 7.55 (s, 1 H) 7.59 -

7.64 (m, 4 H) 4.11 (q 2H J = 8.02Hz), 1.99(s 3H), 1.18 (t 3H J = 6.84Hz)
TLC: SiO2; Hexane:EtOAc 4:1 Rf = 0.73
General synthesis of (3-Biphenyl-4-yl-5-methyl-isoxazol-4-yl)-methanol. An oven
dried 100ml 2-neck round bottom was charged with 2.04g of 3-Biphenyl-4-yl-5-methylisoxazole-4-carboxylic acid ethyl ester, a magnetic stir bar and the vessel was sealed and
placed under a vacuum. An oven dried condenser was then attached to the 2 neck round
bottom and the system was seal and placed under a vacuum and flushed with argon, this
process was done three times. The 2-neck round bottom was then placed in an ice bath
and was allowed to reach 0ºC. 100mL of freshly distilled THF was then added to the 2neck round bottom and the solution was again allowed to reach 0ºC. 0.198g of LiAlH4
was then added in potions to the solution, there was slight foaming that was observed.
The reaction was then left to react and was allowed to come to room temperature.
Reaction process was monitored by TLC after the reaction was completed the mixture
was quenched with sodium sulfate decahydrate, foaming was observed. The solution was
then purified via filtering it threw a silica plug with Et2O, the resulting solution was then
concentrated via rotovap yielding a yellow oil. (1.33g, 5.01mmol, 75.6%)
1

H NMR: (CDCl3)  ppm 7.36 - 7.41 (m, 2 H) 7.45 - 7.50 (m, 4 H) 7.55 (s, 1 H) 7.59 -

7.64 (m, 4 H) 5.24 (s 3H), 2.54 (s 3H)
TLC: SiO2; Hexane:EtOAc 4:1 Rf = 0.51
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General synthesis of 3-Biphenyl-4-yl-5-methyl-isoxazole-4-carbaldehyde. An oven
dried 100mL round bottom was charged with 0.481g of 3-Biphenyl-4-yl-5-methylisoxazol-4-yl)-methanol, 50ml of dichloromethane, 1.76g of anhydrous magnesium
sulfate and a magnetic stir bar. 0.75g of pyridinium chlorochromate was then added and
the vessel was capped with a rubber septa and was allowed to react for 3 hours. Reaction
progress was monitored via TLC, once the reaction was complete excess solvent was
removed via rotovap. The solution was then purified via a silica column and recrystalized
via slow evaporation using hexanes and EtOH. The re-crystallization yielded clear
crystals. (0.356g 1.35 mmol, 74.8%)
1

H NMR: (CDCl3)  ppm 9.88 (s 1H) 7.36 - 7.41 (m, 2 H) 7.45 - 7.50 (m, 4 H) 7.55 (s, 1

H) 7.59 - 7.64 (m, 4 H), 2.62 (s 3H)
TLC: SiO2; Hexane:EtOAc 4:1 Rf = 0.52
General Synthesis of 4-(3-Biphenyl-4-yl-5-methyl-isoxazol-4-yl)-2,6-dimethyl-1,4dihydro-pyridine-3,5-dicarboxylic acid diethyl ester. An oven dried 100mL round
bottom was charged with 0.356g of 3-Biphenyl-4-yl-5-methyl-isoxazole-4-carbaldehyde,
0.37g of ethyl acetoacatate, 50ml of EtOH and a magnetic stir bar. The solution was
allowed to stir at room temperature until homologues. 0.337ml of 30% ammonia
hydroxide was then added and the round bottom was fitted with a dean stark trap. The
round bottom was then fitted with an oven dried condenser and the solution was brought
to reflux. The reaction process was monitored via TLC. Once complete the solution was
then cooled to room temperature and the excess solvent was removed via rotovap. The
solution was then purified via a silica column yielding yellow oil (0.309g, 1.35 mmol,
46.2%)
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1

H NMR: (CDCl3) δ 7.58 - 7.68 (m, 4 H) 7.55 (s, 1 H) 7.48 (s, 4 H) 7.33 - 7.42 (m, 1 H)

5.22 (br. s., 1 H) 5.05 (s, 1 H) 4.04 - 4.17 (m, 3 H) 3.93 - 4.04 (m, 2 H) 2.44 - 2.52 (m, 3
H) 1.99 (s, 5 H) 1.18 (t, J=7.15 Hz, 5 H)
13

C NMR: (CDCl3) δ 167.41, 165.86, 163.52, 143.87, 141.15, 140.47, 13.09, 129.01,

127.01, 126.15, 119.58, 101.17, 59.82, 29.35, 19.44, 14.51, 11.50
HRMS: calculated for C29H31 N2O5 487.2233 found 487.2256
MS: m/z = 486 ([M] 40), 487 ([M+1] 100), 488 ([M+1] 30)
TLC: SiO2; Hexane:EtOAc 4:1 Rf = 0.23
4-(3-Anthracen-9-yl-5-methyl-isoxazol-4-yl)-2,6-dimethyl-1,4-dihydro-pyridine-3,5dicarboxylic acid diethyl ester
1

H NMR: (CDCl3) δ 8.49 (s, 1 H) 8.11 (s, 1 H) 7.97 (d, J=9.03 Hz, 1 H) 7.41 - 7.54 (m, 3

H) 7.30 - 7.40 (m, 1 H) 4.96 (s, 1 H) 4.09 - 4.28 (m, 4 H) 2.75 (s, 3 H) 1.20 - 1.38 (m, 6
H) 0.88 (s, 6 H)
13

C NMR: (CDCl3) δ 167.13, 166.10, 161.10, 145.05, 131.24, 131.06, 129.77, 127.78,

126.46, 125.87, 125.50, 119.89, 99.22, 59.71, 29.44, 18.17, 14.69, 11.72
HRMS: calculated for C31H31 N2O5 511.2233 found 511.2228
MS: m/z = 509 ([M-1] 80), 510 ([M] 30), 511([M+1] 100), 512 ([M+1] 30)
TLC: SiO2; Hexane:EtOAc 4:1 Rf = 0.14
4-[3-(2-Methoxy-naphthalen-1-yl)-5-methyl-isoxazol-4-yl]-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid diethyl ester
1

H NMR: (CDCl3) δ 7.89 (d, J=8.91 Hz, 1 H) 7.69 - 7.77 (m, 1 H) 7.23 - 7.38 (m, 5 H)

7.18 (s, 1 H) 4.96 (s, 1 H) 4.09 - 4.25 (m, 4 H) 3.79 (s, 3 H) 2.64 (s, 3 H) 1.87 (s, 3 H)
1.28 (dt, J=8.85, 7.18 Hz, 6 H) 1.01 (s, 3 H)
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13

C NMR: (CDCl3) δ 167.36, 165.52, 159.42, 155.23, 144.61, 143.98, 134.18, 130.49,

128.29, 127.29, 126.70, 125.09, 123.56, 119.49, 113.22, 112.25, 99.94, 99.80, 59.65,
59.57, 56.17, 29.46, 19.14, 18.33, 14.67, 14.58, 11.67
HRMS: calculated for C28H31 N2O6 491.2182 found 491.2205
MS: m/z =489 ([M-1] 100), 490 ([M] 30), 491([M+1] 70), 512 ([M+1] 30)
TLC: SiO2; Hexane:EtOAc 4:1 Rf = 0.18
2,6-Dimethyl-4-(5-methyl-3-naphthalen-1-yl-isoxazol-4-yl)-1,4-dihydro-pyridine-3,5dicarboxylic acid diethyl ester
1

H NMR: (CDCl3) δ 7.89 (d, J= 8.28Hz, 2H), 7.83(d, J=8.03Hz, 1H), 7.46(m, 2H),

7.36(m, 2H), 4.96 (s, 1 H), 4.16 (q, J=7.15Hz, 4 H) 2.65 (s, 3 H) 1.41 (bs, 6 H) 1.29 (t,
J=7.09 Hz, 6 H)
13

C NMR: (CDCl3) δ 167.27, 165.35, 162.54, 144.67, 133.00, 132.84, 128.79, 128.45,

127.99, 127.57, 126.40, 126.40, 126.08, 124.68, 199.38, 99.98, 59.76, 29.38, 18.81,
14.62, 11.57
HRMS: calculated for C27H29 N2O5 460.2076 found 461.2087
MS: m/z =461 ([M+1] 100), 462 ([M+2] 50)
TLC: SiO2; Hexane:EtOAc 4:1 Rf = 0.28
4-[3-(4-Methoxy-phenyl)-5-methyl-isoxazol-4-yl]-2,6-dimethyl-1,4-dihydro-pyridine3,5-dicarboxylic acid diethyl ester
1

H NMR: (CDCl3) δ 7.21 - 7.26 (m, 2 H) 6.79 - 6.86 (m, 2 H) 4.93 (s, 1 H) 4.79 (s, 1 H)

3.99 - 4.09 (m, 2 H) 3.89 - 3.99 (m, 2 H) 3.77 (s, 3 H) 2.39 - 2.43 (m, 3 H) 1.94 (s, 6 H)
1.13 (t, J=7.03 Hz, 6 H)
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C NMR: (CDCl3) δ 167.68, 157.90, 143.49, 140.33, 128.99, 113.20, 104.48, 59.71,

55.16, 38.76, 19.65, 14.29
HRMS: calculated for C24H29 N2O6 441.2026 found 441.2057
MS: m/z =439 ([M-1] 80), 440 ([M] 20), 441([M+1] 100), 442 ([M+2] 30)
TLC: SiO2; Hexane:EtOAc 4:1 Rf = 0.18
4-[3-(3,4-Dimethoxy-phenyl)-5-methyl-isoxazol-4-yl]-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid diethyl ester
1

H NMR: (CDCl3) δ 6.95 - 7.01 (m, 2 H) 6.80 - 6.86 (m, 1 H) 6.60 (s, 1 H) 5.62 (s, 1 H)

5.00 (s, 1 H) 3.98 - 4.12 (m, 2 H) 3.86 - 3.97 (m, 2 H) 3.83 (s, 3 H) 3.79 (s, 3 H) 2.39 (s,
3H) 1.95 (s, 6 H) 1.08 - 1.15 (q, 6H)
13

C NMR: (CDCl3) δ 167.53, 166.14, 163.26, 149.27, 148.33, 144.21, 123.33, 122.14,

119.59, 112.87, 110.48, 100.68, 59.68, 55.99, 29.30, 18.93, 14.42, 11.43
HRMS: calculated for C25H29 N2O7 469.1975 found 469.1990
MS: m/z =469 ([M-1] 100), 470 ([M] 40), 471([M+1] 80), 472 ([M+1] 20)
TLC: SiO2; Hexane:EtOAc 4:1 Rf = 0.07
2,6-Dimethyl-4-[5-methyl-3-(3-phenoxy-phenyl)-isoxazol-4-yl]-1,4-dihydro-pyridine3,5-dicarboxylic acid diethyl ester
1

H NMR: (CDCl3) δ 7.28 - 7.35 (m, 1 H) 7.13 - 7.21 (m, 1 H) 7.01 - 7.11 (m, 1 H) 6.94 -

7.01 (m, 2 H) 6.76 (ddd, J=8.03, 2.51, 1.00 Hz, 1 H) 5.48 (bs, 1 H) 4.87 (s, 1 H) 3.98 4.21 (m, 4 H) 2.33 (s, 3 H) 2.18 (s, 6 H) 1.20 (q, 6 H)
13

C NMR: (CDCl3) δ 167.50, 157.53, 156.72, 149.81, 143.96, 129.58, 129.01, 123.06,

118.81, 116.57, 103.97, 59.76, 39.53, 30.96, 19.60, 14.26
HRMS: calculated for C29H29 N2O6 501.2026 found 501.2019
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MS: m/z =500 ([M-1] 20), 501 ([M] 100), 502([M+1] 60)
TLC: SiO2; Hexane:EtOAc 4:1 Rf = 0.28
4-[3-(2,4-Dimethoxy-phenyl)-5-methyl-isoxazol-4-yl]-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid diethyl ester
1

H NMR: (CDCl3) δ 7.27 (s, 2 H) 7.11 (s, 1 H) 6.48 (s, 1 H) 4.93 (s, 1 H) 4.80 (s, 1 H)

4.05 - 4.19 (m, 4 H) 3.95 (s, 3 H) 3.69 (s, 3 H) 2.54 (s, 3 H) 2.00 (s, 6 H) 1.25(q, 6 H)
13

C NMR: (CDCl3) δ 167.36, 165.13, 159.79, 157.70, 156.11, 143.87, 132.19, 119.27,

112.68, 100.66, 95.72, 59.74, 56.42, 55.95, 29.44, 19.31, 14.53, 11.52
HRMS: calculated for C25H31 N2O7 623.2757 found 623.2709
MS: m/z = 469 ([M-1] 30), 470 ([M] 20), 471([M+1] 100), 472 ([M+2] 30)
TLC: SiO2; Hexane:EtOAc 4:1 Rf = 0.05
4-[3-(3,4-Bis-benzyloxy-phenyl)-5-methyl-isoxazol-4-yl]-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid diethyl ester
1

H NMR: (CDCl3) δ 7.19 - 7.41 (m, 13 H), 6.92 (s, 2H), 6.76 (s, 2H), 5.21 (s, 1 H) 5.03

(t, J=3.76 Hz, 3 H) 4.85 (m, 1 H) 3.88 - 4.12 (m, 4 H) 2.39 (s, 3 H) 2.19 (s, 3 H) 1.73 (s,
3 H) 1.12 (t, J=12.30 Hz 6H)
13

C NMR: (CDCl3) δ 167.60, 167.4, 165.53, 163.52, 148.68. 148.16, 144.00,

143.56,141.33,137.88, 137.68, 137.63, 136.88, 128.69, 128.56, 128.42, 128.40, 128.11,
128.02, 127.66, 127.61, 127.56, 127.46, 127.32, 127.26, 124.20, 122.92, 120.92, 119.15,
116.29, 115.51, 114.77, 114.41, 104.17, 100.72, 77.36, 77.25, 77.04, 76.72, 71.44, 71.38,
71.34, 70.69, 59.76, 59.70, 38.86, 29.25, 19.63, 19.08, 14.51, 14.35, 11.46,
HRMS: calculated for C37H39 N2O7 623.2757 found 623.2807
MS: m/z = 621 ([M-1] 20), 622 ([M] 10), 623([M+1] 100), 624 ([M+2] 50)
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TLC: SiO2; Hexane:EtOAc 4:1 Rf = 0.16

5.9 Generation 5 experimental
General synthesis for 2,7,7-Trimethyl-4-(5-methyl-3-phenyl-isoxazol-4-yl)-5-oxo1,4,5,6,7,8-hexahydro-quinoline-3-carboxylic acid ethyl ester: An oven dried 50mL
round bottom was charged with 0.27g (1.44mmol) of starting material, 0.202g of
dimedone, 0.187g of ethyl acetoacetate, 0.046g of Ytterbium (III)
trifluoromethanesulfonate and a magnetic stir bar. The mixture is then taken up in
3.61mL of absolute Ethanol and is allowed to stir at room temperature. Once homologues
0.11g of ammonium acetate is added to the stirring solution and the round bottom is
capped. The solution is then allowed to stir at room temperature for 48hr. After which
reaction progress was monitored via TLC. Once the reaction was complete excess solvent
was removed via rotovap. The solution was then purified via a silica column.
1

H NMR: (CDCl3) δ 7.50 (d, J=9.03Hz 2H), 7.38 (s 1H), 7.36 (d, J=11.04Hz 2H), 5.73

(s, 1H), 5.01 (s, 1H), 4.05 (m, 2H), 3.89 (m, 2H), 2.54 (s, 3H), 2.15 (d, J=4.02Hz 2H),
2.00 (s, 2H), 1.08 (t, J=7.28Hz, 3H), 0.99 (s, 6H)
13

C NMR: (CDCl3) δ 195.48, 167.15, 166.70, 163.40, 148.45, 143.86, 130.90, 129.60,

128.58, 127.70, 118.74, 109.21, 103.32, 59.78, 50.75, 40.66, 32.33, 28.52, 28.42, 26.50,
19.05, 14.31, 11.47
HRMS: calculated for C25H29 N2O4 421.2127 found 421.2132
MS: m/z = 419 ([M-1] 10), 421 ([M+1] 100), 422 ([M+2] 30)
TLC: SiO2; Hexane:EtOAc 3:2 Rf = 0.23
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4-[3-(2-Bromo-phenyl)-5-methyl-isoxazol-4-yl]-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8hexahydro-quinoline-3-carboxylic acid ethyl ester
1

H NMR: (CDCl3) δ 7.59 (d, J=7.78Hz 1H), 7.32 (t, J=7.53Hz 1H), 7.23 (m, 1H), 7.16

(m, 1H), 4.97 (s, 1H), 4.94 (s, 1H),4.12 (q, J=7.28Hz, 2H), 4.11(q, J=7.03Hz, 2H), 2.68
(s, 3H), 2.05 (s, 2H), 1.96(s, 2H), 1.24 (t, J=7.28Hz 3H), 1.08 (s, 3H), 0.98 (s, 6H)
13

C NMR: (CDCl3) δ 195.47, 167.07, 166.58, 162.43, 148.09, 144.42, 132.42, 132.42,

132.30, 130.04, 126.24, 124.82, 117.30, 109.20, 102.30, 60.41, 58.89, 50.56, 40.94,
32.99, 26.27, 19.52, 14.50, 11.45
HRMS: calculated for C25H28N2O4Br 499.1232 found 499.1248
MS: m/z = 499 ([M] 90), 500 ([M+1] 40), 501 ([M+1] 100) 502 ([M+2] 30)
TLC: SiO2; Hexane:EtOAc 3:2 Rf = 0.21
4-[3-(3-Bromo-phenyl)-5-methyl-isoxazol-4-yl]-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8hexahydro-quinoline-3-carboxylic acid ethyl ester
1

H NMR: (CDCl3) δ 7.67 (s, 1H), 7.48 (d, J=8.78Hz 1H), 7.27 (s, 1H), 7.24 (d, J=8.03Hz

1H), 6.50 (s, 1H), 4.98 (s, 1H), 4.04 (q, J=10.79Hz 2H), 3.89 (q, J=10.79Hz 2H), 2.51
(s,3H), 2.14 (d, J=6.53Hz 2H), 1.99 (s, 2H), 1.07(t, J=7.03Hz 3H), 0.97 (s, 6H)
13

C NMR: (CDCl3) δ 195.68, 167.25, 167.09, 162.00, 149.19, 144.24, 132.91, 132.91,

132.31, 131.71, 129.46, 128.25, 121.78, 119.11, 108.86, 103.05, 59.79, 50.75, 40.39,
32.23, 28.52, 28.30, 26.67, 18.87, 14.31, 11.52
HRMS: calculated for C25H27N2O4Br 499.1232 found 499.1324
MS: m/z = 499 ([M] 100), 500 ([M+1] 50), 501 ([M+2] 90), 502 ([M+3] 30)
TLC: SiO2; Hexane:EtOAc 4:1 Rf = 0.23
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4-[3-(4-Bromo-phenyl)-5-methyl-isoxazol-4-yl]-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8hexahydro-quinoline-3-carboxylic acid ethyl ester
1

H NMR: (CDCl3) δ 7.54 (d, J=8.53Hz 2H), 7.51 (d, J=8.53Hz 2H), 5.24 (bs, 1H), 5.02

(s, 1H), 4.06 (m, J=7.03Hz 2H), 3.88 (m, J=7.28Hz 2H), 2.52(s, 3H), 2.18 (d, J=5.27Hz
2H), 2.10 (s, 2H), 1.08 (t, J=6.78Hz 3H), 1.03 (s 6H)
13

C NMR: (CDCl3) δ 195.36, 167.21, 166.95, 162.28, 147.76, 143.06, 131.27, 130.91,

130.09, 122.99, 118.78, 109.59, 103.88, 59.92, 50.68, 41.03, 32.45, 28.58, 28.36,
26.52,19.27, 14.24, 11.47
HRMS: calculated for C25H28 N2O4Br 499.1232 found 499.1251
MS: m/z = 499 ([M] 100), 500 ([M+1] 30), 501 ([M+1] 90), 502 ([M+2] 30)
TLC: SiO2; Hexane:EtOAc 3:2 Rf = 0.18
4-(3-Biphenyl-4-yl-5-methyl-isoxazol-4-yl)-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8hexahydro-quinoline-3-carboxylic acid ethyl ester
1

H NMR: (CDCl3) δ 7.69 (d, J=7.78Hz 2H ), 7.61 (t, J=8.53Hz 2H ), 7.53 (s 1H), 7.45 (t,

J=7.28Hz 2H ), 7.36 (t, J=7.28Hz 2H ), 6.57 (bs, 1H), 5.05 (s, 1H), 4.02 (m, J=10.54Hz
2H), 3.79 (m, J=10.54Hz 2H), 2.44 (s, 3H), 2.12 (d, J=2.76Hz, 2H), 2.04 (s, 2H), 1.95 (s,
2H), 0.99 (t, J=7.03Hz 3H), 0.94 (s, 6H)
13

C NMR: (CDCl3) δ 195.77, 167.21, 167.11, 162.95, 149.11, 143.97, 141.49, 140.53,

129.90, 129.81, 128.96, 127.70, 127.05, 126.49, 119.49, 109.04, 103.37, 59.71, 50.75,
40.42, 32.24, 28.52, 28.25, 26.55, 18.79, 14.22, 11.47
HRMS: calculated for C31H31 N2O4 495.2284 found 495.2309
MS: m/z = 495 ([M] 100), 496 ([M+1] 50), 497 ([M+1] 60)
TLC: SiO2; Hexane:EtOAc 4:1 Rf = 0.23
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The general synthesis of (-)- 2,7,7-Trimethyl-4-(5-methyl-3-phenyl-isoxazol-4-yl)-5oxo-1,4,5,6,7,8-hexahydro-quinoline-3-carboxylic acid ethyl ester. An oven dried
50mL round bottom was charged with 0.027g (1.5eq) of dimedone, 0.025g of ethyl
acetoacetate, and 0.014g (10mol%) of (R)- 4-Oxo-2,6-bis-(2,4,6-triisopropyl-phenyl)3,5-dioxa-4l5-phospha-cyclohepta[2,1-a;3,4-a']dinaphthalen-4-ol and a magnetic stir bar.
The mixture was then taken up in 1.5mL of acetonitrile, capped and put under an inert
atmosphere of argon, after which the solution was allowed to stir at room temperature for
20 minutes. Once homologues 0.036g (0.193mmol) of aldehyde and 0.015g of
ammonium acetate is added to the stirring solution, the solution is then allowed to stir at
room temperature for 48hr. After which reaction progress was monitored via TLC. Once
the reaction was complete excess solvent was removed via rotovap. The solution was
then purified via a silica column.
1

H NMR: (CDCl3) δ 7.46 (d, J=9.03Hz 2H), 7.39 (s 1H), 7.38 (d, J=11.54Hz 2H), 5.02

(s, 1H), 4.14-4.06 (m, 1H), 3.96-3.92 (m, 1H), 2.57 (s, 3H), 2.18 (d, J=2.76Hz 2H), 2.03
(s, 3H), 1.13 (t, J=7.28Hz, 3H), 1.04 (s, 3H), 1.03 (s, 3H)
13

C NMR: (CDCl3) δ 194.29, 165.90, 166.72, 147.85, 143.51, 137.74, 129.72, 129.23,

127.63, 115.26, 109.56, 103.56, 59.87, 57.53, 50.71, 40.98, 32.57, 32.48, 28.66, 28.42,
26.49, 24.58,19.34,14.32. []D - 11.2 (c = 0.09 CH3OH)
(-)-4-[3-(2-Bromo-phenyl)-5-methyl-isoxazol-4-yl]-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8hexahydro-quinoline-3-carboxylic acid ethyl ester
1

H NMR: (CDCl3) δ 7.61 (d, J=7.78Hz 1H), 7.33 (t, J=7.28Hz 1H), 7.24 (m, 1H), 7.19

(d, J=7.53Hz 2H), 4.97 (s, 1H), 4.77 (s, 1H),4.12 (q, J=7.28Hz, 2H), 2.68 (s, 3H), 2.30 (d,
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J=16.31Hz 2H), 2.17 (d, J=16.31Hz 2H), 1.97 (s,3H), 1.25 (t, J=7.03Hz 3H), 1.98 (s,
3H), 0.99 (s, 3H)
13

C NMR: (CDCl3) δ 195.45, 167.06, 166.60, 147.95, 144.30, 132.49, 132.31, 130.01,

126.24, 124.86, 117.24, 109.28, 102.39, 60.41, 59.92, 50.55, 41.03, 33.02, 26.26, 19.59,
14.49, 11.44... []D -13.5 (c = 0.15, CH3OH)
(-)-4-[3-(3-Bromo-phenyl)-5-methyl-isoxazol-4-yl]-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8hexahydro-quinoline-3-carboxylic acid ethyl ester
1

H NMR: (CDCl3) δ 7.62 (s, 1H), 7.54 (d, J=8.03Hz 1H), 7.42 (d, J=7.53Hz 1H), 7.30

(d, J=7.53Hz 1H), 5.18 (s, 1H), 5.01 (s, 1H), 4.12-4.06 (m,1H), 4.00-3.95 (m,1H), 2.60
(s,3H), 2.20 (d, J=14.81Hz 2H), 2.07(d, J=16.31Hz 2H), 2.04(s,3H), 1.14 (t, J=7.03Hz
3H), 1.06 (s, 6H)
13

C NMR: (CDCl3) δ 195.54, 167.60, 166.89, 163.57, 149.96, 144.52, 132.50, 132.30,

132.31, 131.84, 129.68, 127.56, 125.61, 118.11, 108.65, 102.42, 58.67, 50.62, 40.69,
33.25, 27.62, 26.74, 18.65, 14.53, 11.52. []D - 2.36 (c = 0.28, CH3OH).
(-)-4-[3-(4-Bromo-phenyl)-5-methyl-isoxazol-4-yl]-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8hexahydro-quinoline-3-carboxylic acid ethyl ester
1

H NMR: (CDCl3) δ 7.56 (d, J=8.28Hz 2H), 7.51 (d, J=8.28Hz 2H), 5.21 (bs, 1H), 5.02

(s, 1H), 4.08-4.04 (m,1H), 3.90-3.86 (m,1H), 2.52(s, 3H), 2.18 (d, J=5.02Hz 2H), 2.11 (s,
3H), 2.09 (d, J=9.29Hz 2H), 1.08 (t, J=7.28Hz 3H), 1.04 (s 6H)
13

C NMR: (CDCl3) δ 195.37, 167.22, 166.95, 162.29, 147.77, 131.28, 130.92, 130.09,

123.00, 118.79, 109.59, 103.89, 59.93, 50.68, 41.04, 32.45, 28.58, 28.37, 26.53,19.28,
14.25, 11.48. []D - 0.032 (c = 0.08, CH3OH)
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(-)-4-[3-(4-Bromo-phenyl)-5-methyl-isoxazol-4-yl]-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid 3-ethyl ester 5-(1-phenethyl-1H-[1,2,3]triazol-4ylmethyl) ester
1

H NMR: (CDCl3) δ 7.41(d, 2H J = 8.28Hz), 7.18 (d, 2H J = 8.28Hz), 7.07(s, 1H),

7.24(d, 2H J = 9.29Hz), 7.01(d, 2H J = 6.78Hz), 5.73(s, 1H), 5.09 (d, 2H J = 12.80Hz),
4.97 (d, 2H J = 12.80Hz), 4.90(s, 1H), 4.48 (t, 2H J = 7.28Hz), 4.05 (q, 2H J = 7.03Hz),
4.07 (q 2H J = 7.03Hz), 3.11(t, 2H J = 7.53Hz), 2.26(s, 3H), 1.92(d, 6H J = 8.03Hz),
1.06(t, 3H J = 7.03Hz)
13

C NMR: (CDCl3) δ 167.35, 167.11, 166.63, 144.30, 142.98, 136.86, 131.09, 130.82,

128.82, 128.66, 127.11, 122.95, 119.76, 101.09, 59.80, 58.25, 56.72, 51.63, 42.90, 36.59,
29.36,19.03, 18.85, 18.40, 14.45, 14.43, 11.33. []D -2.68 (c = 0.48, CH3OH).
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